Ericdao的个人主页 - 老虎社区

Ericdao

Ericdao

暂无个人介绍

IP属地：未知

396关注

14粉丝

0主题

0勋章

2022-01-22

Cathy will be gone soon

抱歉，原内容已删除

2022-01-17

Nice

Moderna: High Upside Potential At Current Prices<blockquote>Moderna：当前价格上涨潜力巨大</blockquote>

2021-12-24

It's always the up and down

抱歉，原内容已删除

2021-12-21

Should start positioning at 86. 70 is too bearish

抱歉，原内容已删除

2021-12-18

Semicon industry nvr die

Wedbush's Dan Ives: Don't throw in the towel on tech<blockquote>韦德布什的丹·艾夫斯：不要在科技上认输</blockquote>

2021-11-26

Will it ? Well market is insane, anything can happen [开心] [开心]

抱歉，原内容已删除

2021-11-07

Over aggressive expansion, Convid killed him

Popular Hot Pot Restaurant Brand Haidilao to Shut Down 300 Restaurants in China<blockquote>受欢迎的火锅餐厅品牌海底捞将在中国关闭300家餐厅</blockquote>

2021-10-18

Buy. No regrets

抱歉，原内容已删除

2021-10-17

GOOD PICK

抱歉，原内容已删除

2021-10-15

Too high already, time for it to cool down

抱歉，原内容已删除

2021-10-13

Buy

BBIG Stock: What Is Going on With Red-Hot Vinco Ventures Today?<blockquote>BBIG股票：炙手可热的Vinco Ventures今天发生了什么？</blockquote>

2021-10-06

Still a falling knife

抱歉，原内容已删除

2021-10-06

Dead cat rebound

抱歉，原内容已删除

2021-10-04

Still need to be careful with amc, virus situation still bad. It could mutate again and become more resilient and powerful

3 Stocks That Can Double Again in the Fourth Quarter<blockquote>四季度可以再次翻倍的3只股票</blockquote>

2021-10-04

V good recommendations. I will include visa also

抱歉，原内容已删除

2021-10-02

Will report at the hell. Not worth trading [开心]

抱歉，原内容已删除

2021-09-10

See, con women, say Tesla worth $3000/share, but dump it after her announcement not long ago. Her followers all have to safe keep those she dumped

抱歉，原内容已删除

2021-09-09

$GameStop(GME)$Aviod, more downside to come.

2021-09-08

She's playing with fire. Hopeful to win big. A dangerous speculators. Not worth following.

Wall Street's hottest investor is betting big on a handful of stocks. Critics say she's playing with fire<blockquote>华尔街最炙手可热的投资者正在少数股票上下大赌注。批评者说她在玩火</blockquote>

2021-09-05

This lady fickle minded, be more careful if u follow her. Anyway, she's right this time to buy into China mkt

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3574662162410712","uuid":"3574662162410712","gmtCreate":1611568139053,"gmtModify":1628390403937,"name":"Ericdao","pinyin":"ericdao","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":14,"headSize":396,"tweetSize":26,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"02aa7f16703b4ce4ace6f1a7665789cc-1","templateUuid":"02aa7f16703b4ce4ace6f1a7665789cc","name":"知识体验官","description":"观看学堂课程满5节","bigImgUrl":"https://static.tigerbbs.com/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://static.tigerbbs.com/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.98%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.16%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":6,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":630619131,"gmtCreate":1642812029157,"gmtModify":1642812029359,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"htmlText":"Cathy will be gone soon&nbsp;","listText":"Cathy will be gone soon&nbsp;","text":"Cathy will be gone soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/630619131","repostId":"1116834406","repostType":4,"isVote":1,"tweetType":1,"viewCount":2489,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":697840047,"gmtCreate":1642415216001,"gmtModify":1642415216206,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/697840047","repostId":"1131862461","repostType":4,"repost":{"id":"1131862461","kind":"news","pubTimestamp":1642412568,"share":"https://www.laohu8.com/m/news/1131862461?lang=zh_CN&edition=full","pubTime":"2022-01-17 17:42","market":"us","language":"en","title":"Moderna: High Upside Potential At Current Prices<blockquote>Moderna：当前价格上涨潜力巨大</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1131862461","media":"Seeking Alpha","summary":"SummaryModerna has a significant first mover competitive advantage by not only developing the COVID-","content":"<p><html><head></head><body><b>Summary</b></p><p><blockquote><html><head></head><body><b>总结</b></body></html></blockquote></p><p><ul><li>Moderna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company&#39;s mRNA manufacturing capacity.</li><li>Moderna recently reported the preliminary COVID-19 estimate for product sales in 2021 as being approximately $17.5 billion.</li><li>Recently, Singapore released data showing that COVID-19 deaths were the lowest among Moderna vaccine takers.</li><li>One of the ways that Moderna is keeping ahead of potential mRNA competition is using its $15.3 billion in cash and $3.2 billion in Free Cash Flow to continue building out significant mRNA manufacturing capability across the world.</li><li>The 58% pullback from Moderna&#39;s all-time high of $497.49 gives aggressive growth investors a chance to buy into a company with significant upside potential.</li></ul><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/466434ab0d3291095a83741482c15948\" tg-width=\"1536\" tg-height=\"1024\" width=\"100%\" height=\"auto\"/><span>Maddie Meyer/Getty Images News</span></p><p><blockquote><ul><li>Moderna不仅开发了COVID-19疫苗，还扩大了公司的mRNA生产能力，从而拥有显着的先发竞争优势。</li><li>Moderna最近报告了COVID-19对2021年产品销售额的初步估计约为175亿美元。</li><li>近日，新加坡发布数据显示，Moderna疫苗接种者中新冠肺炎死亡人数最低。</li><li>Moderna在潜在的mRNA竞争中保持领先地位的方法之一是利用其153亿美元的现金和32亿美元的自由现金流继续在全球范围内建立重要的mRNA制造能力。</li><li>Moderna较497.49美元的历史高点回调58%，为激进的增长投资者提供了买入一家具有巨大上涨潜力的公司的机会。</li></ul><p class=\"t-img-caption\"><span>麦迪·迈耶/盖蒂图片社新闻</span></p></blockquote></p><p>Moderna (NASDAQ:MRNA) has extremely high upside from being a first mover in developing the world&#39;s most advanced mRNA platform. One of the most promising potential solutions for helping prevent or cure some of the most intractable diseases known to man is mRNA technology and Moderna has not only developed the most advanced mRNA platform but has also built out significant mRNA manufacturing capacity worldwide. There are many companies that are in various stages of developing mRNA technology but there are very few that have advanced as far as Moderna has in both developing mRNA technology, as well as having the manufacturing capacity and other commercial infrastructure to produce billions of doses of a vaccine per year. At this time, the only companies that have both the knowledge of advanced mRNA techniques and the manufacturing capacity to compete in the same arena as Moderna is the BioNTech (NASDAQ:BNTX) - Pfizer (NYSE:PFE) partnership.</p><p><blockquote>Moderna（纳斯达克：MRNA）作为开发世界上最先进的mRNA平台的先行者，具有极高的优势。mRNA技术是帮助预防或治愈人类已知的一些最棘手疾病的最有前途的潜在解决方案之一，Moderna不仅开发了最先进的mRNA平台，还在全球范围内建立了重要的mRNA制造能力。有许多公司处于开发mRNA技术的不同阶段，但很少有公司像Moderna那样在开发mRNA技术以及拥有生产数十亿剂疫苗的制造能力和其他商业基础设施方面取得了进步。每年的疫苗。目前，唯一同时拥有先进mRNA技术知识和制造能力与Moderna在同一舞台上竞争的公司是BioNTech（纳斯达克股票代码：BNTX）-辉瑞（纽约证券交易所股票代码：PFE）合作伙伴。</blockquote></p><p>Moderna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company&#39;s mRNA manufacturing capacity. It is one thing to produce mRNA in a lab setting but quite another to safely mass produce effective vaccines in regulator approved manufacturing sites around the world. Moderna&#39;s first mover advantage has translated into a very large war chest of cash from COVID-19 sales in which the company can use to further its lead by investing in advancing mRNA technology, improving mRNA manufacturing processes, and building out significant manufacturing capability worldwide. Moderna is also well along in developing one of the deepest drug pipelines in the world.</p><p><blockquote>Moderna不仅开发了COVID-19疫苗，还扩大了公司的mRNA生产能力，从而拥有显着的先发竞争优势。在实验室环境中生产mRNA是一回事，但在世界各地监管机构批准的生产基地安全地大规模生产有效的疫苗则完全是另一回事。Moderna的先发优势已转化为来自COVID-19销售的巨额现金，该公司可以通过投资推进mRNA技术、改进mRNA制造工艺以及在全球范围内建立强大的制造能力来进一步保持领先地位。Moderna在开发世界上最深的药物管道之一方面也进展顺利。</blockquote></p><p>While a first mover advantage is not exactly a moat, for the next several years at least, Moderna should enjoy a significant lead in developing many different mRNA-based therapies or vaccines to treat numerous difficult to treat diseases. Moderna currently has 40 different drug development programs, which is almost unheard of for such a relatively young biotech company that only two years ago was simply a research outfit. In the end, Moderna&#39;s mRNA platform and manufacturing capacity should result in significant long-term upside for investors buying into Moderna&#39;s stock today.</p><p><blockquote>虽然先发优势并不完全是护城河，但至少在未来几年内，Moderna应该在开发许多不同的基于mRNA的疗法或疫苗来治疗许多难以治疗的疾病方面享有显着的领先地位。Moderna目前拥有40个不同的药物开发项目，对于这样一家相对年轻的生物技术公司来说，这几乎是闻所未闻的，两年前它还只是一个研究机构。最终，Moderna的mRNA平台和制造能力应该会给今天购买Moderna股票的投资者带来显着的长期上涨空间。</blockquote></p><p>Advantages of mRNA Technology</p><p><blockquote>mRNA技术的优势</blockquote></p><p>The reason why Moderna was able to rapidly develop a COVID-19 solution, while at the same time continuing to build out a significant number of drug development programs is because of the nature of mRNA technology.</p><p><blockquote>Moderna之所以能够快速开发出COVID-19解决方案，同时继续建立大量药物开发项目，是因为mRNA技术的性质。</blockquote></p><p>The development and manufacturing of mRNA for use as therapeutics<i>and</i>vaccines are comparatively simple, scalable<i>and</i>extremely rapid.Source:Millapore SigmaThere are numerous advantages of a mRNA platform over traditional drug making. The major advantages of a mRNA platform that were demonstrated by the response to the COVID-19 pandemic was the ability to take the sequence of the virus and quickly move from development, to clinical trials, to approval, to mass manufacturing of a vaccine in a very rapid period of time. As Moderna and others get more experience and regulatory bodies get more comfortable with mRNA technology, I can see the day in the future where the response time of discovery of a virulent virus to clinical trials of a vaccine, to vaccine approval, to mass manufacturing of the vaccine could significantly shrink. Right now, it looks like it takes about 9 months to a year to move from virus discovery to eventually making it into people&#39;s arms. Eventually, this response time could shrink to matter of a few months.</p><p><blockquote>用作治疗剂的mRNA的开发和制造<i>和</i>疫苗相对简单、可扩展<i>和</i>速度极快。资料来源：Millapore Sigma与传统药物制造相比，mRNA平台有许多优势。对新冠肺炎疫情的反应证明了mRNA平台的主要优势，即能够获取病毒序列，并在非常短的时间内快速从开发、临床试验、批准到大规模生产疫苗。随着Moderna等人获得更多经验，监管机构对mRNA技术的使用更加舒适，我可以看到未来一天，发现一种毒力病毒对疫苗临床试验、疫苗审批、疫苗大规模生产的反应时间可能会明显缩短。现在看来，从病毒发现到最终投入人们的怀抱，大约需要9个月到一年的时间。最终，这个响应时间可能会缩短到几个月。</blockquote></p><p></p><p>Omnicron was first identified as a variant around November 24, 2021. Moderna CEO Stéphane Bancel said in a CNBC interview that clinical trials for an Omnicron vaccine will start soon and a Omnicron vaccine should be available by fall. This type of rapid response to infectious diseases is unheard of before now and as time goes along, mRNA platform companies could not only become proficient in rapidly producing vaccines against specific viruses but also become proficient at producing vaccines against specific strains of a virus, in specific regions of the world. Among the reason why I think Moderna is building manufacturing capacity in different countries and regions of the world is because vaccines will eventually be less of a one size fits all countries and be more along the lines of regional manufacturing sites creating vaccines specific for the most prevalent viruses and strains of virus in that specific region.</p><p><blockquote>Omnicron在2021年11月24日左右首次被确定为变种。Moderna首席执行官Stéphane Bancel在接受CNBC采访时表示，Omnicron疫苗的临床试验将很快开始，Omnicron疫苗应该会在秋季上市。这种对传染病的快速反应在以前是闻所未闻的，随着时间的推移，mRNA平台公司不仅可以熟练快速生产针对特定病毒的疫苗，还可以熟练生产针对特定病毒株的疫苗，在世界的特定地区。我认为Moderna正在世界不同国家和地区建设生产能力的原因之一是，疫苗最终将不再是一刀切的，而是更多地沿着区域生产基地的路线，为该特定地区最流行的病毒和病毒株生产特定疫苗。</blockquote></p><p>Another potential huge advantage of a mRNA platform is flexibility. Theoretically, a mRNA manufacturing plant can be relatively rapidly switched to producing any other mRNA-based drug. It is possible that a mRNA plant that makes COVID-19 vaccines could be rapidly switched to making an Ebola vaccine, for instance. This is in contrast to the manufacturing process of many traditional drugs that require a dedicated plant to produce a drug. This could make the CapEx involved for producing multiple different types of drugs, far lower than a traditional drug manufacturer.</p><p><blockquote>mRNA平台的另一个潜在的巨大优势是灵活性。理论上，mRNA制造厂可以相对快速地转向生产任何其他基于mRNA的药物。例如，生产COVID-19疫苗的mRNA工厂可能会迅速转向生产埃博拉疫苗。这与许多传统药物的制造过程形成对比，传统药物需要专门的工厂来生产药物。这可能会使生产多种不同类型药物的资本支出远低于传统药品制造商。</blockquote></p><p>The COVID-19 pandemic has highlighted exactly how easy it is to change the vaccine simply by plugging the genetic sequence of any virus that Moderna wants to target right into its basic mRNA platform. This is not only useful for being able to attack different strains of COVID-19 but also means that Moderna has the ability of using the sequence of any virus whether that be the flu, HIV, CMV, Tuberculosis, Zika, or Rabies and quickly produce a vaccine ready for testing.</p><p><blockquote>新冠肺炎·疫情强调了改变疫苗是多么容易，只需将Moderna想要针对的任何病毒的基因序列插入其基本mRNA平台。这不仅有助于攻击不同的新冠肺炎病毒株，还意味着Moderna有能力使用任何病毒的序列，无论是流感、艾滋病毒、巨细胞病毒、结核病、寨卡病毒还是狂犬病，并快速生产出可供测试的疫苗。</blockquote></p><p><b>COVID-19 Progress</b></p><p><blockquote><b>COVID-19进展</b></blockquote></p><p>COVID-19 has totally changed the fortunes of Moderna within just two years. Up until 2020, Moderna was only a little-known drug research outfit that had very little revenues but being the second company to bring a viable vaccine to protect against COVID-19 into US markets, has made Moderna very widely known worldwide and the company has built a huge brand that is on the verge of becoming a giant within the drug industry.</p><p><blockquote>新冠肺炎在短短两年内彻底改变了Moderna的命运。直到2020年，Moderna只是一家鲜为人知的药物研究机构，收入很少，但作为第二家将针对COVID-19的可行疫苗引入美国市场的公司，Moderna在全球范围内广为人知，该公司已经建立了一个巨大的品牌，即将成为制药行业的巨头。</blockquote></p><p>There is real world evidence that up until now, Moderna has produced the most effective COVID-19 vaccine. Data from all over the world supports the very strong efficacy that was shown in phase III data in the USA. Recently, Singapore released data showing that COVID-19 deaths were lowest among Moderna takers. Singapore had 802 deaths out of which 70% were unvaccinated. Between Moderna, Pfizer-BioNTech, Sinopharm and Sinovac vaccines, Moderna had the least death rates:</p><p><blockquote>有现实世界的证据表明，到目前为止，Moderna已经生产出了最有效的新冠肺炎疫苗。来自世界各地的数据支持美国III期数据显示的非常强的疗效。最近，新加坡发布的数据显示，Moderna服用者中新冠肺炎死亡人数最低。新加坡有802人死亡，其中70%未接种疫苗。在Moderna、辉瑞-BioNTech、国药控股和科兴疫苗之间，Moderna的死亡率最低：</blockquote></p><p><ul><li>11 deaths per 100,000: Sinovac</li><li>7.8 deaths per 100,000: Sinopharm</li><li>6.2 deaths per 100,000: Pfizer/BioNTech</li><li>1 death per 100,000: Moderna</li></ul>Over the course of 2021, Moderna shipped 807 million doses of Spikevax, Moderna&#39;s COVID-19 vaccine, to many different locations around the world, with around 25% of those doses going to low-income and middle-income countries. Moderna reported recently during the JPMorgan 40th Annual Healthcare Conference on January 10th, that the preliminary estimate for Spikevax product sales in 2021 is around $17.5 billion.</p><p><blockquote><ul><li>每10万人中有11人死亡：科兴</li><li>每10万人中有7.8人死亡：国药集团</li><li>每100,000人中有6.2人死亡：辉瑞/BioNTech</li><li>每10万人中有1人死亡：Moderna</li></ul>2021年期间，Moderna向世界各地运送了8.07亿剂Moderna的COVID-19疫苗Spikevax，其中约25%运往低收入和中等收入国家。Moderna最近在1月10日摩根大通第40届年度医疗保健会议上报告称，2021年Spikevax产品销售额的初步估计约为175亿美元。</blockquote></p><p>Because of the huge demand for Moderna&#39;s vaccine worldwide, for a decent part of 2021, the company was supply constrained but that situation is beginning to turn around now. Moderna CEO Stephane Bancel attributes the reason for supply constraints as Moderna having a higher dose than the Pfizer-BioNTech vaccine. The higher dose was a big drain on manufacturing resources. Moderna has since built out additional manufacturing capacity over the course of 2021 and is now in much better shape to address COVID-19 demand. In Q4, Moderna shipped 300 million doses, which is a run rate of 1.2 billion doses. Moderna believes that they can produce two billion to three billion doses of boosters over the course of 2022, if necessary.</p><p><blockquote>由于全球对Moderna疫苗的巨大需求，在2021年的相当一部分时间里，该公司的供应受到限制，但这种情况现在开始扭转。Moderna首席执行官Stephane Bancel将供应限制的原因归因于Moderna的剂量高于辉瑞-BioNTech疫苗。较高的剂量会极大地消耗制造资源。此后，Moderna在2021年期间建立了额外的制造能力，现在能够更好地满足COVID-19的需求。第四季度，Moderna出货量为3亿剂，运行率为12亿剂。Moderna认为，如果有必要，他们可以在2022年生产20亿至30亿剂加强剂。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f41315e4b985027121aaf2dfca75dc71\" tg-width=\"640\" tg-height=\"356\" width=\"100%\" height=\"auto\"/><span>Moderna Spikevax advanced purchase agreements</span></p><p><blockquote><p class=\"t-img-caption\"><span>Moderna Spikevax提前购买协议</span></p></blockquote></p><p></p><p>Because COVID-19 vaccine makers have lately been having to play whack-a-mole with new variants, the demand for Spikevax is still rising. As can be seen from the above graphic, from November 4th to January 10th, Moderna has gained and additional $1.5 billion in advanced purchase agreements (&#34;APA&#34;) and $0.5 Billion in options, with those numbers being mostly heavily weighted toward the first half of the year. Moderna is still having ongoing discussions with many countries about whether additional vaccines will need to be added to address the fall moving into winter of &#39;22. I expect that when all is said and done, Moderna could wind up signing additional APAs over the course of the year. So, it looks like 2022 might again be another banner year for Moderna.</p><p><blockquote>由于COVID-19疫苗制造商最近不得不与新变种玩打地鼠游戏，因此对Spikevax的需求仍在上升。从上图可以看出，从11月4日到1月10日，Moderna额外获得了15亿美元的预购协议（“APA”）和5亿美元的期权，这些数字大多在上半年占很大比重。年。Moderna仍在与许多国家进行讨论，讨论是否需要添加额外的疫苗来应对22年秋季进入冬季的问题。我预计，当该说的都说了，该做的都做了，Moderna可能会在今年签署更多的APA。因此，看起来2022年可能会再次成为Moderna的又一个辉煌的一年。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e1246421e026d6fd58bec48546a19260\" tg-width=\"640\" tg-height=\"362\" width=\"100%\" height=\"auto\"/><span>How COVID-19 is likely to evolve</span></p><p><blockquote><p class=\"t-img-caption\"><span>COVID-19可能如何演变</span></p></blockquote></p><p>Currently, the world is in the midst of variant reinfection waves, which will likely continue throughout 2022 but by 2023 COVID-19 should become more seasonal and endemic. Morbidity waves are expected to become lower and lower over the next several years and there is a good chance that COVID-19 will be seen more like the flu is perceived today within a year or two. Post-pandemic, COVID-19 is expected to mostly only affect people aged 50-plus, health care workers, immunocompromised people and other high-risk populations. These groups will likely need boosters to ensure that they do not get severe disease and hospitalization. As COVID-19 winds down, demand for Spikevax will probably begin dropping in the 2023-to-2024-time frame. This is why some people have been predicting revenue declines for Moderna. Well, what is Moderna&#39;s post pandemic plan to replace the likely COVID-19 vaccine declining revenues?</p><p><blockquote>目前，世界正处于变异再感染浪潮中，这可能会持续到2022年，但到2023年，新冠肺炎应该会变得更加季节性和地方性。预计未来几年发病率会越来越低，一两年内，新冠肺炎很有可能会更像今天的流感。大流行后，新冠肺炎预计主要只影响50岁以上的人、医护人员、免疫功能低下的人和其他高危人群。这些群体可能需要加强剂，以确保他们不会患上严重疾病和住院。随着COVID-19的消退，对Spikevax的需求可能会在2023年至2024年期间开始下降。这就是为什么有人一直预测Moderna的收入会下降。那么，Moderna的后疫情计划是什么，以取代可能下降的新冠肺炎疫苗收入？</blockquote></p><p><b>Moderna&#39;s Plan Moving Forward</b></p><p><blockquote><b>Moderna的计划向前推进</b></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a9965c1224ac3e57e5a4c764bbb50975\" tg-width=\"640\" tg-height=\"360\" width=\"100%\" height=\"auto\"/><span>Moderna Product Strategy in 2022</span></p><p><blockquote><p class=\"t-img-caption\"><span>Moderna 2022年产品策略</span></p></blockquote></p><p>The initial way that Moderna plans on countering the likely COVID-19 vaccine decline is by bundling different seasonal respiratory vaccines together into just one vaccine. The days of getting COVID-19 specific vaccine seem to be waning and a pan-respiratory vaccine will likely compete extremely effectively with any laggards coming to the market late with only a COVID-19 solution.</p><p><blockquote>Moderna计划应对新冠肺炎疫苗可能下降的最初方法是将不同的季节性呼吸道疫苗捆绑在一起，形成一种疫苗。获得新冠肺炎特定疫苗的日子似乎正在过去，泛呼吸道疫苗可能会非常有效地与任何只有新冠肺炎解决方案才进入市场的落后者竞争。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4995949c9a253ebe6663e2deeb5ccce3\" tg-width=\"640\" tg-height=\"360\" width=\"100%\" height=\"auto\"/><span>Moderna vision for pan-respiratory vaccine</span></p><p><blockquote><p class=\"t-img-caption\"><span>Moderna泛呼吸道疫苗愿景</span></p></blockquote></p><p>Moderna&#39;s vision is that an annual single-dose pan-respiratory booster can be customized to fit different demographics, different geographies, and different respiratory diseases over time. Eventually, Moderna even expects to target specific strains of respiratory diseases in specific regions. I wouldn&#39;t be surprised if a pan-respiratory vaccine starts to appear within two years.</p><p><blockquote>Moderna的愿景是，随着时间的推移，可以定制年度单剂量泛呼吸加强剂，以适应不同的人口统计、不同的地理位置和不同的呼吸道疾病。最终，Moderna甚至希望针对特定地区的特定呼吸道疾病毒株。如果泛呼吸道疫苗在两年内开始出现，我不会感到惊讶。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/eb027ec45a0750fdcd8b65307c4008d1\" tg-width=\"640\" tg-height=\"359\" width=\"100%\" height=\"auto\"/><span>Moderna Strategy After COVID-19</span></p><p><blockquote><p class=\"t-img-caption\"><span>COVID-19后的Moderna战略</span></p></blockquote></p><p>Unlike vaccine technology from companies like Novavax (NASDAQ:NVAX), mRNA can be used for many other different purposes besides infectious diseases.Novavax&#39;s pipeline only consists of 9 programs that target 5 other infectious diseases other than COVID-19. Most of Novavax&#39;s pipeline is mostly concerned with respiratory diseases, with only one direct contact latent virus, Ebola, appearing on the list.</p><p><blockquote>与Novavax（纳斯达克股票代码：NVAX）等公司的疫苗技术不同，mRNA可用于传染病之外的许多其他不同目的。Novavax的管道仅包括9个项目，针对除COVID-19以外的5种其他传染病。Novavax的大部分管道主要与呼吸道疾病有关，只有一种直接接触的潜伏病毒Ebola出现在名单上。</blockquote></p><p>In contrast, Moderna is much further ahead in developing solutions against multiple latent viruses that are a lot more prevalent than Ebola. The first ones being targeted and are already in clinical trials are CMV and EBV, with HIV soon to begin trials. CMV is Moderna&#39;s most advanced drug in the pipeline and the first patient has already been dosed in phase III trials. Besides CMV, EBV, and HIV, there a many other undisclosed latent viruses being worked on in the labs.</p><p><blockquote>相比之下，Moderna在开发针对多种潜伏病毒的解决方案方面遥遥领先，这些病毒比埃博拉病毒流行得多。第一批被瞄准并已经进入临床试验的是巨细胞病毒和EBV，HIV很快就会开始试验。CMV是Moderna在研发中最先进的药物，第一位患者已经在III期试验中接受了给药。除了CMV、EBV和HIV，还有许多其他未公开的潜伏病毒正在实验室中研究。</blockquote></p><p></p><p>The next area that Moderna is prioritizing is in developing therapeutics using mRNA technology which allows the company to produce oncology products, cardio products, rare genetic disease products and autoimmune disease products. This is an area that has significant upside for Moderna. Moderna will be using totally new approaches to develop solutions against cancer and develop solutions for diseases that currently have no significant solutions. Recently, Moderna formed a partnership with Carisma Therapeutics. Moderna plans to combine its mRNA technology with Carisma Therapeutics&#39; engineered macrophage technology to develop solutions against solid tumor cancer. The reason why this is important is because while autologous CAR-Ts have really good data in Heme malignancies, which are blood cancers, they have not been very effective in solid tumors and eighty percent of cancer patients die of solid tumors. I won&#39;t go deep into the science behind it but scientist know the reasons why CAR-Ts are not as effective with solid tumors, and both companies think Carisma Therapeutics&#39; CAR-Macrophage&#39;s technology combined with mRNA technology can produce revolutionary new ways to essentially cure the most prevalent and difficult to treat form of cancer deaths which are solid tumors.</p><p><blockquote>Moderna优先考虑的下一个领域是使用mRNA技术开发疗法，该技术使该公司能够生产肿瘤产品、心脏产品、罕见遗传病产品和自身免疫性疾病产品。对于Moderna来说，这是一个具有巨大优势的领域。Moderna将使用全新的方法来开发抗癌解决方案，并为目前没有重要解决方案的疾病开发解决方案。最近，Moderna与Carisma Therapeutics建立了合作伙伴关系。Moderna计划将其mRNA技术与Carisma Therapeutics的工程巨噬细胞技术相结合，开发针对实体瘤癌症的解决方案。这一点之所以重要，是因为虽然自体CAR-T在血红素恶性肿瘤（血癌）中有非常好的数据，但它们在实体瘤中并不是很有效，80%的癌症患者死于实体瘤。我不会深入探讨其背后的科学，但科学家知道CAR-T对实体瘤不那么有效的原因，两家公司都认为Carisma Therapeutics的CAR-Macrophage技术与mRNA技术相结合可以产生革命性的新方法，从根本上治愈最普遍和最难治疗的癌症死亡形式，即实体瘤。</blockquote></p><p>Moderna&#39;s deep expertise in mRNA and LNP technologies opens up a potentially game-changing opportunity for engineered macrophages. In vivo delivery directly to monocytes and macrophages enables an off-the-shelf therapeutic approach that uses the patients&#39; own cells to provide a truly personalized treatment.Source: Steven Kelly, President and Chief Executive Officer of CarismaRight now, there is no way to factor in the upside of Moderna potentially developing a significantly better solution to attacking and possibly curing solid tumor cancer. The therapies that could come out of partnerships like the one Moderna has with Carisma could potentially produce home runs just as big, if not bigger than the COVID-19 vaccine.</p><p><blockquote>Moderna在mRNA和LNP技术方面的深厚专业知识为工程巨噬细胞带来了潜在的改变游戏规则的机会。体内直接递送至单核细胞和巨噬细胞实现了使用患者自身细胞提供真正个性化治疗的现成治疗方法。资料来源：Steven Kelly，CarismaRight总裁兼首席执行官现在，没有办法考虑到Moderna可能开发出一种明显更好的解决方案来攻击并可能治愈实体瘤癌症的优势。像Moderna与Carisma这样的合作伙伴关系可能产生的疗法可能会产生与COVID-19疫苗一样大的本垒打，如果不是更大的话。</blockquote></p><p>The fourth area that Moderna is developing solutions using gene-editing enzymes. Moderna has only seriously got into gene editing relatively recently when the company signed a collaboration with Metagenomi. For those unaware,gene-editing is the same strategy that companies like Editas (NASDAQ:EDIT) and CRISPR Therapeutics (NASDAQ:CRSP) are pursuing. The focus for the Metagenomi collaboration will be on serious genetic diseases.</p><p><blockquote>Moderna正在开发使用基因编辑酶的解决方案的第四个领域。Moderna直到最近才认真涉足基因编辑领域，当时该公司与Metagenomi签署了合作协议。对于那些不知道的人来说，基因编辑与Editas（纳斯达克：EDIT）和CRISPR Therapeutics（纳斯达克：CRSP）等公司正在追求的策略相同。宏基因组学合作的重点将是严重的遗传疾病。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8041f6f8edad22795cbe4a3295d68973\" tg-width=\"640\" tg-height=\"361\" width=\"100%\" height=\"auto\"/><span>Moderna capital allocation priorities</span></p><p><blockquote><p class=\"t-img-caption\"><span>Moderna资本配置优先事项</span></p></blockquote></p><p>Moderna has already started spending its huge cash flows derived from COVID-19 vaccine sales. I just wanted to include the above slide in this article because it shows that Moderna&#39;s number one capital allocation priority is investing in R&amp;D, manufacturing infrastructure and continuing to build out the company&#39;s commercial infrastructure. The second priority is investing in external investment opportunities, either in the form of collaborations or M&amp;A. The collaborations with Metagenomi and Carisma Therapeutics are examples of this second priority.</p><p><blockquote>Moderna已经开始花费其从COVID-19疫苗销售中获得的巨额现金流。我只是想将上面的幻灯片包含在本文中，因为它表明Moderna的头号资本配置优先事项是投资研发、制造基础设施并继续建设公司的商业基础设施。第二个优先事项是投资外部投资机会，无论是以合作还是并购的形式。与Metagenomi和Carisma Therapeutics的合作就是第二个优先事项的例子。</blockquote></p><p><b>Manufacturing Capacity</b></p><p><blockquote><b>制造能力</b></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/36484ebc09cffbacbfa8ce06eea49f22\" tg-width=\"640\" tg-height=\"357\" width=\"100%\" height=\"auto\"/><span>Moderna In-country vaccine manufacturing</span></p><p><blockquote><p class=\"t-img-caption\"><span>Moderna国内疫苗生产</span></p></blockquote></p><p>There is a rather large set of existing potential competitors to Moderna and there are also countries like India that are supporting rising home-grown mRNA platform companies. One of the ways that Moderna is keeping ahead of such efforts from competitors is using its $15.3 billion in cash and $3.2 billion in Free Cash Flow at the end of Q3, to build out significant mRNA manufacturing capability across the world. Moderna has announced in principle agreements with Australia and Canadato build out mRNA vaccine manufacturing plants within those countries. These announcements are in addition to the plans to build a factory capable of producing up to 500 million vaccine doses in Africa each year. I believe Moderna is still in the process of choosing which African country the manufacturing site will be located in.</p><p><blockquote>Moderna现有的潜在竞争对手相当多，也有像印度这样的国家正在支持崛起的本土mRNA平台公司。Moderna领先于竞争对手的方法之一是利用第三季度末的153亿美元现金和32亿美元自由现金流，在全球范围内建立重要的mRNA制造能力。Moderna已宣布原则上与澳大利亚和加拿大达成协议，在这些国家建立mRNA疫苗制造厂。这些公告是对在非洲建立一个每年能够生产多达5亿剂疫苗的工厂的计划的补充。我相信Moderna仍在选择生产基地将设在哪个非洲国家。</blockquote></p><p><b>Risks</b></p><p><blockquote><b>风险</b></blockquote></p><p>The major risk that Moderna faces in the short term is revenue from the COVID-19 declining faster than Moderna can get other vaccines or therapies on to market and show superior results. The closest drug to approval is a CMV vaccine. An approval of the CMV vaccine would likely shoot Moderna&#39;s stock higher because it would show that mRNA is viable for addressing other diseases. A CMV rejection would likely drop Moderna&#39;s stock much lower.</p><p><blockquote>Moderna短期内面临的主要风险是来自COVID-19的收入下降速度快于Moderna将其他疫苗或疗法推向市场并显示出卓越效果的速度。最接近批准的药物是巨细胞病毒疫苗。CMV疫苗的批准可能会推高Moderna的股价，因为它将表明mRNA对于治疗其他疾病是可行的。CMV被拒绝可能会导致Moderna的股价大幅下跌。</blockquote></p><p></p><p>Another major risk for Moderna are patent disputes and lawsuits. Moderna recently had to back down in a dispute with the NIH over COVID-19 patents and Moderna could also soon face a patent infringement lawsuit from Arbutus (NASDAQ:ABUS) over the COVID-19 vaccine. Currently, it is unknown how these disputes will impact Moderna over the longer term.</p><p><blockquote>Moderna面临的另一个主要风险是专利纠纷和诉讼。Moderna最近不得不在与NIH关于COVID-19专利的纠纷中让步，Moderna也可能很快面临Arbutus（纳斯达克：ABUS）关于COVID-19疫苗的专利侵权诉讼。目前，尚不清楚这些纠纷将如何长期影响Moderna。</blockquote></p><p><b>Analyst Price Targets</b></p><p><blockquote><b>分析师目标价</b></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0c0e5d79d00e415b16e4141b35eaaad4\" tg-width=\"461\" tg-height=\"416\" width=\"100%\" height=\"auto\"/><span>Moderna Analyst Price Targets</span></p><p><blockquote><p class=\"t-img-caption\"><span>Moderna分析师价格目标</span></p></blockquote></p><p>The above is based on 15 Wall Street analysts offering 12-month price targets for Moderna in the last 3 months. The average price target is $289.07 with a high forecast of $506.00 and a low forecast of $86.00. The average price target represents a 38% increase from the last price of $210.17.</p><p><blockquote>以上是基于15位华尔街分析师在过去3个月内为Moderna提供的12个月目标价。平均目标价为289.07美元，高预测为506.00美元，低预测为86.00美元。平均目标价较上次价格210.17美元上涨38%。</blockquote></p><p><b>Valuation</b></p><p><blockquote><b>估值</b></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/19ae061dd4c060bb37f43ff041dc2577\" tg-width=\"635\" tg-height=\"450\" width=\"100%\" height=\"auto\"/><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4ff983411a9b9571f66378eddc98653c\" tg-width=\"635\" tg-height=\"450\" width=\"100%\" height=\"auto\"/><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/259a902789541a798fdf388cf46d6b37\" tg-width=\"635\" tg-height=\"450\" width=\"100%\" height=\"auto\"/><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p>The comparisons between these three relatively new biotechs with COVID-19 vaccines already shipping, shows Moderna is the most highly valued stock but BioNTech has the best revenue growth and operating margins. Going strictly by value, BioNTech is probably the best buy but in reality, all three companies are biotechs, in which one hit product or one large dismal failure can change the fortunes of the company. I view all three companies as very speculative, even with the success achieved by producing solutions for the COVID-19 pandemic.</p><p><blockquote>这三种相对较新的生物技术公司与已经发货的COVID-19疫苗之间的比较表明，Moderna是估值最高的股票，但BioNTech拥有最好的收入增长和营业利润率。严格按照价值计算，BioNTech可能是最好的选择，但实际上，这三家公司都是生物技术公司，一个热门产品或一次惨淡的失败就可以改变公司的命运。我认为这三家公司都非常投机，尽管它们通过为COVID-19大流行提供解决方案取得了成功。</blockquote></p><p>I am not a big fan of trying to use valuation techniques on any biotech company. There is simply no way to value the future potential success or failure of the bets that many biotech companies make. If Moderna is part of curing solid tumor cancer, for instance, Moderna&#39;s current valuation will be viewed in hindsight as being way too low. If most of Moderna&#39;s pipeline fails then the valuation will be viewed in hindsight as being way too high.</p><p><blockquote>我不太喜欢尝试对任何生物技术公司使用估值技术。根本没有办法评估许多生物技术公司所下的赌注未来潜在的成功或失败。例如，如果Moderna是治疗实体瘤癌症的一部分，那么Moderna目前的估值事后会被认为太低。如果Moderna的大部分产品线都失败了，那么事后看来，估值将被视为过高。</blockquote></p><p><b>Conclusion</b></p><p><blockquote><b>结论</b></blockquote></p><p>Moderna is a high risk, high reward bet on mRNA technology succeeding in either preventing or curing many difficult to treat diseases. This is a stock that is strictly for long-term aggressive growth investors that are interested in speculating on potential home-run type products over a five-to-ten-year time frame. The risk that Moderna is only a one-product company is somewhat mitigated by the fact that the efficacy of the COVID-19 vaccine was so high, that is serves as a kind of proof of concept that a mRNA platform can produce other novel ways of addressing other difficult diseases.</p><p><blockquote>Moderna是对mRNA技术的高风险、高回报赌注，成功预防或治愈许多难以治疗的疾病。这是一只严格适合长期激进增长投资者的股票，他们有兴趣在五到十年的时间范围内投机潜在的本垒打型产品。Moderna只是一家单一产品公司的风险在一定程度上被COVID-19疫苗的功效如此之高这一事实所缓解，即mRNA平台可以产生其他新方法来解决其他疑难疾病。</blockquote></p><p>The 58% pullback from Moderna&#39;s all-time high of $497.49 gives aggressive growth investors a chance to buy into a company with significant potential upside. However, risk averse or investors sensitive to short-term price movements should avoid Moderna&#39;s stock for now because there is significant downside risk if COVID-19 revenue drops off too rapidly before Moderna can show that it can achieve similar success in addressing other diseases.</p><p><blockquote>Moderna较497.49美元的历史高点回调58%，为激进的增长投资者提供了买入一家具有巨大潜在上涨空间的公司的机会。然而，规避风险或对短期价格变动敏感的投资者目前应避开Moderna的股票，因为如果在Moderna证明它可以在解决其他疾病方面取得类似成功之前，COVID-19收入下降过快，则存在巨大的下行风险。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna: High Upside Potential At Current Prices<blockquote>Moderna：当前价格上涨潜力巨大</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna: High Upside Potential At Current Prices<blockquote>Moderna：当前价格上涨潜力巨大</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2022-01-17 17:42</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body><b>Summary</b></p><p><blockquote><html><head></head><body><b>总结</b></body></html></blockquote></p><p><ul><li>Moderna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company&#39;s mRNA manufacturing capacity.</li><li>Moderna recently reported the preliminary COVID-19 estimate for product sales in 2021 as being approximately $17.5 billion.</li><li>Recently, Singapore released data showing that COVID-19 deaths were the lowest among Moderna vaccine takers.</li><li>One of the ways that Moderna is keeping ahead of potential mRNA competition is using its $15.3 billion in cash and $3.2 billion in Free Cash Flow to continue building out significant mRNA manufacturing capability across the world.</li><li>The 58% pullback from Moderna&#39;s all-time high of $497.49 gives aggressive growth investors a chance to buy into a company with significant upside potential.</li></ul><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/466434ab0d3291095a83741482c15948\" tg-width=\"1536\" tg-height=\"1024\" width=\"100%\" height=\"auto\"/><span>Maddie Meyer/Getty Images News</span></p><p><blockquote><ul><li>Moderna不仅开发了COVID-19疫苗，还扩大了公司的mRNA生产能力，从而拥有显着的先发竞争优势。</li><li>Moderna最近报告了COVID-19对2021年产品销售额的初步估计约为175亿美元。</li><li>近日，新加坡发布数据显示，Moderna疫苗接种者中新冠肺炎死亡人数最低。</li><li>Moderna在潜在的mRNA竞争中保持领先地位的方法之一是利用其153亿美元的现金和32亿美元的自由现金流继续在全球范围内建立重要的mRNA制造能力。</li><li>Moderna较497.49美元的历史高点回调58%，为激进的增长投资者提供了买入一家具有巨大上涨潜力的公司的机会。</li></ul><p class=\"t-img-caption\"><span>麦迪·迈耶/盖蒂图片社新闻</span></p></blockquote></p><p>Moderna (NASDAQ:MRNA) has extremely high upside from being a first mover in developing the world&#39;s most advanced mRNA platform. One of the most promising potential solutions for helping prevent or cure some of the most intractable diseases known to man is mRNA technology and Moderna has not only developed the most advanced mRNA platform but has also built out significant mRNA manufacturing capacity worldwide. There are many companies that are in various stages of developing mRNA technology but there are very few that have advanced as far as Moderna has in both developing mRNA technology, as well as having the manufacturing capacity and other commercial infrastructure to produce billions of doses of a vaccine per year. At this time, the only companies that have both the knowledge of advanced mRNA techniques and the manufacturing capacity to compete in the same arena as Moderna is the BioNTech (NASDAQ:BNTX) - Pfizer (NYSE:PFE) partnership.</p><p><blockquote>Moderna（纳斯达克：MRNA）作为开发世界上最先进的mRNA平台的先行者，具有极高的优势。mRNA技术是帮助预防或治愈人类已知的一些最棘手疾病的最有前途的潜在解决方案之一，Moderna不仅开发了最先进的mRNA平台，还在全球范围内建立了重要的mRNA制造能力。有许多公司处于开发mRNA技术的不同阶段，但很少有公司像Moderna那样在开发mRNA技术以及拥有生产数十亿剂疫苗的制造能力和其他商业基础设施方面取得了进步。每年的疫苗。目前，唯一同时拥有先进mRNA技术知识和制造能力与Moderna在同一舞台上竞争的公司是BioNTech（纳斯达克股票代码：BNTX）-辉瑞（纽约证券交易所股票代码：PFE）合作伙伴。</blockquote></p><p>Moderna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company&#39;s mRNA manufacturing capacity. It is one thing to produce mRNA in a lab setting but quite another to safely mass produce effective vaccines in regulator approved manufacturing sites around the world. Moderna&#39;s first mover advantage has translated into a very large war chest of cash from COVID-19 sales in which the company can use to further its lead by investing in advancing mRNA technology, improving mRNA manufacturing processes, and building out significant manufacturing capability worldwide. Moderna is also well along in developing one of the deepest drug pipelines in the world.</p><p><blockquote>Moderna不仅开发了COVID-19疫苗，还扩大了公司的mRNA生产能力，从而拥有显着的先发竞争优势。在实验室环境中生产mRNA是一回事，但在世界各地监管机构批准的生产基地安全地大规模生产有效的疫苗则完全是另一回事。Moderna的先发优势已转化为来自COVID-19销售的巨额现金，该公司可以通过投资推进mRNA技术、改进mRNA制造工艺以及在全球范围内建立强大的制造能力来进一步保持领先地位。Moderna在开发世界上最深的药物管道之一方面也进展顺利。</blockquote></p><p>While a first mover advantage is not exactly a moat, for the next several years at least, Moderna should enjoy a significant lead in developing many different mRNA-based therapies or vaccines to treat numerous difficult to treat diseases. Moderna currently has 40 different drug development programs, which is almost unheard of for such a relatively young biotech company that only two years ago was simply a research outfit. In the end, Moderna&#39;s mRNA platform and manufacturing capacity should result in significant long-term upside for investors buying into Moderna&#39;s stock today.</p><p><blockquote>虽然先发优势并不完全是护城河，但至少在未来几年内，Moderna应该在开发许多不同的基于mRNA的疗法或疫苗来治疗许多难以治疗的疾病方面享有显着的领先地位。Moderna目前拥有40个不同的药物开发项目，对于这样一家相对年轻的生物技术公司来说，这几乎是闻所未闻的，两年前它还只是一个研究机构。最终，Moderna的mRNA平台和制造能力应该会给今天购买Moderna股票的投资者带来显着的长期上涨空间。</blockquote></p><p>Advantages of mRNA Technology</p><p><blockquote>mRNA技术的优势</blockquote></p><p>The reason why Moderna was able to rapidly develop a COVID-19 solution, while at the same time continuing to build out a significant number of drug development programs is because of the nature of mRNA technology.</p><p><blockquote>Moderna之所以能够快速开发出COVID-19解决方案，同时继续建立大量药物开发项目，是因为mRNA技术的性质。</blockquote></p><p>The development and manufacturing of mRNA for use as therapeutics<i>and</i>vaccines are comparatively simple, scalable<i>and</i>extremely rapid.Source:Millapore SigmaThere are numerous advantages of a mRNA platform over traditional drug making. The major advantages of a mRNA platform that were demonstrated by the response to the COVID-19 pandemic was the ability to take the sequence of the virus and quickly move from development, to clinical trials, to approval, to mass manufacturing of a vaccine in a very rapid period of time. As Moderna and others get more experience and regulatory bodies get more comfortable with mRNA technology, I can see the day in the future where the response time of discovery of a virulent virus to clinical trials of a vaccine, to vaccine approval, to mass manufacturing of the vaccine could significantly shrink. Right now, it looks like it takes about 9 months to a year to move from virus discovery to eventually making it into people&#39;s arms. Eventually, this response time could shrink to matter of a few months.</p><p><blockquote>用作治疗剂的mRNA的开发和制造<i>和</i>疫苗相对简单、可扩展<i>和</i>速度极快。资料来源：Millapore Sigma与传统药物制造相比，mRNA平台有许多优势。对新冠肺炎疫情的反应证明了mRNA平台的主要优势，即能够获取病毒序列，并在非常短的时间内快速从开发、临床试验、批准到大规模生产疫苗。随着Moderna等人获得更多经验，监管机构对mRNA技术的使用更加舒适，我可以看到未来一天，发现一种毒力病毒对疫苗临床试验、疫苗审批、疫苗大规模生产的反应时间可能会明显缩短。现在看来，从病毒发现到最终投入人们的怀抱，大约需要9个月到一年的时间。最终，这个响应时间可能会缩短到几个月。</blockquote></p><p></p><p>Omnicron was first identified as a variant around November 24, 2021. Moderna CEO Stéphane Bancel said in a CNBC interview that clinical trials for an Omnicron vaccine will start soon and a Omnicron vaccine should be available by fall. This type of rapid response to infectious diseases is unheard of before now and as time goes along, mRNA platform companies could not only become proficient in rapidly producing vaccines against specific viruses but also become proficient at producing vaccines against specific strains of a virus, in specific regions of the world. Among the reason why I think Moderna is building manufacturing capacity in different countries and regions of the world is because vaccines will eventually be less of a one size fits all countries and be more along the lines of regional manufacturing sites creating vaccines specific for the most prevalent viruses and strains of virus in that specific region.</p><p><blockquote>Omnicron在2021年11月24日左右首次被确定为变种。Moderna首席执行官Stéphane Bancel在接受CNBC采访时表示，Omnicron疫苗的临床试验将很快开始，Omnicron疫苗应该会在秋季上市。这种对传染病的快速反应在以前是闻所未闻的，随着时间的推移，mRNA平台公司不仅可以熟练快速生产针对特定病毒的疫苗，还可以熟练生产针对特定病毒株的疫苗，在世界的特定地区。我认为Moderna正在世界不同国家和地区建设生产能力的原因之一是，疫苗最终将不再是一刀切的，而是更多地沿着区域生产基地的路线，为该特定地区最流行的病毒和病毒株生产特定疫苗。</blockquote></p><p>Another potential huge advantage of a mRNA platform is flexibility. Theoretically, a mRNA manufacturing plant can be relatively rapidly switched to producing any other mRNA-based drug. It is possible that a mRNA plant that makes COVID-19 vaccines could be rapidly switched to making an Ebola vaccine, for instance. This is in contrast to the manufacturing process of many traditional drugs that require a dedicated plant to produce a drug. This could make the CapEx involved for producing multiple different types of drugs, far lower than a traditional drug manufacturer.</p><p><blockquote>mRNA平台的另一个潜在的巨大优势是灵活性。理论上，mRNA制造厂可以相对快速地转向生产任何其他基于mRNA的药物。例如，生产COVID-19疫苗的mRNA工厂可能会迅速转向生产埃博拉疫苗。这与许多传统药物的制造过程形成对比，传统药物需要专门的工厂来生产药物。这可能会使生产多种不同类型药物的资本支出远低于传统药品制造商。</blockquote></p><p>The COVID-19 pandemic has highlighted exactly how easy it is to change the vaccine simply by plugging the genetic sequence of any virus that Moderna wants to target right into its basic mRNA platform. This is not only useful for being able to attack different strains of COVID-19 but also means that Moderna has the ability of using the sequence of any virus whether that be the flu, HIV, CMV, Tuberculosis, Zika, or Rabies and quickly produce a vaccine ready for testing.</p><p><blockquote>新冠肺炎·疫情强调了改变疫苗是多么容易，只需将Moderna想要针对的任何病毒的基因序列插入其基本mRNA平台。这不仅有助于攻击不同的新冠肺炎病毒株，还意味着Moderna有能力使用任何病毒的序列，无论是流感、艾滋病毒、巨细胞病毒、结核病、寨卡病毒还是狂犬病，并快速生产出可供测试的疫苗。</blockquote></p><p><b>COVID-19 Progress</b></p><p><blockquote><b>COVID-19进展</b></blockquote></p><p>COVID-19 has totally changed the fortunes of Moderna within just two years. Up until 2020, Moderna was only a little-known drug research outfit that had very little revenues but being the second company to bring a viable vaccine to protect against COVID-19 into US markets, has made Moderna very widely known worldwide and the company has built a huge brand that is on the verge of becoming a giant within the drug industry.</p><p><blockquote>新冠肺炎在短短两年内彻底改变了Moderna的命运。直到2020年，Moderna只是一家鲜为人知的药物研究机构，收入很少，但作为第二家将针对COVID-19的可行疫苗引入美国市场的公司，Moderna在全球范围内广为人知，该公司已经建立了一个巨大的品牌，即将成为制药行业的巨头。</blockquote></p><p>There is real world evidence that up until now, Moderna has produced the most effective COVID-19 vaccine. Data from all over the world supports the very strong efficacy that was shown in phase III data in the USA. Recently, Singapore released data showing that COVID-19 deaths were lowest among Moderna takers. Singapore had 802 deaths out of which 70% were unvaccinated. Between Moderna, Pfizer-BioNTech, Sinopharm and Sinovac vaccines, Moderna had the least death rates:</p><p><blockquote>有现实世界的证据表明，到目前为止，Moderna已经生产出了最有效的新冠肺炎疫苗。来自世界各地的数据支持美国III期数据显示的非常强的疗效。最近，新加坡发布的数据显示，Moderna服用者中新冠肺炎死亡人数最低。新加坡有802人死亡，其中70%未接种疫苗。在Moderna、辉瑞-BioNTech、国药控股和科兴疫苗之间，Moderna的死亡率最低：</blockquote></p><p><ul><li>11 deaths per 100,000: Sinovac</li><li>7.8 deaths per 100,000: Sinopharm</li><li>6.2 deaths per 100,000: Pfizer/BioNTech</li><li>1 death per 100,000: Moderna</li></ul>Over the course of 2021, Moderna shipped 807 million doses of Spikevax, Moderna&#39;s COVID-19 vaccine, to many different locations around the world, with around 25% of those doses going to low-income and middle-income countries. Moderna reported recently during the JPMorgan 40th Annual Healthcare Conference on January 10th, that the preliminary estimate for Spikevax product sales in 2021 is around $17.5 billion.</p><p><blockquote><ul><li>每10万人中有11人死亡：科兴</li><li>每10万人中有7.8人死亡：国药集团</li><li>每100,000人中有6.2人死亡：辉瑞/BioNTech</li><li>每10万人中有1人死亡：Moderna</li></ul>2021年期间，Moderna向世界各地运送了8.07亿剂Moderna的COVID-19疫苗Spikevax，其中约25%运往低收入和中等收入国家。Moderna最近在1月10日摩根大通第40届年度医疗保健会议上报告称，2021年Spikevax产品销售额的初步估计约为175亿美元。</blockquote></p><p>Because of the huge demand for Moderna&#39;s vaccine worldwide, for a decent part of 2021, the company was supply constrained but that situation is beginning to turn around now. Moderna CEO Stephane Bancel attributes the reason for supply constraints as Moderna having a higher dose than the Pfizer-BioNTech vaccine. The higher dose was a big drain on manufacturing resources. Moderna has since built out additional manufacturing capacity over the course of 2021 and is now in much better shape to address COVID-19 demand. In Q4, Moderna shipped 300 million doses, which is a run rate of 1.2 billion doses. Moderna believes that they can produce two billion to three billion doses of boosters over the course of 2022, if necessary.</p><p><blockquote>由于全球对Moderna疫苗的巨大需求，在2021年的相当一部分时间里，该公司的供应受到限制，但这种情况现在开始扭转。Moderna首席执行官Stephane Bancel将供应限制的原因归因于Moderna的剂量高于辉瑞-BioNTech疫苗。较高的剂量会极大地消耗制造资源。此后，Moderna在2021年期间建立了额外的制造能力，现在能够更好地满足COVID-19的需求。第四季度，Moderna出货量为3亿剂，运行率为12亿剂。Moderna认为，如果有必要，他们可以在2022年生产20亿至30亿剂加强剂。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f41315e4b985027121aaf2dfca75dc71\" tg-width=\"640\" tg-height=\"356\" width=\"100%\" height=\"auto\"/><span>Moderna Spikevax advanced purchase agreements</span></p><p><blockquote><p class=\"t-img-caption\"><span>Moderna Spikevax提前购买协议</span></p></blockquote></p><p></p><p>Because COVID-19 vaccine makers have lately been having to play whack-a-mole with new variants, the demand for Spikevax is still rising. As can be seen from the above graphic, from November 4th to January 10th, Moderna has gained and additional $1.5 billion in advanced purchase agreements (&#34;APA&#34;) and $0.5 Billion in options, with those numbers being mostly heavily weighted toward the first half of the year. Moderna is still having ongoing discussions with many countries about whether additional vaccines will need to be added to address the fall moving into winter of &#39;22. I expect that when all is said and done, Moderna could wind up signing additional APAs over the course of the year. So, it looks like 2022 might again be another banner year for Moderna.</p><p><blockquote>由于COVID-19疫苗制造商最近不得不与新变种玩打地鼠游戏，因此对Spikevax的需求仍在上升。从上图可以看出，从11月4日到1月10日，Moderna额外获得了15亿美元的预购协议（“APA”）和5亿美元的期权，这些数字大多在上半年占很大比重。年。Moderna仍在与许多国家进行讨论，讨论是否需要添加额外的疫苗来应对22年秋季进入冬季的问题。我预计，当该说的都说了，该做的都做了，Moderna可能会在今年签署更多的APA。因此，看起来2022年可能会再次成为Moderna的又一个辉煌的一年。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e1246421e026d6fd58bec48546a19260\" tg-width=\"640\" tg-height=\"362\" width=\"100%\" height=\"auto\"/><span>How COVID-19 is likely to evolve</span></p><p><blockquote><p class=\"t-img-caption\"><span>COVID-19可能如何演变</span></p></blockquote></p><p>Currently, the world is in the midst of variant reinfection waves, which will likely continue throughout 2022 but by 2023 COVID-19 should become more seasonal and endemic. Morbidity waves are expected to become lower and lower over the next several years and there is a good chance that COVID-19 will be seen more like the flu is perceived today within a year or two. Post-pandemic, COVID-19 is expected to mostly only affect people aged 50-plus, health care workers, immunocompromised people and other high-risk populations. These groups will likely need boosters to ensure that they do not get severe disease and hospitalization. As COVID-19 winds down, demand for Spikevax will probably begin dropping in the 2023-to-2024-time frame. This is why some people have been predicting revenue declines for Moderna. Well, what is Moderna&#39;s post pandemic plan to replace the likely COVID-19 vaccine declining revenues?</p><p><blockquote>目前，世界正处于变异再感染浪潮中，这可能会持续到2022年，但到2023年，新冠肺炎应该会变得更加季节性和地方性。预计未来几年发病率会越来越低，一两年内，新冠肺炎很有可能会更像今天的流感。大流行后，新冠肺炎预计主要只影响50岁以上的人、医护人员、免疫功能低下的人和其他高危人群。这些群体可能需要加强剂，以确保他们不会患上严重疾病和住院。随着COVID-19的消退，对Spikevax的需求可能会在2023年至2024年期间开始下降。这就是为什么有人一直预测Moderna的收入会下降。那么，Moderna的后疫情计划是什么，以取代可能下降的新冠肺炎疫苗收入？</blockquote></p><p><b>Moderna&#39;s Plan Moving Forward</b></p><p><blockquote><b>Moderna的计划向前推进</b></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a9965c1224ac3e57e5a4c764bbb50975\" tg-width=\"640\" tg-height=\"360\" width=\"100%\" height=\"auto\"/><span>Moderna Product Strategy in 2022</span></p><p><blockquote><p class=\"t-img-caption\"><span>Moderna 2022年产品策略</span></p></blockquote></p><p>The initial way that Moderna plans on countering the likely COVID-19 vaccine decline is by bundling different seasonal respiratory vaccines together into just one vaccine. The days of getting COVID-19 specific vaccine seem to be waning and a pan-respiratory vaccine will likely compete extremely effectively with any laggards coming to the market late with only a COVID-19 solution.</p><p><blockquote>Moderna计划应对新冠肺炎疫苗可能下降的最初方法是将不同的季节性呼吸道疫苗捆绑在一起，形成一种疫苗。获得新冠肺炎特定疫苗的日子似乎正在过去，泛呼吸道疫苗可能会非常有效地与任何只有新冠肺炎解决方案才进入市场的落后者竞争。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4995949c9a253ebe6663e2deeb5ccce3\" tg-width=\"640\" tg-height=\"360\" width=\"100%\" height=\"auto\"/><span>Moderna vision for pan-respiratory vaccine</span></p><p><blockquote><p class=\"t-img-caption\"><span>Moderna泛呼吸道疫苗愿景</span></p></blockquote></p><p>Moderna&#39;s vision is that an annual single-dose pan-respiratory booster can be customized to fit different demographics, different geographies, and different respiratory diseases over time. Eventually, Moderna even expects to target specific strains of respiratory diseases in specific regions. I wouldn&#39;t be surprised if a pan-respiratory vaccine starts to appear within two years.</p><p><blockquote>Moderna的愿景是，随着时间的推移，可以定制年度单剂量泛呼吸加强剂，以适应不同的人口统计、不同的地理位置和不同的呼吸道疾病。最终，Moderna甚至希望针对特定地区的特定呼吸道疾病毒株。如果泛呼吸道疫苗在两年内开始出现，我不会感到惊讶。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/eb027ec45a0750fdcd8b65307c4008d1\" tg-width=\"640\" tg-height=\"359\" width=\"100%\" height=\"auto\"/><span>Moderna Strategy After COVID-19</span></p><p><blockquote><p class=\"t-img-caption\"><span>COVID-19后的Moderna战略</span></p></blockquote></p><p>Unlike vaccine technology from companies like Novavax (NASDAQ:NVAX), mRNA can be used for many other different purposes besides infectious diseases.Novavax&#39;s pipeline only consists of 9 programs that target 5 other infectious diseases other than COVID-19. Most of Novavax&#39;s pipeline is mostly concerned with respiratory diseases, with only one direct contact latent virus, Ebola, appearing on the list.</p><p><blockquote>与Novavax（纳斯达克股票代码：NVAX）等公司的疫苗技术不同，mRNA可用于传染病之外的许多其他不同目的。Novavax的管道仅包括9个项目，针对除COVID-19以外的5种其他传染病。Novavax的大部分管道主要与呼吸道疾病有关，只有一种直接接触的潜伏病毒Ebola出现在名单上。</blockquote></p><p>In contrast, Moderna is much further ahead in developing solutions against multiple latent viruses that are a lot more prevalent than Ebola. The first ones being targeted and are already in clinical trials are CMV and EBV, with HIV soon to begin trials. CMV is Moderna&#39;s most advanced drug in the pipeline and the first patient has already been dosed in phase III trials. Besides CMV, EBV, and HIV, there a many other undisclosed latent viruses being worked on in the labs.</p><p><blockquote>相比之下，Moderna在开发针对多种潜伏病毒的解决方案方面遥遥领先，这些病毒比埃博拉病毒流行得多。第一批被瞄准并已经进入临床试验的是巨细胞病毒和EBV，HIV很快就会开始试验。CMV是Moderna在研发中最先进的药物，第一位患者已经在III期试验中接受了给药。除了CMV、EBV和HIV，还有许多其他未公开的潜伏病毒正在实验室中研究。</blockquote></p><p></p><p>The next area that Moderna is prioritizing is in developing therapeutics using mRNA technology which allows the company to produce oncology products, cardio products, rare genetic disease products and autoimmune disease products. This is an area that has significant upside for Moderna. Moderna will be using totally new approaches to develop solutions against cancer and develop solutions for diseases that currently have no significant solutions. Recently, Moderna formed a partnership with Carisma Therapeutics. Moderna plans to combine its mRNA technology with Carisma Therapeutics&#39; engineered macrophage technology to develop solutions against solid tumor cancer. The reason why this is important is because while autologous CAR-Ts have really good data in Heme malignancies, which are blood cancers, they have not been very effective in solid tumors and eighty percent of cancer patients die of solid tumors. I won&#39;t go deep into the science behind it but scientist know the reasons why CAR-Ts are not as effective with solid tumors, and both companies think Carisma Therapeutics&#39; CAR-Macrophage&#39;s technology combined with mRNA technology can produce revolutionary new ways to essentially cure the most prevalent and difficult to treat form of cancer deaths which are solid tumors.</p><p><blockquote>Moderna优先考虑的下一个领域是使用mRNA技术开发疗法，该技术使该公司能够生产肿瘤产品、心脏产品、罕见遗传病产品和自身免疫性疾病产品。对于Moderna来说，这是一个具有巨大优势的领域。Moderna将使用全新的方法来开发抗癌解决方案，并为目前没有重要解决方案的疾病开发解决方案。最近，Moderna与Carisma Therapeutics建立了合作伙伴关系。Moderna计划将其mRNA技术与Carisma Therapeutics的工程巨噬细胞技术相结合，开发针对实体瘤癌症的解决方案。这一点之所以重要，是因为虽然自体CAR-T在血红素恶性肿瘤（血癌）中有非常好的数据，但它们在实体瘤中并不是很有效，80%的癌症患者死于实体瘤。我不会深入探讨其背后的科学，但科学家知道CAR-T对实体瘤不那么有效的原因，两家公司都认为Carisma Therapeutics的CAR-Macrophage技术与mRNA技术相结合可以产生革命性的新方法，从根本上治愈最普遍和最难治疗的癌症死亡形式，即实体瘤。</blockquote></p><p>Moderna&#39;s deep expertise in mRNA and LNP technologies opens up a potentially game-changing opportunity for engineered macrophages. In vivo delivery directly to monocytes and macrophages enables an off-the-shelf therapeutic approach that uses the patients&#39; own cells to provide a truly personalized treatment.Source: Steven Kelly, President and Chief Executive Officer of CarismaRight now, there is no way to factor in the upside of Moderna potentially developing a significantly better solution to attacking and possibly curing solid tumor cancer. The therapies that could come out of partnerships like the one Moderna has with Carisma could potentially produce home runs just as big, if not bigger than the COVID-19 vaccine.</p><p><blockquote>Moderna在mRNA和LNP技术方面的深厚专业知识为工程巨噬细胞带来了潜在的改变游戏规则的机会。体内直接递送至单核细胞和巨噬细胞实现了使用患者自身细胞提供真正个性化治疗的现成治疗方法。资料来源：Steven Kelly，CarismaRight总裁兼首席执行官现在，没有办法考虑到Moderna可能开发出一种明显更好的解决方案来攻击并可能治愈实体瘤癌症的优势。像Moderna与Carisma这样的合作伙伴关系可能产生的疗法可能会产生与COVID-19疫苗一样大的本垒打，如果不是更大的话。</blockquote></p><p>The fourth area that Moderna is developing solutions using gene-editing enzymes. Moderna has only seriously got into gene editing relatively recently when the company signed a collaboration with Metagenomi. For those unaware,gene-editing is the same strategy that companies like Editas (NASDAQ:EDIT) and CRISPR Therapeutics (NASDAQ:CRSP) are pursuing. The focus for the Metagenomi collaboration will be on serious genetic diseases.</p><p><blockquote>Moderna正在开发使用基因编辑酶的解决方案的第四个领域。Moderna直到最近才认真涉足基因编辑领域，当时该公司与Metagenomi签署了合作协议。对于那些不知道的人来说，基因编辑与Editas（纳斯达克：EDIT）和CRISPR Therapeutics（纳斯达克：CRSP）等公司正在追求的策略相同。宏基因组学合作的重点将是严重的遗传疾病。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8041f6f8edad22795cbe4a3295d68973\" tg-width=\"640\" tg-height=\"361\" width=\"100%\" height=\"auto\"/><span>Moderna capital allocation priorities</span></p><p><blockquote><p class=\"t-img-caption\"><span>Moderna资本配置优先事项</span></p></blockquote></p><p>Moderna has already started spending its huge cash flows derived from COVID-19 vaccine sales. I just wanted to include the above slide in this article because it shows that Moderna&#39;s number one capital allocation priority is investing in R&amp;D, manufacturing infrastructure and continuing to build out the company&#39;s commercial infrastructure. The second priority is investing in external investment opportunities, either in the form of collaborations or M&amp;A. The collaborations with Metagenomi and Carisma Therapeutics are examples of this second priority.</p><p><blockquote>Moderna已经开始花费其从COVID-19疫苗销售中获得的巨额现金流。我只是想将上面的幻灯片包含在本文中，因为它表明Moderna的头号资本配置优先事项是投资研发、制造基础设施并继续建设公司的商业基础设施。第二个优先事项是投资外部投资机会，无论是以合作还是并购的形式。与Metagenomi和Carisma Therapeutics的合作就是第二个优先事项的例子。</blockquote></p><p><b>Manufacturing Capacity</b></p><p><blockquote><b>制造能力</b></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/36484ebc09cffbacbfa8ce06eea49f22\" tg-width=\"640\" tg-height=\"357\" width=\"100%\" height=\"auto\"/><span>Moderna In-country vaccine manufacturing</span></p><p><blockquote><p class=\"t-img-caption\"><span>Moderna国内疫苗生产</span></p></blockquote></p><p>There is a rather large set of existing potential competitors to Moderna and there are also countries like India that are supporting rising home-grown mRNA platform companies. One of the ways that Moderna is keeping ahead of such efforts from competitors is using its $15.3 billion in cash and $3.2 billion in Free Cash Flow at the end of Q3, to build out significant mRNA manufacturing capability across the world. Moderna has announced in principle agreements with Australia and Canadato build out mRNA vaccine manufacturing plants within those countries. These announcements are in addition to the plans to build a factory capable of producing up to 500 million vaccine doses in Africa each year. I believe Moderna is still in the process of choosing which African country the manufacturing site will be located in.</p><p><blockquote>Moderna现有的潜在竞争对手相当多，也有像印度这样的国家正在支持崛起的本土mRNA平台公司。Moderna领先于竞争对手的方法之一是利用第三季度末的153亿美元现金和32亿美元自由现金流，在全球范围内建立重要的mRNA制造能力。Moderna已宣布原则上与澳大利亚和加拿大达成协议，在这些国家建立mRNA疫苗制造厂。这些公告是对在非洲建立一个每年能够生产多达5亿剂疫苗的工厂的计划的补充。我相信Moderna仍在选择生产基地将设在哪个非洲国家。</blockquote></p><p><b>Risks</b></p><p><blockquote><b>风险</b></blockquote></p><p>The major risk that Moderna faces in the short term is revenue from the COVID-19 declining faster than Moderna can get other vaccines or therapies on to market and show superior results. The closest drug to approval is a CMV vaccine. An approval of the CMV vaccine would likely shoot Moderna&#39;s stock higher because it would show that mRNA is viable for addressing other diseases. A CMV rejection would likely drop Moderna&#39;s stock much lower.</p><p><blockquote>Moderna短期内面临的主要风险是来自COVID-19的收入下降速度快于Moderna将其他疫苗或疗法推向市场并显示出卓越效果的速度。最接近批准的药物是巨细胞病毒疫苗。CMV疫苗的批准可能会推高Moderna的股价，因为它将表明mRNA对于治疗其他疾病是可行的。CMV被拒绝可能会导致Moderna的股价大幅下跌。</blockquote></p><p></p><p>Another major risk for Moderna are patent disputes and lawsuits. Moderna recently had to back down in a dispute with the NIH over COVID-19 patents and Moderna could also soon face a patent infringement lawsuit from Arbutus (NASDAQ:ABUS) over the COVID-19 vaccine. Currently, it is unknown how these disputes will impact Moderna over the longer term.</p><p><blockquote>Moderna面临的另一个主要风险是专利纠纷和诉讼。Moderna最近不得不在与NIH关于COVID-19专利的纠纷中让步，Moderna也可能很快面临Arbutus（纳斯达克：ABUS）关于COVID-19疫苗的专利侵权诉讼。目前，尚不清楚这些纠纷将如何长期影响Moderna。</blockquote></p><p><b>Analyst Price Targets</b></p><p><blockquote><b>分析师目标价</b></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0c0e5d79d00e415b16e4141b35eaaad4\" tg-width=\"461\" tg-height=\"416\" width=\"100%\" height=\"auto\"/><span>Moderna Analyst Price Targets</span></p><p><blockquote><p class=\"t-img-caption\"><span>Moderna分析师价格目标</span></p></blockquote></p><p>The above is based on 15 Wall Street analysts offering 12-month price targets for Moderna in the last 3 months. The average price target is $289.07 with a high forecast of $506.00 and a low forecast of $86.00. The average price target represents a 38% increase from the last price of $210.17.</p><p><blockquote>以上是基于15位华尔街分析师在过去3个月内为Moderna提供的12个月目标价。平均目标价为289.07美元，高预测为506.00美元，低预测为86.00美元。平均目标价较上次价格210.17美元上涨38%。</blockquote></p><p><b>Valuation</b></p><p><blockquote><b>估值</b></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/19ae061dd4c060bb37f43ff041dc2577\" tg-width=\"635\" tg-height=\"450\" width=\"100%\" height=\"auto\"/><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4ff983411a9b9571f66378eddc98653c\" tg-width=\"635\" tg-height=\"450\" width=\"100%\" height=\"auto\"/><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/259a902789541a798fdf388cf46d6b37\" tg-width=\"635\" tg-height=\"450\" width=\"100%\" height=\"auto\"/><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p>The comparisons between these three relatively new biotechs with COVID-19 vaccines already shipping, shows Moderna is the most highly valued stock but BioNTech has the best revenue growth and operating margins. Going strictly by value, BioNTech is probably the best buy but in reality, all three companies are biotechs, in which one hit product or one large dismal failure can change the fortunes of the company. I view all three companies as very speculative, even with the success achieved by producing solutions for the COVID-19 pandemic.</p><p><blockquote>这三种相对较新的生物技术公司与已经发货的COVID-19疫苗之间的比较表明，Moderna是估值最高的股票，但BioNTech拥有最好的收入增长和营业利润率。严格按照价值计算，BioNTech可能是最好的选择，但实际上，这三家公司都是生物技术公司，一个热门产品或一次惨淡的失败就可以改变公司的命运。我认为这三家公司都非常投机，尽管它们通过为COVID-19大流行提供解决方案取得了成功。</blockquote></p><p>I am not a big fan of trying to use valuation techniques on any biotech company. There is simply no way to value the future potential success or failure of the bets that many biotech companies make. If Moderna is part of curing solid tumor cancer, for instance, Moderna&#39;s current valuation will be viewed in hindsight as being way too low. If most of Moderna&#39;s pipeline fails then the valuation will be viewed in hindsight as being way too high.</p><p><blockquote>我不太喜欢尝试对任何生物技术公司使用估值技术。根本没有办法评估许多生物技术公司所下的赌注未来潜在的成功或失败。例如，如果Moderna是治疗实体瘤癌症的一部分，那么Moderna目前的估值事后会被认为太低。如果Moderna的大部分产品线都失败了，那么事后看来，估值将被视为过高。</blockquote></p><p><b>Conclusion</b></p><p><blockquote><b>结论</b></blockquote></p><p>Moderna is a high risk, high reward bet on mRNA technology succeeding in either preventing or curing many difficult to treat diseases. This is a stock that is strictly for long-term aggressive growth investors that are interested in speculating on potential home-run type products over a five-to-ten-year time frame. The risk that Moderna is only a one-product company is somewhat mitigated by the fact that the efficacy of the COVID-19 vaccine was so high, that is serves as a kind of proof of concept that a mRNA platform can produce other novel ways of addressing other difficult diseases.</p><p><blockquote>Moderna是对mRNA技术的高风险、高回报赌注，成功预防或治愈许多难以治疗的疾病。这是一只严格适合长期激进增长投资者的股票，他们有兴趣在五到十年的时间范围内投机潜在的本垒打型产品。Moderna只是一家单一产品公司的风险在一定程度上被COVID-19疫苗的功效如此之高这一事实所缓解，即mRNA平台可以产生其他新方法来解决其他疑难疾病。</blockquote></p><p>The 58% pullback from Moderna&#39;s all-time high of $497.49 gives aggressive growth investors a chance to buy into a company with significant potential upside. However, risk averse or investors sensitive to short-term price movements should avoid Moderna&#39;s stock for now because there is significant downside risk if COVID-19 revenue drops off too rapidly before Moderna can show that it can achieve similar success in addressing other diseases.</p><p><blockquote>Moderna较497.49美元的历史高点回调58%，为激进的增长投资者提供了买入一家具有巨大潜在上涨空间的公司的机会。然而，规避风险或对短期价格变动敏感的投资者目前应避开Moderna的股票，因为如果在Moderna证明它可以在解决其他疾病方面取得类似成功之前，COVID-19收入下降过快，则存在巨大的下行风险。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/article/4479930-moderna-high-upside-potential-at-current-prices\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/article/4479930-moderna-high-upside-potential-at-current-prices","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131862461","content_text":"SummaryModerna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company's mRNA manufacturing capacity.Moderna recently reported the preliminary COVID-19 estimate for product sales in 2021 as being approximately $17.5 billion.Recently, Singapore released data showing that COVID-19 deaths were the lowest among Moderna vaccine takers.One of the ways that Moderna is keeping ahead of potential mRNA competition is using its $15.3 billion in cash and $3.2 billion in Free Cash Flow to continue building out significant mRNA manufacturing capability across the world.The 58% pullback from Moderna's all-time high of $497.49 gives aggressive growth investors a chance to buy into a company with significant upside potential.Maddie Meyer/Getty Images NewsModerna (NASDAQ:MRNA) has extremely high upside from being a first mover in developing the world's most advanced mRNA platform. One of the most promising potential solutions for helping prevent or cure some of the most intractable diseases known to man is mRNA technology and Moderna has not only developed the most advanced mRNA platform but has also built out significant mRNA manufacturing capacity worldwide. There are many companies that are in various stages of developing mRNA technology but there are very few that have advanced as far as Moderna has in both developing mRNA technology, as well as having the manufacturing capacity and other commercial infrastructure to produce billions of doses of a vaccine per year. At this time, the only companies that have both the knowledge of advanced mRNA techniques and the manufacturing capacity to compete in the same arena as Moderna is the BioNTech (NASDAQ:BNTX) - Pfizer (NYSE:PFE) partnership.Moderna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company's mRNA manufacturing capacity. It is one thing to produce mRNA in a lab setting but quite another to safely mass produce effective vaccines in regulator approved manufacturing sites around the world. Moderna's first mover advantage has translated into a very large war chest of cash from COVID-19 sales in which the company can use to further its lead by investing in advancing mRNA technology, improving mRNA manufacturing processes, and building out significant manufacturing capability worldwide. Moderna is also well along in developing one of the deepest drug pipelines in the world.While a first mover advantage is not exactly a moat, for the next several years at least, Moderna should enjoy a significant lead in developing many different mRNA-based therapies or vaccines to treat numerous difficult to treat diseases. Moderna currently has 40 different drug development programs, which is almost unheard of for such a relatively young biotech company that only two years ago was simply a research outfit. In the end, Moderna's mRNA platform and manufacturing capacity should result in significant long-term upside for investors buying into Moderna's stock today.Advantages of mRNA TechnologyThe reason why Moderna was able to rapidly develop a COVID-19 solution, while at the same time continuing to build out a significant number of drug development programs is because of the nature of mRNA technology.The development and manufacturing of mRNA for use as therapeuticsandvaccines are comparatively simple, scalableandextremely rapid.Source:Millapore SigmaThere are numerous advantages of a mRNA platform over traditional drug making. The major advantages of a mRNA platform that were demonstrated by the response to the COVID-19 pandemic was the ability to take the sequence of the virus and quickly move from development, to clinical trials, to approval, to mass manufacturing of a vaccine in a very rapid period of time. As Moderna and others get more experience and regulatory bodies get more comfortable with mRNA technology, I can see the day in the future where the response time of discovery of a virulent virus to clinical trials of a vaccine, to vaccine approval, to mass manufacturing of the vaccine could significantly shrink. Right now, it looks like it takes about 9 months to a year to move from virus discovery to eventually making it into people's arms. Eventually, this response time could shrink to matter of a few months.Omnicron was first identified as a variant around November 24, 2021. Moderna CEO Stéphane Bancel said in a CNBC interview that clinical trials for an Omnicron vaccine will start soon and a Omnicron vaccine should be available by fall. This type of rapid response to infectious diseases is unheard of before now and as time goes along, mRNA platform companies could not only become proficient in rapidly producing vaccines against specific viruses but also become proficient at producing vaccines against specific strains of a virus, in specific regions of the world. Among the reason why I think Moderna is building manufacturing capacity in different countries and regions of the world is because vaccines will eventually be less of a one size fits all countries and be more along the lines of regional manufacturing sites creating vaccines specific for the most prevalent viruses and strains of virus in that specific region.Another potential huge advantage of a mRNA platform is flexibility. Theoretically, a mRNA manufacturing plant can be relatively rapidly switched to producing any other mRNA-based drug. It is possible that a mRNA plant that makes COVID-19 vaccines could be rapidly switched to making an Ebola vaccine, for instance. This is in contrast to the manufacturing process of many traditional drugs that require a dedicated plant to produce a drug. This could make the CapEx involved for producing multiple different types of drugs, far lower than a traditional drug manufacturer.The COVID-19 pandemic has highlighted exactly how easy it is to change the vaccine simply by plugging the genetic sequence of any virus that Moderna wants to target right into its basic mRNA platform. This is not only useful for being able to attack different strains of COVID-19 but also means that Moderna has the ability of using the sequence of any virus whether that be the flu, HIV, CMV, Tuberculosis, Zika, or Rabies and quickly produce a vaccine ready for testing.COVID-19 ProgressCOVID-19 has totally changed the fortunes of Moderna within just two years. Up until 2020, Moderna was only a little-known drug research outfit that had very little revenues but being the second company to bring a viable vaccine to protect against COVID-19 into US markets, has made Moderna very widely known worldwide and the company has built a huge brand that is on the verge of becoming a giant within the drug industry.There is real world evidence that up until now, Moderna has produced the most effective COVID-19 vaccine. Data from all over the world supports the very strong efficacy that was shown in phase III data in the USA. Recently, Singapore released data showing that COVID-19 deaths were lowest among Moderna takers. Singapore had 802 deaths out of which 70% were unvaccinated. Between Moderna, Pfizer-BioNTech, Sinopharm and Sinovac vaccines, Moderna had the least death rates:11 deaths per 100,000: Sinovac7.8 deaths per 100,000: Sinopharm6.2 deaths per 100,000: Pfizer/BioNTech1 death per 100,000: ModernaOver the course of 2021, Moderna shipped 807 million doses of Spikevax, Moderna's COVID-19 vaccine, to many different locations around the world, with around 25% of those doses going to low-income and middle-income countries. Moderna reported recently during the JPMorgan 40th Annual Healthcare Conference on January 10th, that the preliminary estimate for Spikevax product sales in 2021 is around $17.5 billion.Because of the huge demand for Moderna's vaccine worldwide, for a decent part of 2021, the company was supply constrained but that situation is beginning to turn around now. Moderna CEO Stephane Bancel attributes the reason for supply constraints as Moderna having a higher dose than the Pfizer-BioNTech vaccine. The higher dose was a big drain on manufacturing resources. Moderna has since built out additional manufacturing capacity over the course of 2021 and is now in much better shape to address COVID-19 demand. In Q4, Moderna shipped 300 million doses, which is a run rate of 1.2 billion doses. Moderna believes that they can produce two billion to three billion doses of boosters over the course of 2022, if necessary.Moderna Spikevax advanced purchase agreementsBecause COVID-19 vaccine makers have lately been having to play whack-a-mole with new variants, the demand for Spikevax is still rising. As can be seen from the above graphic, from November 4th to January 10th, Moderna has gained and additional $1.5 billion in advanced purchase agreements (\"APA\") and $0.5 Billion in options, with those numbers being mostly heavily weighted toward the first half of the year. Moderna is still having ongoing discussions with many countries about whether additional vaccines will need to be added to address the fall moving into winter of '22. I expect that when all is said and done, Moderna could wind up signing additional APAs over the course of the year. So, it looks like 2022 might again be another banner year for Moderna.How COVID-19 is likely to evolveCurrently, the world is in the midst of variant reinfection waves, which will likely continue throughout 2022 but by 2023 COVID-19 should become more seasonal and endemic. Morbidity waves are expected to become lower and lower over the next several years and there is a good chance that COVID-19 will be seen more like the flu is perceived today within a year or two. Post-pandemic, COVID-19 is expected to mostly only affect people aged 50-plus, health care workers, immunocompromised people and other high-risk populations. These groups will likely need boosters to ensure that they do not get severe disease and hospitalization. As COVID-19 winds down, demand for Spikevax will probably begin dropping in the 2023-to-2024-time frame. This is why some people have been predicting revenue declines for Moderna. Well, what is Moderna's post pandemic plan to replace the likely COVID-19 vaccine declining revenues?Moderna's Plan Moving ForwardModerna Product Strategy in 2022The initial way that Moderna plans on countering the likely COVID-19 vaccine decline is by bundling different seasonal respiratory vaccines together into just one vaccine. The days of getting COVID-19 specific vaccine seem to be waning and a pan-respiratory vaccine will likely compete extremely effectively with any laggards coming to the market late with only a COVID-19 solution.Moderna vision for pan-respiratory vaccineModerna's vision is that an annual single-dose pan-respiratory booster can be customized to fit different demographics, different geographies, and different respiratory diseases over time. Eventually, Moderna even expects to target specific strains of respiratory diseases in specific regions. I wouldn't be surprised if a pan-respiratory vaccine starts to appear within two years.Moderna Strategy After COVID-19Unlike vaccine technology from companies like Novavax (NASDAQ:NVAX), mRNA can be used for many other different purposes besides infectious diseases.Novavax's pipeline only consists of 9 programs that target 5 other infectious diseases other than COVID-19. Most of Novavax's pipeline is mostly concerned with respiratory diseases, with only one direct contact latent virus, Ebola, appearing on the list.In contrast, Moderna is much further ahead in developing solutions against multiple latent viruses that are a lot more prevalent than Ebola. The first ones being targeted and are already in clinical trials are CMV and EBV, with HIV soon to begin trials. CMV is Moderna's most advanced drug in the pipeline and the first patient has already been dosed in phase III trials. Besides CMV, EBV, and HIV, there a many other undisclosed latent viruses being worked on in the labs.The next area that Moderna is prioritizing is in developing therapeutics using mRNA technology which allows the company to produce oncology products, cardio products, rare genetic disease products and autoimmune disease products. This is an area that has significant upside for Moderna. Moderna will be using totally new approaches to develop solutions against cancer and develop solutions for diseases that currently have no significant solutions. Recently, Moderna formed a partnership with Carisma Therapeutics. Moderna plans to combine its mRNA technology with Carisma Therapeutics' engineered macrophage technology to develop solutions against solid tumor cancer. The reason why this is important is because while autologous CAR-Ts have really good data in Heme malignancies, which are blood cancers, they have not been very effective in solid tumors and eighty percent of cancer patients die of solid tumors. I won't go deep into the science behind it but scientist know the reasons why CAR-Ts are not as effective with solid tumors, and both companies think Carisma Therapeutics' CAR-Macrophage's technology combined with mRNA technology can produce revolutionary new ways to essentially cure the most prevalent and difficult to treat form of cancer deaths which are solid tumors.Moderna's deep expertise in mRNA and LNP technologies opens up a potentially game-changing opportunity for engineered macrophages. In vivo delivery directly to monocytes and macrophages enables an off-the-shelf therapeutic approach that uses the patients' own cells to provide a truly personalized treatment.Source: Steven Kelly, President and Chief Executive Officer of CarismaRight now, there is no way to factor in the upside of Moderna potentially developing a significantly better solution to attacking and possibly curing solid tumor cancer. The therapies that could come out of partnerships like the one Moderna has with Carisma could potentially produce home runs just as big, if not bigger than the COVID-19 vaccine.The fourth area that Moderna is developing solutions using gene-editing enzymes. Moderna has only seriously got into gene editing relatively recently when the company signed a collaboration with Metagenomi. For those unaware,gene-editing is the same strategy that companies like Editas (NASDAQ:EDIT) and CRISPR Therapeutics (NASDAQ:CRSP) are pursuing. The focus for the Metagenomi collaboration will be on serious genetic diseases.Moderna capital allocation prioritiesModerna has already started spending its huge cash flows derived from COVID-19 vaccine sales. I just wanted to include the above slide in this article because it shows that Moderna's number one capital allocation priority is investing in R&D, manufacturing infrastructure and continuing to build out the company's commercial infrastructure. The second priority is investing in external investment opportunities, either in the form of collaborations or M&A. The collaborations with Metagenomi and Carisma Therapeutics are examples of this second priority.Manufacturing CapacityModerna In-country vaccine manufacturingThere is a rather large set of existing potential competitors to Moderna and there are also countries like India that are supporting rising home-grown mRNA platform companies. One of the ways that Moderna is keeping ahead of such efforts from competitors is using its $15.3 billion in cash and $3.2 billion in Free Cash Flow at the end of Q3, to build out significant mRNA manufacturing capability across the world. Moderna has announced in principle agreements with Australia and Canadato build out mRNA vaccine manufacturing plants within those countries. These announcements are in addition to the plans to build a factory capable of producing up to 500 million vaccine doses in Africa each year. I believe Moderna is still in the process of choosing which African country the manufacturing site will be located in.RisksThe major risk that Moderna faces in the short term is revenue from the COVID-19 declining faster than Moderna can get other vaccines or therapies on to market and show superior results. The closest drug to approval is a CMV vaccine. An approval of the CMV vaccine would likely shoot Moderna's stock higher because it would show that mRNA is viable for addressing other diseases. A CMV rejection would likely drop Moderna's stock much lower.Another major risk for Moderna are patent disputes and lawsuits. Moderna recently had to back down in a dispute with the NIH over COVID-19 patents and Moderna could also soon face a patent infringement lawsuit from Arbutus (NASDAQ:ABUS) over the COVID-19 vaccine. Currently, it is unknown how these disputes will impact Moderna over the longer term.Analyst Price TargetsModerna Analyst Price TargetsThe above is based on 15 Wall Street analysts offering 12-month price targets for Moderna in the last 3 months. The average price target is $289.07 with a high forecast of $506.00 and a low forecast of $86.00. The average price target represents a 38% increase from the last price of $210.17.ValuationData by YChartsData by YChartsData by YChartsThe comparisons between these three relatively new biotechs with COVID-19 vaccines already shipping, shows Moderna is the most highly valued stock but BioNTech has the best revenue growth and operating margins. Going strictly by value, BioNTech is probably the best buy but in reality, all three companies are biotechs, in which one hit product or one large dismal failure can change the fortunes of the company. I view all three companies as very speculative, even with the success achieved by producing solutions for the COVID-19 pandemic.I am not a big fan of trying to use valuation techniques on any biotech company. There is simply no way to value the future potential success or failure of the bets that many biotech companies make. If Moderna is part of curing solid tumor cancer, for instance, Moderna's current valuation will be viewed in hindsight as being way too low. If most of Moderna's pipeline fails then the valuation will be viewed in hindsight as being way too high.ConclusionModerna is a high risk, high reward bet on mRNA technology succeeding in either preventing or curing many difficult to treat diseases. This is a stock that is strictly for long-term aggressive growth investors that are interested in speculating on potential home-run type products over a five-to-ten-year time frame. The risk that Moderna is only a one-product company is somewhat mitigated by the fact that the efficacy of the COVID-19 vaccine was so high, that is serves as a kind of proof of concept that a mRNA platform can produce other novel ways of addressing other difficult diseases.The 58% pullback from Moderna's all-time high of $497.49 gives aggressive growth investors a chance to buy into a company with significant potential upside. However, risk averse or investors sensitive to short-term price movements should avoid Moderna's stock for now because there is significant downside risk if COVID-19 revenue drops off too rapidly before Moderna can show that it can achieve similar success in addressing other diseases.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1717,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698891874,"gmtCreate":1640331386141,"gmtModify":1640331634599,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"htmlText":"It's always the up and down&nbsp;","listText":"It's always the up and down&nbsp;","text":"It's always the up and down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698891874","repostId":"2193078140","repostType":4,"isVote":1,"tweetType":1,"viewCount":3650,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693469990,"gmtCreate":1640063725361,"gmtModify":1640064058108,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"htmlText":"Should start positioning at 86. 70 is too bearish&nbsp;","listText":"Should start positioning at 86. 70 is too bearish&nbsp;","text":"Should start positioning at 86. 70 is too bearish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693469990","repostId":"1180317442","repostType":4,"isVote":1,"tweetType":1,"viewCount":2544,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699267737,"gmtCreate":1639815129172,"gmtModify":1639815129921,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"htmlText":"Semicon industry nvr die","listText":"Semicon industry nvr die","text":"Semicon industry nvr die","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699267737","repostId":"1161245886","repostType":4,"repost":{"id":"1161245886","kind":"news","pubTimestamp":1639806035,"share":"https://www.laohu8.com/m/news/1161245886?lang=zh_CN&edition=full","pubTime":"2021-12-18 13:40","market":"us","language":"en","title":"Wedbush's Dan Ives: Don't throw in the towel on tech<blockquote>韦德布什的丹·艾夫斯：不要在科技上认输</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1161245886","media":"Seeking Alpha","summary":"Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.\"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.Calling the current era \"a fourth industrial revolution,\" Ives backed such stocks as $CyberArk Software $, $Palo Alto Networks $, $Zscaler $, $NVIDIA $ and $Apple $.\"This is an opportunity, not the start of a downtrend ","content":"<p>Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.</p><p><blockquote>Wedbush Securities董事总经理Dan Ives建议投资者坚持持有科技股，尽管美联储加息可能会导致估值紧缩。</blockquote></p><p> \"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.</p><p><blockquote>“现在不是向科技认输的时候，”他周五对CNBC表示。</blockquote></p><p> Calling the current era \"a fourth industrial revolution,\" Ives backed such stocks as <a href=\"https://laohu8.com/S/CYBR\">CyberArk Software </a>, <a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks </a>, <a href=\"https://laohu8.com/S/ZS\">Zscaler </a>, <a href=\"https://laohu8.com/S/NVDA\">NVIDIA </a> and <a href=\"https://laohu8.com/S/AAPL\">Apple </a>.</p><p><blockquote>艾夫斯将当前时代称为“第四次工业革命”，他支持以下股票：<a href=\"https://laohu8.com/S/CYBR\">赛博方舟软件</a>,<a href=\"https://laohu8.com/S/PANW\">帕洛阿尔托网络</a>,<a href=\"https://laohu8.com/S/ZS\">Zscaler</a>,<a href=\"https://laohu8.com/S/NVDA\">英伟达</a>和<a href=\"https://laohu8.com/S/AAPL\">苹果</a>.</blockquote></p><p> \"This is an opportunity, not the start of a downtrend for tech,\" he said.</p><p><blockquote>“这是一个机会，而不是科技股下跌趋势的开始，”他说。</blockquote></p><p> Ives argued that a large number of tech names will see significant growth in coming years thanks to heavy spending on technologies like cybersecurity, 5G and further moves into the cloud.</p><p><blockquote>艾夫斯认为，由于在网络安全、5G等技术上的大量支出以及进一步向云的转移，大量科技公司将在未来几年实现显着增长。</blockquote></p><p> He estimated that this \"digital transformation\" would fuel another $2T in spending over the next six to seven years.</p><p><blockquote>他估计，这种“数字化转型”将在未来六到七年内推动另外2T美元的支出。</blockquote></p><p> That said, Ives warned investors that they had to be selective with their portfolios, as some stocks will lose momentum once the massive pandemic-related stimulus comes to an end.</p><p><blockquote>尽管如此，艾夫斯警告投资者，他们必须有选择性地选择投资组合，因为一旦与大流行相关的大规模刺激措施结束，一些股票将失去动力。</blockquote></p><p> \"You have to separate the winners from the losers and the long-term winners versus the ones that benefited from the pandemic,\" he said.</p><p><blockquote>他说：“你必须区分赢家和输家，区分长期赢家和从大流行中受益的人。”</blockquote></p><p> Rather, Ives suggested investors \"double down on their winners.\"</p><p><blockquote>相反，艾夫斯建议投资者“加倍押注赢家”。</blockquote></p><p> Looking at some of the stocks mentioned by Ives, NVDA has done by far the best in 2021, more than doubling over the course of the year. ZS and PANW have both risen nearly 50%. AAPL lags behind its smaller rivals, although it has rallied about 30% for 2021.</p><p><blockquote>从艾夫斯提到的一些股票来看，NVDA在2021年的表现是迄今为止最好的，一年中上涨了一倍多。ZS和PANW均上涨近50%。尽管苹果公司2021年股价上涨了约30%，但仍落后于规模较小的竞争对手。</blockquote></p><p> The main laggard in the group is CYBR, which is basically flat on the year:</p><p><blockquote>集团内主要落后者为CYBR，同比基本持平：</blockquote></p><p> <img src=\"https://static.tigerbbs.com/25aa45389fe8b89d41006f304e02894e\" tg-width=\"1201\" tg-height=\"405\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wedbush's Dan Ives: Don't throw in the towel on tech<blockquote>韦德布什的丹·艾夫斯：不要在科技上认输</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWedbush's Dan Ives: Don't throw in the towel on tech<blockquote>韦德布什的丹·艾夫斯：不要在科技上认输</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-12-18 13:40</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.</p><p><blockquote>Wedbush Securities董事总经理Dan Ives建议投资者坚持持有科技股，尽管美联储加息可能会导致估值紧缩。</blockquote></p><p> \"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.</p><p><blockquote>“现在不是向科技认输的时候，”他周五对CNBC表示。</blockquote></p><p> Calling the current era \"a fourth industrial revolution,\" Ives backed such stocks as <a href=\"https://laohu8.com/S/CYBR\">CyberArk Software </a>, <a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks </a>, <a href=\"https://laohu8.com/S/ZS\">Zscaler </a>, <a href=\"https://laohu8.com/S/NVDA\">NVIDIA </a> and <a href=\"https://laohu8.com/S/AAPL\">Apple </a>.</p><p><blockquote>艾夫斯将当前时代称为“第四次工业革命”，他支持以下股票：<a href=\"https://laohu8.com/S/CYBR\">赛博方舟软件</a>,<a href=\"https://laohu8.com/S/PANW\">帕洛阿尔托网络</a>,<a href=\"https://laohu8.com/S/ZS\">Zscaler</a>,<a href=\"https://laohu8.com/S/NVDA\">英伟达</a>和<a href=\"https://laohu8.com/S/AAPL\">苹果</a>.</blockquote></p><p> \"This is an opportunity, not the start of a downtrend for tech,\" he said.</p><p><blockquote>“这是一个机会，而不是科技股下跌趋势的开始，”他说。</blockquote></p><p> Ives argued that a large number of tech names will see significant growth in coming years thanks to heavy spending on technologies like cybersecurity, 5G and further moves into the cloud.</p><p><blockquote>艾夫斯认为，由于在网络安全、5G等技术上的大量支出以及进一步向云的转移，大量科技公司将在未来几年实现显着增长。</blockquote></p><p> He estimated that this \"digital transformation\" would fuel another $2T in spending over the next six to seven years.</p><p><blockquote>他估计，这种“数字化转型”将在未来六到七年内推动另外2T美元的支出。</blockquote></p><p> That said, Ives warned investors that they had to be selective with their portfolios, as some stocks will lose momentum once the massive pandemic-related stimulus comes to an end.</p><p><blockquote>尽管如此，艾夫斯警告投资者，他们必须有选择性地选择投资组合，因为一旦与大流行相关的大规模刺激措施结束，一些股票将失去动力。</blockquote></p><p> \"You have to separate the winners from the losers and the long-term winners versus the ones that benefited from the pandemic,\" he said.</p><p><blockquote>他说：“你必须区分赢家和输家，区分长期赢家和从大流行中受益的人。”</blockquote></p><p> Rather, Ives suggested investors \"double down on their winners.\"</p><p><blockquote>相反，艾夫斯建议投资者“加倍押注赢家”。</blockquote></p><p> Looking at some of the stocks mentioned by Ives, NVDA has done by far the best in 2021, more than doubling over the course of the year. ZS and PANW have both risen nearly 50%. AAPL lags behind its smaller rivals, although it has rallied about 30% for 2021.</p><p><blockquote>从艾夫斯提到的一些股票来看，NVDA在2021年的表现是迄今为止最好的，一年中上涨了一倍多。ZS和PANW均上涨近50%。尽管苹果公司2021年股价上涨了约30%，但仍落后于规模较小的竞争对手。</blockquote></p><p> The main laggard in the group is CYBR, which is basically flat on the year:</p><p><blockquote>集团内主要落后者为CYBR，同比基本持平：</blockquote></p><p> <img src=\"https://static.tigerbbs.com/25aa45389fe8b89d41006f304e02894e\" tg-width=\"1201\" tg-height=\"405\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3781354-dont-throw-in-the-towel-on-tech-wedbushs-dan-ives\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZS":"Zscaler Inc.","CYBR":"Cyber-Ark Software","PANW":"Palo Alto Networks","NVDA":"英伟达"},"source_url":"https://seekingalpha.com/news/3781354-dont-throw-in-the-towel-on-tech-wedbushs-dan-ives","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161245886","content_text":"Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.\n\"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.\nCalling the current era \"a fourth industrial revolution,\" Ives backed such stocks as CyberArk Software , Palo Alto Networks , Zscaler , NVIDIA  and Apple .\n\"This is an opportunity, not the start of a downtrend for tech,\" he said.\nIves argued that a large number of tech names will see significant growth in coming years thanks to heavy spending on technologies like cybersecurity, 5G and further moves into the cloud.\nHe estimated that this \"digital transformation\" would fuel another $2T in spending over the next six to seven years.\nThat said, Ives warned investors that they had to be selective with their portfolios, as some stocks will lose momentum once the massive pandemic-related stimulus comes to an end.\n\"You have to separate the winners from the losers and the long-term winners versus the ones that benefited from the pandemic,\" he said.\nRather, Ives suggested investors \"double down on their winners.\"\nLooking at some of the stocks mentioned by Ives, NVDA has done by far the best in 2021, more than doubling over the course of the year. ZS and PANW have both risen nearly 50%. AAPL lags behind its smaller rivals, although it has rallied about 30% for 2021.\nThe main laggard in the group is CYBR, which is basically flat on the year:","news_type":1,"symbols_score_info":{"ZS":0.9,"PANW":0.9,"CYBR":0.9,"NVDA":0.9}},"isVote":1,"tweetType":1,"viewCount":3643,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877922815,"gmtCreate":1637881319600,"gmtModify":1637881319742,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"htmlText":"Will it ? Well market is insane, anything can happen&nbsp;[开心]&nbsp;[开心]&nbsp;","listText":"Will it ? Well market is insane, anything can happen&nbsp;[开心]&nbsp;[开心]&nbsp;","text":"Will it ? Well market is insane, anything can happen [开心] [开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/877922815","repostId":"2186916023","repostType":4,"isVote":1,"tweetType":1,"viewCount":2516,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842783902,"gmtCreate":1636244599834,"gmtModify":1636249290606,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"htmlText":"Over aggressive expansion, Convid killed him&nbsp;","listText":"Over aggressive expansion, Convid killed him&nbsp;","text":"Over aggressive expansion, Convid killed him","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842783902","repostId":"2181744416","repostType":4,"repost":{"id":"2181744416","kind":"highlight","pubTimestamp":1636161660,"share":"https://www.laohu8.com/m/news/2181744416?lang=zh_CN&edition=full","pubTime":"2021-11-06 09:21","market":"hk","language":"en","title":"Popular Hot Pot Restaurant Brand Haidilao to Shut Down 300 Restaurants in China<blockquote>受欢迎的火锅餐厅品牌海底捞将在中国关闭300家餐厅</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2181744416","media":"钛媒体","summary":"BEIJING, November 5 (TMTPOST) — Popular Chinese hot pot restaurant brand Haidilao (06862.HK) has ann","content":"<p>BEIJING, November 5 (TMTPOST) — <a href=\"https://laohu8.com/S/BPOPN\">Popular</a> Chinese hot pot restaurant brand Haidilao (06862.HK) has announced on Friday that it will close down around 300 restaurants in China that fail to meet revenue expectations or have low customer traffic by December 31st 2021. According to Haidilao’s statement, some of the restaurants will suspend operation temporarily and will reopen after adjustment within two years. Haidilao has promised that it will not lay off staff and will rearrange employees working in the affected restaurants.</p><p><blockquote>北京11月5日电（钛媒体）——<a href=\"https://laohu8.com/S/BPOPN\">流行的</a>中国火锅餐厅品牌海底捞（06862.HK）周五宣布，将在2021年12月31日之前关闭中国约300家未达到收入预期或客流量较低的餐厅。根据海底捞的声明，部分餐厅将暂时停止营业，两年内调整后重新开业。海底捞承诺不会裁员，将重新安排在受影响餐厅工作的员工。</blockquote></p><p> Haidilao is a popular go-to hot pot restaurant brand in China, especially popular among young consumers.</p><p><blockquote>海底捞是中国广受欢迎的火锅餐厅品牌，尤其受到年轻消费者的欢迎。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/35715cef35710a06dc52a2418de4d934\" tg-width=\"1400\" tg-height=\"849\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Haidilao’s business adjustment plan, titled “the Woodpecker”, will be directed by the company’s executive director and vice CEO Yang Lijuan. Besides paying close attention to Haidilao restaurants with poor business performance both at home and overseas, the plan also includes measures such as rebuilding some key departments and restoring the regional management systems. In addition, scientific key performance indicators will be set up for all departments while the promotion of the brand’s culture will be further strengthened. Business expansion plans will be limited accordingly. According to Haidilao, the company will not in principle consider expanding if the table turnover rate remains lower than four times a day.</p><p><blockquote>海底捞的业务调整计划名为“啄木鸟”，将由公司执行董事兼副首席执行官杨丽娟负责。除了密切关注国内外经营业绩不佳的海底捞餐厅外，该计划还包括重建部分关键部门、恢复区域管理系统等措施。此外，将为各部门设立科学的关键绩效指标，同时进一步加强品牌文化的推广。业务扩张计划将受到相应限制。按照海底捞的说法，如果翻桌率保持在每天4次以下，公司原则上不会考虑扩张。</blockquote></p><p> Haidilao started a massive business expansion in 2020. The company’s 2020 fiscal report shows the number of Haidilao restaurants grew by 530 to 1,298. Haidilao opened 544 new restaurants while closing 14 restaurants in 2020. However, Haidilao’s table turnover rate decreased from 2019’s 4.8 times per day to 3.5 times per day.</p><p><blockquote>海底捞在2020年开始了大规模的业务扩张。该公司2020年财报显示，海底捞餐厅数量增长530家至1298家。海底捞在2020年新开了544家餐厅，同时关闭了14家餐厅。不过，海底捞翻台率从2019年的4.8次/天下降至3.5次/天。</blockquote></p><p> “I was wrong. I made the decision to expand last year, a decision turned out to be based on blind faith in the market,” Zhang Yong, Haidilao’s founder said. “I only realized this back in January this year. But it wasn’t until March that I took action about it.”</p><p><blockquote>海底捞创始人张勇表示：“我错了。我去年做出了扩张的决定，结果证明这个决定是基于对市场的盲目信念。”“我是今年1月份才意识到这一点的。但直到3月份我才采取行动。”</blockquote></p><p> Haidilao’s share price experienced a sharp dive after rapid growth after the Spring Festival earlier this year. Haidilao’s share price grew by 5.46% and closed at HK$21.05 per share today, setting the company’s valuation at HK$115 billion. In comparison, Haidilao’s share price hit HK$85.75 per share in February, a record high for the company. Haidilao’s valuation even surpassed HK$460 billion at <a href=\"https://laohu8.com/S/AONE.U\">one</a> point.</p><p><blockquote>海底捞股价在今年初春节后快速增长后出现大幅跳水。海底捞股价增长5.46%，今日收报21.05港元/股，将公司估值定为1150亿港元。相比之下，海底捞股价在2月份触及每股85.75港元，创该公司历史新高。海底捞估值甚至超过4600亿港元<a href=\"https://laohu8.com/S/AONE.U\">一</a>点。</blockquote></p><p></p>","source":"taimeiti","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Popular Hot Pot Restaurant Brand Haidilao to Shut Down 300 Restaurants in China<blockquote>受欢迎的火锅餐厅品牌海底捞将在中国关闭300家餐厅</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPopular Hot Pot Restaurant Brand Haidilao to Shut Down 300 Restaurants in China<blockquote>受欢迎的火锅餐厅品牌海底捞将在中国关闭300家餐厅</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">钛媒体</strong><span class=\"h-time small\">2021-11-06 09:21</span>\n</p>\n</h4>\n</header>\n<article>\n<p>BEIJING, November 5 (TMTPOST) — <a href=\"https://laohu8.com/S/BPOPN\">Popular</a> Chinese hot pot restaurant brand Haidilao (06862.HK) has announced on Friday that it will close down around 300 restaurants in China that fail to meet revenue expectations or have low customer traffic by December 31st 2021. According to Haidilao’s statement, some of the restaurants will suspend operation temporarily and will reopen after adjustment within two years. Haidilao has promised that it will not lay off staff and will rearrange employees working in the affected restaurants.</p><p><blockquote>北京11月5日电（钛媒体）——<a href=\"https://laohu8.com/S/BPOPN\">流行的</a>中国火锅餐厅品牌海底捞（06862.HK）周五宣布，将在2021年12月31日之前关闭中国约300家未达到收入预期或客流量较低的餐厅。根据海底捞的声明，部分餐厅将暂时停止营业，两年内调整后重新开业。海底捞承诺不会裁员，将重新安排在受影响餐厅工作的员工。</blockquote></p><p> Haidilao is a popular go-to hot pot restaurant brand in China, especially popular among young consumers.</p><p><blockquote>海底捞是中国广受欢迎的火锅餐厅品牌，尤其受到年轻消费者的欢迎。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/35715cef35710a06dc52a2418de4d934\" tg-width=\"1400\" tg-height=\"849\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Haidilao’s business adjustment plan, titled “the Woodpecker”, will be directed by the company’s executive director and vice CEO Yang Lijuan. Besides paying close attention to Haidilao restaurants with poor business performance both at home and overseas, the plan also includes measures such as rebuilding some key departments and restoring the regional management systems. In addition, scientific key performance indicators will be set up for all departments while the promotion of the brand’s culture will be further strengthened. Business expansion plans will be limited accordingly. According to Haidilao, the company will not in principle consider expanding if the table turnover rate remains lower than four times a day.</p><p><blockquote>海底捞的业务调整计划名为“啄木鸟”，将由公司执行董事兼副首席执行官杨丽娟负责。除了密切关注国内外经营业绩不佳的海底捞餐厅外，该计划还包括重建部分关键部门、恢复区域管理系统等措施。此外，将为各部门设立科学的关键绩效指标，同时进一步加强品牌文化的推广。业务扩张计划将受到相应限制。按照海底捞的说法，如果翻桌率保持在每天4次以下，公司原则上不会考虑扩张。</blockquote></p><p> Haidilao started a massive business expansion in 2020. The company’s 2020 fiscal report shows the number of Haidilao restaurants grew by 530 to 1,298. Haidilao opened 544 new restaurants while closing 14 restaurants in 2020. However, Haidilao’s table turnover rate decreased from 2019’s 4.8 times per day to 3.5 times per day.</p><p><blockquote>海底捞在2020年开始了大规模的业务扩张。该公司2020年财报显示，海底捞餐厅数量增长530家至1298家。海底捞在2020年新开了544家餐厅，同时关闭了14家餐厅。不过，海底捞翻台率从2019年的4.8次/天下降至3.5次/天。</blockquote></p><p> “I was wrong. I made the decision to expand last year, a decision turned out to be based on blind faith in the market,” Zhang Yong, Haidilao’s founder said. “I only realized this back in January this year. But it wasn’t until March that I took action about it.”</p><p><blockquote>海底捞创始人张勇表示：“我错了。我去年做出了扩张的决定，结果证明这个决定是基于对市场的盲目信念。”“我是今年1月份才意识到这一点的。但直到3月份我才采取行动。”</blockquote></p><p> Haidilao’s share price experienced a sharp dive after rapid growth after the Spring Festival earlier this year. Haidilao’s share price grew by 5.46% and closed at HK$21.05 per share today, setting the company’s valuation at HK$115 billion. In comparison, Haidilao’s share price hit HK$85.75 per share in February, a record high for the company. Haidilao’s valuation even surpassed HK$460 billion at <a href=\"https://laohu8.com/S/AONE.U\">one</a> point.</p><p><blockquote>海底捞股价在今年初春节后快速增长后出现大幅跳水。海底捞股价增长5.46%，今日收报21.05港元/股，将公司估值定为1150亿港元。相比之下，海底捞股价在2月份触及每股85.75港元，创该公司历史新高。海底捞估值甚至超过4600亿港元<a href=\"https://laohu8.com/S/AONE.U\">一</a>点。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.tmtpost.com/5842325.html?rss=qcloud\">钛媒体</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"06862":"海底捞"},"source_url":"https://www.tmtpost.com/5842325.html?rss=qcloud","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2181744416","content_text":"BEIJING, November 5 (TMTPOST) — Popular Chinese hot pot restaurant brand Haidilao (06862.HK) has announced on Friday that it will close down around 300 restaurants in China that fail to meet revenue expectations or have low customer traffic by December 31st 2021. According to Haidilao’s statement, some of the restaurants will suspend operation temporarily and will reopen after adjustment within two years. Haidilao has promised that it will not lay off staff and will rearrange employees working in the affected restaurants.\nHaidilao is a popular go-to hot pot restaurant brand in China, especially popular among young consumers.\n\nHaidilao’s business adjustment plan, titled “the Woodpecker”, will be directed by the company’s executive director and vice CEO Yang Lijuan. Besides paying close attention to Haidilao restaurants with poor business performance both at home and overseas, the plan also includes measures such as rebuilding some key departments and restoring the regional management systems. In addition, scientific key performance indicators will be set up for all departments while the promotion of the brand’s culture will be further strengthened. Business expansion plans will be limited accordingly. According to Haidilao, the company will not in principle consider expanding if the table turnover rate remains lower than four times a day.\nHaidilao started a massive business expansion in 2020. The company’s 2020 fiscal report shows the number of Haidilao restaurants grew by 530 to 1,298. Haidilao opened 544 new restaurants while closing 14 restaurants in 2020. However, Haidilao’s table turnover rate decreased from 2019’s 4.8 times per day to 3.5 times per day.\n“I was wrong. I made the decision to expand last year, a decision turned out to be based on blind faith in the market,” Zhang Yong, Haidilao’s founder said. “I only realized this back in January this year. But it wasn’t until March that I took action about it.”\nHaidilao’s share price experienced a sharp dive after rapid growth after the Spring Festival earlier this year. Haidilao’s share price grew by 5.46% and closed at HK$21.05 per share today, setting the company’s valuation at HK$115 billion. In comparison, Haidilao’s share price hit HK$85.75 per share in February, a record high for the company. Haidilao’s valuation even surpassed HK$460 billion at one point.","news_type":1,"symbols_score_info":{"06862":0.9}},"isVote":1,"tweetType":1,"viewCount":1983,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827789810,"gmtCreate":1634523506698,"gmtModify":1634523506960,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"htmlText":"Buy. No regrets&nbsp;","listText":"Buy. No regrets&nbsp;","text":"Buy. No regrets","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/827789810","repostId":"1195761146","repostType":4,"isVote":1,"tweetType":1,"viewCount":2237,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827350558,"gmtCreate":1634425900287,"gmtModify":1634425900490,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"htmlText":"GOOD PICK&nbsp;","listText":"GOOD PICK&nbsp;","text":"GOOD PICK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/827350558","repostId":"2175112192","repostType":4,"isVote":1,"tweetType":1,"viewCount":3492,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":824922247,"gmtCreate":1634271546601,"gmtModify":1634274410181,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"htmlText":"Too high already, time for it to cool down&nbsp;","listText":"Too high already, time for it to cool down&nbsp;","text":"Too high already, time for it to cool down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/824922247","repostId":"2175197255","repostType":4,"isVote":1,"tweetType":1,"viewCount":2827,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":822372590,"gmtCreate":1634096770755,"gmtModify":1634096771021,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"htmlText":"Buy","listText":"Buy","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/822372590","repostId":"1167212018","repostType":4,"repost":{"id":"1167212018","kind":"news","pubTimestamp":1634092916,"share":"https://www.laohu8.com/m/news/1167212018?lang=zh_CN&edition=full","pubTime":"2021-10-13 10:41","market":"us","language":"en","title":"BBIG Stock: What Is Going on With Red-Hot Vinco Ventures Today?<blockquote>BBIG股票：炙手可热的Vinco Ventures今天发生了什么？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1167212018","media":"InvestorPlace","summary":"One of the red-hot stocks that’s generating a lot of retail investor interest of late is Vinco Ventu","content":"<p><div> One of the red-hot stocks that’s generating a lot of retail investor interest of late is Vinco Ventures(NASDAQ:BBIG). Indeed, today’s 17% rise in BBIG stock is among a number of rallies over the past ...</p><p><blockquote><div>Vinco Ventures（纳斯达克股票代码：BBIG）是最近引起散户投资者兴趣的热门股票之一。事实上，今天BBIG股票17%的上涨是过去一系列反弹之一……</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/10/bbig-stock-what-is-going-on-with-red-hot-vinco-ventures-today/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/10/bbig-stock-what-is-going-on-with-red-hot-vinco-ventures-today/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BBIG Stock: What Is Going on With Red-Hot Vinco Ventures Today?<blockquote>BBIG股票：炙手可热的Vinco Ventures今天发生了什么？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBBIG Stock: What Is Going on With Red-Hot Vinco Ventures Today?<blockquote>BBIG股票：炙手可热的Vinco Ventures今天发生了什么？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-10-13 10:41</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> One of the red-hot stocks that’s generating a lot of retail investor interest of late is Vinco Ventures(NASDAQ:BBIG). Indeed, today’s 17% rise in BBIG stock is among a number of rallies over the past ...</p><p><blockquote><div>Vinco Ventures（纳斯达克股票代码：BBIG）是最近引起散户投资者兴趣的热门股票之一。事实上，今天BBIG股票17%的上涨是过去一系列反弹之一……</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/10/bbig-stock-what-is-going-on-with-red-hot-vinco-ventures-today/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/10/bbig-stock-what-is-going-on-with-red-hot-vinco-ventures-today/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/10/bbig-stock-what-is-going-on-with-red-hot-vinco-ventures-today/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BBIG":"Vinco Ventures, Inc."},"source_url":"https://investorplace.com/2021/10/bbig-stock-what-is-going-on-with-red-hot-vinco-ventures-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167212018","content_text":"One of the red-hot stocks that’s generating a lot of retail investor interest of late is Vinco Ventures(NASDAQ:BBIG). Indeed, today’s 17% rise in BBIG stock is among a number of rallies over the past five trading days. Over this timeframe, BBIG stock has provided investors with gains of more than 20%. That is, for those with the guts to invest in this high-volatility name.\nPutting BBIG stock in perspective, this is a company that started the year around $1.35 per share. Since then, shares soared to nearly $12.50 per share last month before settling down to below $5 per share last week. What was a near 10-bagger has turned into a five-bagger. For those holding onto this stock long term, perhaps this volatility is nothing to be concerned with.\nOne of the reasons behind the rapid ebb and flow of BBIG stock has been this company’s relatively high short interest. Indeed, any highly shorted stock is one that’s likely to give retail investors goosebumps. We’ve all seen the rallies in other short squeeze stocks this year.\nHowever, there’s another catalyst investors appear to be jumping on today. Let’s dive into what’s propelling Vinco Ventures higher right now.\nBBIG Stock Surges Ahead of Key Crypto Catalyst\nToday, investors appear to be pricing in enthusiasm around a key crypto update set to be unveiled this Friday. Vinco Ventures recently provided investors with a proxy statement for a spinoff. Titled Cryptyde, this spinoff will aim to allow the company to leverage its blockchain technologies further. By doing so, the company will “disrupt consumer facing industries.”\nSounds good to me.\nInvestors appear to be growing increasingly bullish on crypto-related stocks. Crypto prices have continued to surge in recent weeks. Accordingly, companies such as Vinco Ventures that are not only short-squeeze plays but also ones with crypto exposure, represent perhaps the holy grail for speculators right now.\nHow this spinoff ultimately pans out remains to be seen. However, expectations are that BBIG stock could remain a highly volatile one for some time. Accordingly, this is a stock on my watchlist right now.","news_type":1,"symbols_score_info":{"BBIG":0.9}},"isVote":1,"tweetType":1,"viewCount":1175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829159740,"gmtCreate":1633482174945,"gmtModify":1633482175191,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"htmlText":"Still a falling knife&nbsp;","listText":"Still a falling knife&nbsp;","text":"Still a falling knife","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/829159740","repostId":"2173911317","repostType":4,"isVote":1,"tweetType":1,"viewCount":1037,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829164011,"gmtCreate":1633481487949,"gmtModify":1633481488214,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"htmlText":"Dead cat rebound&nbsp;","listText":"Dead cat rebound&nbsp;","text":"Dead cat rebound","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/829164011","repostId":"1101968131","repostType":4,"isVote":1,"tweetType":1,"viewCount":884,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":867564866,"gmtCreate":1633302618177,"gmtModify":1633302618389,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"htmlText":"Still need to be careful with amc, virus situation still bad. It could mutate again and become more resilient and powerful&nbsp;","listText":"Still need to be careful with amc, virus situation still bad. It could mutate again and become more resilient and powerful&nbsp;","text":"Still need to be careful with amc, virus situation still bad. It could mutate again and become more resilient and powerful","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/867564866","repostId":"1134305481","repostType":4,"repost":{"id":"1134305481","kind":"news","pubTimestamp":1633152909,"share":"https://www.laohu8.com/m/news/1134305481?lang=zh_CN&edition=full","pubTime":"2021-10-02 13:35","market":"us","language":"en","title":"3 Stocks That Can Double Again in the Fourth Quarter<blockquote>四季度可以再次翻倍的3只股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1134305481","media":"The motley fool","summary":"Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this mo","content":"<p>Key Points</p><p><blockquote>要点</blockquote></p><p> <ul>  <li>Crocs has jacked up its guidance every quarter this year. It reports again later this month.</li>  <li>AMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.</li>  <li>Upstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.</li> </ul> </p><p><blockquote><ul><li>Crocs今年每个季度都上调了指引。它将于本月晚些时候再次报道。</li><li>AMC必须在此基础上翻一番才能重温6月份的高点。查看即将上映的影院上映名单，了解为什么电影院会变得更好。</li><li>Upstart正在彻底改变消费贷款中确定信用度的方式，并且一直笑到银行。</li></ul></blockquote></p><p> It's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?</p><p><blockquote>对于股市来说，今年是动荡的一年，但自然有些投资的表现比其他投资更好。超过300只股票在2021年上涨了一倍多。如果许多获胜的投资能够在今年最后三个月保持这些收益，那将是幸运的，但那些有潜力再次翻倍的投资呢？</blockquote></p><p> <b>Crocs</b>&nbsp;(NASDAQ:CROX),<b>AMC Entertainment</b>(NYSE:AMC), and<b>Upstart</b>&nbsp;(NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.</p><p><blockquote><b>卡骆驰</b>（纳斯达克：CROX），<b>AMC院线</b>（纽约证券交易所代码：AMC），以及<b>暴发户</b>（纳斯达克：UPST）的价值在2021年前9个月翻了一番多。让我们看看为什么他们有能力在第四季度重复这一壮举。</blockquote></p><p> 1. Crocs</p><p><blockquote>1.Crocs</blockquote></p><p> Remember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.</p><p><blockquote>还记得那双有洞的亮色胶鞋吗？他们大举回来了。自疫情爆发以来，Crocs的销量一直在蓬勃发展，该股也紧随其后，在2021年前9个月上涨了129%。</blockquote></p><p> The comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.</p><p><blockquote>舒适的树脂鞋在新冠肺炎危机之前就已经卷土重来，2019年的收入实现了两位数的增长，然后在2020年重复了这一壮举。动力才是真正让Crocs在2021年更上一层楼的原因。</blockquote></p><p> The year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?</p><p><blockquote>今年年初，这家鞋类制造商在2月份预计全年营收将增长20%至25%。下个季度的指引被上调至40%至50%之间。这种情况在今年夏天再次发生，Crocs现在的目标是2021年全年收入增长60%至65%。如果本月晚些时候公布第三季度业绩时这些目标被推得更高，您认为会发生什么？</blockquote></p><p> Despite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.</p><p><blockquote>尽管自2019年初以来，Crocs的股价已上涨近六倍，但鉴于其加速增长，其定价合理。该公司今年市盈率为21倍，明年目标市盈率仅为17倍。显然还有增加这些市盈率的空间，华尔街终于像客户一样对Crocs作为一项投资感到满意。</blockquote></p><p> 2. AMC Entertainment</p><p><blockquote>2.AMC院线</blockquote></p><p> You may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.</p><p><blockquote>你可能会惊讶地发现这个国家领先的多厅影院运营商在这个名单上，但情节曲折是电影如此优秀的原因。AMC院线确实已经升值——无论是股价还是流通股数量都增长了五倍——以至于其估值相对于同行来说已经不正常了。如果您想对电影院行业的复苏进行纯粹的投资，您会发现价格更具吸引力的股票。</blockquote></p><p> However, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?</p><p><blockquote>然而，作为一种流行的股票和文化现象，很难否认AMC在复苏过程中将其在散户投资者中的受欢迎程度转化为合法的市场份额抢夺。今年没有一家公司的市值像AMC那样膨胀，但这也是一只进入第四季度的股票，股价仅为6月份峰值时的一半多一点。简而言之，它必须在这里翻倍才能重温历史高点——但对于2021年动量股的典型代表来说，这难道不总是可能的吗？</blockquote></p><p> Fundamentally speaking, the catalysts are also there.<i>Shang-Chi and the Legend of the Ten Rings</i>shattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.</p><p><blockquote>从根本上说，催化剂也在。<i>尚气与十环传说</i>劳动节周末打破了票房记录，但最初的兴奋随着随后的周末糟糕透顶而消失。然而，这一切都与管道有关。当德尔塔变异毒株导致新冠肺炎病例激增时，电影公司将9月的上映推迟到10月及以后。我们现在看到备受期待的电影开始回归，从下周末的新詹姆斯·邦德电影开始。该行业第四季度的表现应该比反对者想象的要强劲得多，如果AMC股价回到6月初的水平——这次基本上是盈利的——那么它将不得不在此基础上翻一番。</blockquote></p><p> 3. Upstart</p><p><blockquote>3.暴发户</blockquote></p><p> I love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.</p><p><blockquote>我喜欢颠覆成熟的行业被颠覆，这就是Upstart在贷款行业所做的事情。Upstart使用人工智能和机器学习来更好地评级评估那些通常不会获得消费贷款批准的人的风险状况和信用度。</blockquote></p><p> Growth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.</p><p><blockquote>增长是疯狂的。收入似乎正在急剧减速，过去三年的增长分别放缓了89%、52%和27%。现在，消费者开始意识到Upstart是发薪日贷款和其他掠夺性贷款产品的更好替代品，业务正在飙升。第一季度收入增长90%，但在最新报告中却飙升了1,018%。不，这不是错别字。</blockquote></p><p></p><p> With Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.</p><p><blockquote>随着Upstart现在扩展到汽车贷款市场，其更好的替代乏味信用评分的潜力才刚刚开始。该股在2021年前三个季度已上涨七倍，但对于这款颠覆性喷气式飞机来说，跑道还很长。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Can Double Again in the Fourth Quarter<blockquote>四季度可以再次翻倍的3只股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Can Double Again in the Fourth Quarter<blockquote>四季度可以再次翻倍的3只股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The motley fool</strong><span class=\"h-time small\">2021-10-02 13:35</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Key Points</p><p><blockquote>要点</blockquote></p><p> <ul>  <li>Crocs has jacked up its guidance every quarter this year. It reports again later this month.</li>  <li>AMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.</li>  <li>Upstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.</li> </ul> </p><p><blockquote><ul><li>Crocs今年每个季度都上调了指引。它将于本月晚些时候再次报道。</li><li>AMC必须在此基础上翻一番才能重温6月份的高点。查看即将上映的影院上映名单，了解为什么电影院会变得更好。</li><li>Upstart正在彻底改变消费贷款中确定信用度的方式，并且一直笑到银行。</li></ul></blockquote></p><p> It's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?</p><p><blockquote>对于股市来说，今年是动荡的一年，但自然有些投资的表现比其他投资更好。超过300只股票在2021年上涨了一倍多。如果许多获胜的投资能够在今年最后三个月保持这些收益，那将是幸运的，但那些有潜力再次翻倍的投资呢？</blockquote></p><p> <b>Crocs</b>&nbsp;(NASDAQ:CROX),<b>AMC Entertainment</b>(NYSE:AMC), and<b>Upstart</b>&nbsp;(NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.</p><p><blockquote><b>卡骆驰</b>（纳斯达克：CROX），<b>AMC院线</b>（纽约证券交易所代码：AMC），以及<b>暴发户</b>（纳斯达克：UPST）的价值在2021年前9个月翻了一番多。让我们看看为什么他们有能力在第四季度重复这一壮举。</blockquote></p><p> 1. Crocs</p><p><blockquote>1.Crocs</blockquote></p><p> Remember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.</p><p><blockquote>还记得那双有洞的亮色胶鞋吗？他们大举回来了。自疫情爆发以来，Crocs的销量一直在蓬勃发展，该股也紧随其后，在2021年前9个月上涨了129%。</blockquote></p><p> The comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.</p><p><blockquote>舒适的树脂鞋在新冠肺炎危机之前就已经卷土重来，2019年的收入实现了两位数的增长，然后在2020年重复了这一壮举。动力才是真正让Crocs在2021年更上一层楼的原因。</blockquote></p><p> The year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?</p><p><blockquote>今年年初，这家鞋类制造商在2月份预计全年营收将增长20%至25%。下个季度的指引被上调至40%至50%之间。这种情况在今年夏天再次发生，Crocs现在的目标是2021年全年收入增长60%至65%。如果本月晚些时候公布第三季度业绩时这些目标被推得更高，您认为会发生什么？</blockquote></p><p> Despite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.</p><p><blockquote>尽管自2019年初以来，Crocs的股价已上涨近六倍，但鉴于其加速增长，其定价合理。该公司今年市盈率为21倍，明年目标市盈率仅为17倍。显然还有增加这些市盈率的空间，华尔街终于像客户一样对Crocs作为一项投资感到满意。</blockquote></p><p> 2. AMC Entertainment</p><p><blockquote>2.AMC院线</blockquote></p><p> You may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.</p><p><blockquote>你可能会惊讶地发现这个国家领先的多厅影院运营商在这个名单上，但情节曲折是电影如此优秀的原因。AMC院线确实已经升值——无论是股价还是流通股数量都增长了五倍——以至于其估值相对于同行来说已经不正常了。如果您想对电影院行业的复苏进行纯粹的投资，您会发现价格更具吸引力的股票。</blockquote></p><p> However, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?</p><p><blockquote>然而，作为一种流行的股票和文化现象，很难否认AMC在复苏过程中将其在散户投资者中的受欢迎程度转化为合法的市场份额抢夺。今年没有一家公司的市值像AMC那样膨胀，但这也是一只进入第四季度的股票，股价仅为6月份峰值时的一半多一点。简而言之，它必须在这里翻倍才能重温历史高点——但对于2021年动量股的典型代表来说，这难道不总是可能的吗？</blockquote></p><p> Fundamentally speaking, the catalysts are also there.<i>Shang-Chi and the Legend of the Ten Rings</i>shattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.</p><p><blockquote>从根本上说，催化剂也在。<i>尚气与十环传说</i>劳动节周末打破了票房记录，但最初的兴奋随着随后的周末糟糕透顶而消失。然而，这一切都与管道有关。当德尔塔变异毒株导致新冠肺炎病例激增时，电影公司将9月的上映推迟到10月及以后。我们现在看到备受期待的电影开始回归，从下周末的新詹姆斯·邦德电影开始。该行业第四季度的表现应该比反对者想象的要强劲得多，如果AMC股价回到6月初的水平——这次基本上是盈利的——那么它将不得不在此基础上翻一番。</blockquote></p><p> 3. Upstart</p><p><blockquote>3.暴发户</blockquote></p><p> I love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.</p><p><blockquote>我喜欢颠覆成熟的行业被颠覆，这就是Upstart在贷款行业所做的事情。Upstart使用人工智能和机器学习来更好地评级评估那些通常不会获得消费贷款批准的人的风险状况和信用度。</blockquote></p><p> Growth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.</p><p><blockquote>增长是疯狂的。收入似乎正在急剧减速，过去三年的增长分别放缓了89%、52%和27%。现在，消费者开始意识到Upstart是发薪日贷款和其他掠夺性贷款产品的更好替代品，业务正在飙升。第一季度收入增长90%，但在最新报告中却飙升了1,018%。不，这不是错别字。</blockquote></p><p></p><p> With Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.</p><p><blockquote>随着Upstart现在扩展到汽车贷款市场，其更好的替代乏味信用评分的潜力才刚刚开始。该股在2021年前三个季度已上涨七倍，但对于这款颠覆性喷气式飞机来说，跑道还很长。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/\">The motley fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UPST":"Upstart Holdings, Inc.","AMC":"AMC院线","CROX":"卡骆驰"},"source_url":"https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134305481","content_text":"Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this month.\nAMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.\nUpstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.\n\n\nIt's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?\nCrocs (NASDAQ:CROX),AMC Entertainment(NYSE:AMC), andUpstart (NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.\n1. Crocs\nRemember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.\nThe comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.\nThe year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?\nDespite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.\n2. AMC Entertainment\nYou may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.\nHowever, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?\nFundamentally speaking, the catalysts are also there.Shang-Chi and the Legend of the Ten Ringsshattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.\n3. Upstart\nI love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.\nGrowth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.\nWith Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.","news_type":1,"symbols_score_info":{"CROX":0.9,"AMC":0.9,"UPST":0.9}},"isVote":1,"tweetType":1,"viewCount":1360,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":867566905,"gmtCreate":1633302436726,"gmtModify":1633302436922,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"htmlText":"V good recommendations. I will include visa also&nbsp;","listText":"V good recommendations. I will include visa also&nbsp;","text":"V good recommendations. I will include visa also","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/867566905","repostId":"2172614079","repostType":4,"isVote":1,"tweetType":1,"viewCount":957,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864460267,"gmtCreate":1633139179949,"gmtModify":1633139635194,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"htmlText":"Will report at the hell. Not worth trading&nbsp;[开心]&nbsp;","listText":"Will report at the hell. Not worth trading&nbsp;[开心]&nbsp;","text":"Will report at the hell. Not worth trading [开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/864460267","repostId":"2172968387","repostType":4,"isVote":1,"tweetType":1,"viewCount":1078,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":883295372,"gmtCreate":1631241789396,"gmtModify":1631883559586,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"htmlText":"See, con women, say Tesla worth $3000/share, but dump it after her announcement not long ago. Her followers all have to safe keep those she dumped&nbsp;","listText":"See, con women, say Tesla worth $3000/share, but dump it after her announcement not long ago. Her followers all have to safe keep those she dumped&nbsp;","text":"See, con women, say Tesla worth $3000/share, but dump it after her announcement not long ago. Her followers all have to safe keep those she dumped","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/883295372","repostId":"1117851011","repostType":4,"isVote":1,"tweetType":1,"viewCount":829,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":889432961,"gmtCreate":1631167227953,"gmtModify":1631884166336,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>Aviod, more downside to come.&nbsp;","listText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>Aviod, more downside to come.&nbsp;","text":"$GameStop(GME)$Aviod, more downside to come.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/889432961","isVote":1,"tweetType":1,"viewCount":596,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":889183816,"gmtCreate":1631114512235,"gmtModify":1631889326757,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"htmlText":"She's playing with fire. Hopeful to win big. A dangerous speculators. Not worth following.&nbsp;","listText":"She's playing with fire. Hopeful to win big. A dangerous speculators. Not worth following.&nbsp;","text":"She's playing with fire. Hopeful to win big. A dangerous speculators. Not worth following.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/889183816","repostId":"1180788041","repostType":4,"repost":{"id":"1180788041","kind":"news","pubTimestamp":1631062558,"share":"https://www.laohu8.com/m/news/1180788041?lang=zh_CN&edition=full","pubTime":"2021-09-08 08:55","market":"us","language":"en","title":"Wall Street's hottest investor is betting big on a handful of stocks. Critics say she's playing with fire<blockquote>华尔街最炙手可热的投资者正在少数股票上下大赌注。批评者说她在玩火</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1180788041","media":"CNN Business","summary":"New York  - At a time when many investors are content to follow the crowd and buy top techs like Apple, Amazon and Microsoft, Cathie Wood is looking for the next big innovators in buzzy fields like robotics, fintech and space exploration.It's a high-flying, high-risk, high-reward tier of investing. And it's put Wood's fans on a white-knuckle ride in 2021.Last year, Wood's strategy paid huge dividends for investors in her flagship Ark Innovation exchange-traded fund. It surged nearly 150% in 2020","content":"<p><b>New York (CNN Business)&nbsp;-&nbsp;</b>At a time when many investors are content to follow the crowd and buy top techs like Apple, Amazon and Microsoft, Cathie Wood is looking for the next big innovators in buzzy fields like robotics, fintech and space exploration.</p><p><blockquote><b>纽约（CNN商业）——</b>当许多投资者满足于随大流并购买苹果、亚马逊和微软等顶级科技公司时，凯西·伍德正在机器人、金融科技和太空探索等热门领域寻找下一个大创新者。</blockquote></p><p> It's a high-flying, high-risk, high-reward tier of investing. And it's put Wood's fans on a white-knuckle ride in 2021.</p><p><blockquote>这是一个雄心勃勃、高风险、高回报的投资层次。这让伍德的粉丝们在2021年感到紧张。</blockquote></p><p> Last year, Wood's strategy paid huge dividends for investors in her flagship&nbsp;Ark Innovation(ARKK)&nbsp;exchange-traded fund. It surged nearly 150% in 2020 and helped turn her into a Wall Street superstar — sort of the Warren Buffett of momentum investing.</p><p><blockquote>去年，伍德的策略为其旗舰方舟创新（ARKK）交易所交易基金的投资者带来了巨额股息。2020年股价飙升近150%，帮助她成为华尔街巨星——有点像动量投资界的沃伦·巴菲特。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/120f0d157792edd784c8787a1c05e955\" tg-width=\"1100\" tg-height=\"619\" width=\"100%\" height=\"auto\"><span>Cathie Wood, CEO of Ark Investment Management, has become the face of the growth stock movement on Wall Street.</span></p><p><blockquote><p class=\"t-img-caption\"><span>方舟投资管理公司首席执行官凯西·伍德(Cathie Wood)已成为华尔街成长股运动的代言人。</span></p></blockquote></p><p> But this year hasn't been nearly as kind to Wood as the last. The Innovation ETF was down 2.5% through late August, despite a red-hot market for tech with the Nasdaq up more than 18% so far in 2021.</p><p><blockquote>但是今年对伍德来说并不像去年那么好。尽管科技市场炙手可热，2021年迄今为止纳斯达克上涨了18%以上，但截至8月底，创新ETF仍下跌了2.5%。</blockquote></p><p> Wood wasn't available to comment for this story, but she doubled down in&nbsp;an interview with CNBC&nbsp;in August. She's not worried that the Ark strategy of looking for new tech leaders will end badly, and she maintains that this current rally will not be a repeat of the epic 2000 dot-com implosion.</p><p><blockquote>伍德无法对此事发表评论，但她在8月份接受CNBC采访时加倍了评论。她并不担心寻找新科技领导者的方舟战略会以糟糕的结局告终，她坚持认为当前的反弹不会重演2000年史诗般的互联网内爆。</blockquote></p><p> \"I don't think we're in a bubble, which is what I think many bears think we are,\" Wood told CNBC. \"We have nothing like that right now. In fact, you see a lot of IPOs or SPACs coming out and falling to Earth. We couldn't be further away from a bubble.\"</p><p><blockquote>伍德对CNBC表示：“我不认为我们处于泡沫之中，我认为许多空头认为我们处于泡沫之中。”“我们现在没有这样的东西。事实上，你会看到很多IPO或SPAC上市，然后落地。我们离泡沫已经不远了。”</blockquote></p><p> <b>How Wood developed her strategy</b></p><p><blockquote><b>伍德如何制定她的战略</b></blockquote></p><p> Wood speaks from experience. She's no millennial or Gen Z investor for whom the 2000 tech implosion is merely a war story told by older traders. The 65-year-old Wood lived through the last major tech crash, as well as the infamous Black Monday of 1987.</p><p><blockquote>伍德凭经验说话。她不是千禧一代或Z世代投资者，对他们来说，2000年的科技内爆只是年长交易者讲述的战争故事。65岁的伍德经历了上一次重大科技崩盘，以及1987年臭名昭著的黑色星期一。</blockquote></p><p> She worked for Prudential-owned money manager Jennison Associates for 18 years in the 1980s and 1990s and then spent a dozen years at AllianceBernstein before leaving in 2013.</p><p><blockquote>20世纪80年代和90年代，她在保诚旗下的基金管理公司Jennison Associates工作了18年，然后在联博工作了十几年，然后于2013年离职。</blockquote></p><p> But then, AllianceBernstein passed on her idea to launch a suite of actively managed exchange-traded funds. So she struck out on her own and started Ark in 2014.</p><p><blockquote>但随后，联博传递了她的想法，推出了一套主动管理型交易所交易基金。因此，她独自一人，在2014年创办了Ark。</blockquote></p><p> \"I have been watching disruptive innovation for my entire career — why don't I help my own sector along?\" she&nbsp;told Forbes&nbsp;in a 2014 interview.</p><p><blockquote>“在我的整个职业生涯中，我一直在关注颠覆性创新——为什么我不帮助自己的行业呢？”她在2014年的一次采访中告诉《福布斯》。</blockquote></p><p> That focus on disruption means Wood ties her ETF's fortunes to visionary but mercurial leaders.</p><p><blockquote>这种对颠覆性的关注意味着伍德将她的ETF的命运与富有远见但善变的领导者联系在一起。</blockquote></p><p> In the most prominent example, Wood remains an unabashed fan of&nbsp;Tesla(TSLA)&nbsp;and CEO Elon Musk. The EV maker is the top stock, by far, in Ark's Innovation ETF, accounting for more than 10% of the fund's holdings. It's also the biggest position in Ark's&nbsp;Autonomous Technology &amp; Robotics(ARKQ)&nbsp;and&nbsp;Next Generation Internet(ARKW)&nbsp;ETFs.</p><p><blockquote>最突出的例子是，伍德仍然是特斯拉(TSLA)和首席执行官Elon Musk的毫不掩饰的粉丝。迄今为止，这家电动汽车制造商是Ark创新ETF中排名第一的股票，占该基金持股的10%以上。它也是Ark自主技术与机器人(ARKQ)和下一代互联网(ARKW)ETF中最大的头寸。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/425dc1ea59eb1c068eaba7a392e6c04d\" tg-width=\"1100\" tg-height=\"619\" width=\"100%\" height=\"auto\"><span>Wood is a vocal fan of Tesla, which is a top holding in several of Ark's funds.</span></p><p><blockquote><p class=\"t-img-caption\"><span>伍德是特斯拉的忠实粉丝，该公司是Ark旗下多只基金的重仓股。</span></p></blockquote></p><p> Wood is also OK with companies like Tesla issuing more stock to raise money to fund futuristic projects like autonomous vehicles. Some investors are wary of that strategy because the new shares lower the value of existing investors' holdings, but she thinks that's a short-sighted argument, particularly from Tesla bears.</p><p><blockquote>伍德也同意特斯拉等公司发行更多股票来筹集资金，为自动驾驶汽车等未来项目提供资金。一些投资者对这一策略持谨慎态度，因为新股会降低现有投资者持股的价值，但她认为这是一种短视的观点，尤其是来自特斯拉空头的观点。</blockquote></p><p> \"We're not afraid of dilution ... if we think they're doing it for the right reason,\" she told CNBC. \"We wanted them to scale as quickly as possible because we think if we're right on autonomous ...Tesla could get the lion's share of that market, certainly in the United States.\"</p><p><blockquote>“我们不怕稀释……如果我们认为他们这样做是出于正确的原因，”她告诉CNBC。“我们希望他们尽快扩大规模，因为我们认为如果我们在自动驾驶方面是正确的……特斯拉可以获得该市场的最大份额，当然是在美国。”</blockquote></p><p> Ark's big investment in Tesla is a bet on Musk continuing to innovate beyond the business of electric cars, Wood explained in an&nbsp;interview with Bloomberg Radio&nbsp;in August. She raved about Tesla's plans to&nbsp;build a humanoid robot, for example.</p><p><blockquote>伍德在8月份接受彭博电台采访时解释说，方舟对特斯拉的巨额投资是押注马斯克在电动汽车业务之外继续创新。例如，她对特斯拉制造人形机器人的计划赞不绝口。</blockquote></p><p> \"Every passing day, especially the more we learn about their AI expertise and how they're really driving the space ... we believe they have the pole position,\" she said, noting that Ark analysts were \"blown away\" by Musk's presentation.</p><p><blockquote>“日复一日，尤其是我们对他们的人工智能专业知识以及他们如何真正推动该领域的了解越多……我们相信他们拥有领先地位，”她说，并指出方舟分析师被马斯克的演讲“震惊”了。</blockquote></p><p> <b>Growth at all costs</b></p><p><blockquote><b>不惜一切代价实现增长</b></blockquote></p><p> Wood recognizes her growth-at-all-costs way of investing is not for everyone.</p><p><blockquote>伍德认识到，她不惜一切代价实现增长的投资方式并不适合所有人。</blockquote></p><p> Tesla has lagged the broader market this year. Shares of&nbsp;Teladoc(TDOC), a telehealth company that is the second-largest holding in the Ark Innovation ETF and was a big winner at the start of the pandemic, are down more than 25% in 2021.</p><p><blockquote>特斯拉今年表现落后于大盘。Teladoc(TDOC)是一家远程医疗公司，是Ark Innovation ETF的第二大持股，也是疫情爆发之初的大赢家，其股价在2021年下跌了25%以上。</blockquote></p><p> \"We've seen higher-valuation stocks hit hard this year. But the growth for these innovative companies will still be treated well over time,\" Wood said&nbsp;during a webcast&nbsp;hosted by Cboe Global Markets in March.</p><p><blockquote>“我们看到估值较高的股票今年遭受重创。但随着时间的推移，这些创新型公司的增长仍将受到良好对待，”伍德在3月份由芝加哥期权交易所全球市场主办的网络直播中表示。</blockquote></p><p></p><p> Wood added that she thinks investors also should put a small percentage of their money in bitcoin, another risky bet. And she stressed that investors have to overlook the inevitable short-term bumps that come with any asset. It's essential to maintain longer-term convictions and invest for future growth, Wood believes.</p><p><blockquote>伍德补充说，她认为投资者也应该将一小部分资金投入比特币，这是另一个高风险的赌注。她强调，投资者必须忽视任何资产不可避免的短期波动。伍德认为，保持长期信念并为未来增长进行投资至关重要。</blockquote></p><p> \"A lot of companies catering to short-term investors who wanted profits now [have] invested more in stock buybacks and dividends over innovation,\" she said. \"That puts them in harm's way.\"</p><p><blockquote>“许多迎合想要利润的短期投资者的公司现在在股票回购和股息上的投资超过了创新，”她说。“这让他们处于危险之中。”</blockquote></p><p> A colleague describes Wood's go-big-or-go-home approach as a model for the new way of investing. Too many fund managers are afraid to look far into the future when judging a company's merits, instead focusing myopically on the prior and next quarterly earnings reports.</p><p><blockquote>一位同事将伍德的“要么做大，要么回家”方法描述为新投资方式的典范。太多的基金经理在判断一家公司的优点时不敢展望未来，而是短视地关注上一季度和下一季度的收益报告。</blockquote></p><p> \"Cathie has been focusing on Tesla for a long time. She looks at it not just as an automobile manufacturer. You can't compare it to traditional car companies,\"&nbsp;Ark Invest's Ren Leggi, who works closely with Wood on investment decisions as the company's client portfolio manager, told&nbsp;CNN Business in March.</p><p><blockquote>Ark Invest的Ren Leggi在3月份告诉CNN Business：“Cathie长期以来一直关注特斯拉。她不仅仅将其视为一家汽车制造商。你不能将其与传统汽车公司相提并论。”他作为该公司的客户投资组合经理，在投资决策上与伍德密切合作。</blockquote></p><p> <b>Wood's critics</b></p><p><blockquote><b>伍德的批评者</b></blockquote></p><p> But a growing chorus of skeptics think Wood's funds could eventually collapse. Michael Burry, one of the super-bearish investors made famous in \"The Big Short,\" recently established a short position on the Ark Innovation ETF — essentially betting that it will fall sharply.</p><p><blockquote>但越来越多的怀疑者认为伍德的基金最终可能会崩溃。迈克尔·伯里(Michael Burry)是因《大空头》而闻名的超级看跌投资者之一，他最近在Ark Innovation ETF上建立了空头头寸——本质上是押注该基金将大幅下跌。</blockquote></p><p> Some tech stock veterans also wonder if Wood is just an investing flavor of the month, comparing her to once-popular portfolio managers like Kevin Landis of Firsthand Funds, Alberto Vilar of Amerindo and Garrett Van Wagoner, who ran a popular emerging-growth fund in the late 1990s.</p><p><blockquote>一些科技股资深人士还想知道伍德是否只是本月的投资风云人物，将她与Firsthand Funds的凯文·兰迪斯(Kevin Landis)、Amerindo的阿尔贝托·维拉尔(Alberto Vilar)和在20世纪90年代末运营着一只受欢迎的新兴增长基金的加勒特·范·瓦格纳(Garrett Van Wagoner)等曾经受欢迎的投资组合经理进行了比较。</blockquote></p><p> Many of those tech funds imploded following the 2000 bubble. The<i>Wall Street Journal</i>wrote a catch-up piece about Van Wagoner and other late 1990s tech gurus in 2010&nbsp;with the headline \"From Fame, Fortune to Flamed-Out Stars. Post-Bust Fates of Tech-Fund Mavens.\"</p><p><blockquote>许多科技基金在2000年泡沫之后崩溃了。The<i>华尔街日报</i>2010年，他写了一篇关于范·瓦格纳和其他20世纪90年代末科技大师的后续文章，标题是“从名声、财富到燃烧的明星。科技基金专家的破产后命运。”</blockquote></p><p> Is Wood destined for similar ignominy?</p><p><blockquote>伍德注定会遭受类似的耻辱吗？</blockquote></p><p> Rivals take issue with Wood making such big bets on only a handful of stocks. The Ark Innovation ETF, for example, has nearly half its assets concentrated in its top 10 holdings. Beyond Tesla, that fund also owns sizable stakes in&nbsp;Roku(ROKU),Coinbase,Zoom(ZM)&nbsp;and&nbsp;Square(SQ).</p><p><blockquote>竞争对手对伍德只在少数股票上下如此大的赌注提出异议。例如，Ark Innovation ETF近一半的资产集中在其前10名持股中。除了特斯拉之外，该基金还拥有Roku（Roku）、Coinbase、Zoom（ZM）和Square（SQ）的大量股份。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c02cbbe0138a0aaa5b930521275ad26e\" tg-width=\"1100\" tg-height=\"619\" width=\"100%\" height=\"auto\"><span>Roku is another example of a high-risk/high-reward stock that Wood loves.</span></p><p><blockquote><p class=\"t-img-caption\"><span>Roku是伍德喜欢的高风险/高回报股票的另一个例子。</span></p></blockquote></p><p> \"Our investment approach is similar to Ark in that we are focusing on tech. But we're different in that we avoid concentration,\"Jeremie Capron, head of research at ROBO Global, told CNN Business in March.</p><p><blockquote>ROBO Global研究主管Jeremie Capron 3月份对CNN Business表示：“我们的投资方式与Ark类似，因为我们专注于科技。但我们的不同之处在于我们避免集中。”</blockquote></p><p> The top 10 holdings in theROBO Global Robotics and Automation Index(ROBO)ETF&nbsp;account for less than 20% of the fund's total assets, and the fund owns about 80 stocks. Ark funds typically own shares in only about 30 to 50 companies.</p><p><blockquote>theROBO全球机器人与自动化指数（ROBO）ETF的前10大持股占该基金总资产的比例不到20%，该基金拥有约80只股票。方舟基金通常只拥有大约30到50家公司的股票。</blockquote></p><p> For the time being, Wood is having the last laugh.</p><p><blockquote>目前，伍德笑到了最后。</blockquote></p><p> Yes, her fund's returns may be volatile year-to-year — the Ark Innovation ETF fell nearly 25% in 2018 before rebounding 30% in 2019 — but it has tended to smooth out. The five-year average annualized return for the Ark Innovation ETF through mid-2021 was 48.6%, compared to 17.7% for the S&amp;P 500.</p><p><blockquote>是的，她的基金的回报可能逐年波动——Ark Innovation ETF在2018年下跌了近25%，然后在2019年反弹了30%——但它已经趋于平稳。截至2021年中期，Ark Innovation ETF的五年平均年化回报率为48.6%，而标普500为17.7%。</blockquote></p><p> As long as that long-term trend continues, Ark acolytes may forgive a down year every now and then as Wood continues to swing for the fences.</p><p><blockquote>只要这种长期趋势持续下去，方舟的追随者可能会时不时地原谅低迷的一年，因为伍德继续摇摆。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street's hottest investor is betting big on a handful of stocks. Critics say she's playing with fire<blockquote>华尔街最炙手可热的投资者正在少数股票上下大赌注。批评者说她在玩火</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street's hottest investor is betting big on a handful of stocks. Critics say she's playing with fire<blockquote>华尔街最炙手可热的投资者正在少数股票上下大赌注。批评者说她在玩火</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">CNN Business</strong><span class=\"h-time small\">2021-09-08 08:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>New York (CNN Business)&nbsp;-&nbsp;</b>At a time when many investors are content to follow the crowd and buy top techs like Apple, Amazon and Microsoft, Cathie Wood is looking for the next big innovators in buzzy fields like robotics, fintech and space exploration.</p><p><blockquote><b>纽约（CNN商业）——</b>当许多投资者满足于随大流并购买苹果、亚马逊和微软等顶级科技公司时，凯西·伍德正在机器人、金融科技和太空探索等热门领域寻找下一个大创新者。</blockquote></p><p> It's a high-flying, high-risk, high-reward tier of investing. And it's put Wood's fans on a white-knuckle ride in 2021.</p><p><blockquote>这是一个雄心勃勃、高风险、高回报的投资层次。这让伍德的粉丝们在2021年感到紧张。</blockquote></p><p> Last year, Wood's strategy paid huge dividends for investors in her flagship&nbsp;Ark Innovation(ARKK)&nbsp;exchange-traded fund. It surged nearly 150% in 2020 and helped turn her into a Wall Street superstar — sort of the Warren Buffett of momentum investing.</p><p><blockquote>去年，伍德的策略为其旗舰方舟创新（ARKK）交易所交易基金的投资者带来了巨额股息。2020年股价飙升近150%，帮助她成为华尔街巨星——有点像动量投资界的沃伦·巴菲特。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/120f0d157792edd784c8787a1c05e955\" tg-width=\"1100\" tg-height=\"619\" width=\"100%\" height=\"auto\"><span>Cathie Wood, CEO of Ark Investment Management, has become the face of the growth stock movement on Wall Street.</span></p><p><blockquote><p class=\"t-img-caption\"><span>方舟投资管理公司首席执行官凯西·伍德(Cathie Wood)已成为华尔街成长股运动的代言人。</span></p></blockquote></p><p> But this year hasn't been nearly as kind to Wood as the last. The Innovation ETF was down 2.5% through late August, despite a red-hot market for tech with the Nasdaq up more than 18% so far in 2021.</p><p><blockquote>但是今年对伍德来说并不像去年那么好。尽管科技市场炙手可热，2021年迄今为止纳斯达克上涨了18%以上，但截至8月底，创新ETF仍下跌了2.5%。</blockquote></p><p> Wood wasn't available to comment for this story, but she doubled down in&nbsp;an interview with CNBC&nbsp;in August. She's not worried that the Ark strategy of looking for new tech leaders will end badly, and she maintains that this current rally will not be a repeat of the epic 2000 dot-com implosion.</p><p><blockquote>伍德无法对此事发表评论，但她在8月份接受CNBC采访时加倍了评论。她并不担心寻找新科技领导者的方舟战略会以糟糕的结局告终，她坚持认为当前的反弹不会重演2000年史诗般的互联网内爆。</blockquote></p><p> \"I don't think we're in a bubble, which is what I think many bears think we are,\" Wood told CNBC. \"We have nothing like that right now. In fact, you see a lot of IPOs or SPACs coming out and falling to Earth. We couldn't be further away from a bubble.\"</p><p><blockquote>伍德对CNBC表示：“我不认为我们处于泡沫之中，我认为许多空头认为我们处于泡沫之中。”“我们现在没有这样的东西。事实上，你会看到很多IPO或SPAC上市，然后落地。我们离泡沫已经不远了。”</blockquote></p><p> <b>How Wood developed her strategy</b></p><p><blockquote><b>伍德如何制定她的战略</b></blockquote></p><p> Wood speaks from experience. She's no millennial or Gen Z investor for whom the 2000 tech implosion is merely a war story told by older traders. The 65-year-old Wood lived through the last major tech crash, as well as the infamous Black Monday of 1987.</p><p><blockquote>伍德凭经验说话。她不是千禧一代或Z世代投资者，对他们来说，2000年的科技内爆只是年长交易者讲述的战争故事。65岁的伍德经历了上一次重大科技崩盘，以及1987年臭名昭著的黑色星期一。</blockquote></p><p> She worked for Prudential-owned money manager Jennison Associates for 18 years in the 1980s and 1990s and then spent a dozen years at AllianceBernstein before leaving in 2013.</p><p><blockquote>20世纪80年代和90年代，她在保诚旗下的基金管理公司Jennison Associates工作了18年，然后在联博工作了十几年，然后于2013年离职。</blockquote></p><p> But then, AllianceBernstein passed on her idea to launch a suite of actively managed exchange-traded funds. So she struck out on her own and started Ark in 2014.</p><p><blockquote>但随后，联博传递了她的想法，推出了一套主动管理型交易所交易基金。因此，她独自一人，在2014年创办了Ark。</blockquote></p><p> \"I have been watching disruptive innovation for my entire career — why don't I help my own sector along?\" she&nbsp;told Forbes&nbsp;in a 2014 interview.</p><p><blockquote>“在我的整个职业生涯中，我一直在关注颠覆性创新——为什么我不帮助自己的行业呢？”她在2014年的一次采访中告诉《福布斯》。</blockquote></p><p> That focus on disruption means Wood ties her ETF's fortunes to visionary but mercurial leaders.</p><p><blockquote>这种对颠覆性的关注意味着伍德将她的ETF的命运与富有远见但善变的领导者联系在一起。</blockquote></p><p> In the most prominent example, Wood remains an unabashed fan of&nbsp;Tesla(TSLA)&nbsp;and CEO Elon Musk. The EV maker is the top stock, by far, in Ark's Innovation ETF, accounting for more than 10% of the fund's holdings. It's also the biggest position in Ark's&nbsp;Autonomous Technology &amp; Robotics(ARKQ)&nbsp;and&nbsp;Next Generation Internet(ARKW)&nbsp;ETFs.</p><p><blockquote>最突出的例子是，伍德仍然是特斯拉(TSLA)和首席执行官Elon Musk的毫不掩饰的粉丝。迄今为止，这家电动汽车制造商是Ark创新ETF中排名第一的股票，占该基金持股的10%以上。它也是Ark自主技术与机器人(ARKQ)和下一代互联网(ARKW)ETF中最大的头寸。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/425dc1ea59eb1c068eaba7a392e6c04d\" tg-width=\"1100\" tg-height=\"619\" width=\"100%\" height=\"auto\"><span>Wood is a vocal fan of Tesla, which is a top holding in several of Ark's funds.</span></p><p><blockquote><p class=\"t-img-caption\"><span>伍德是特斯拉的忠实粉丝，该公司是Ark旗下多只基金的重仓股。</span></p></blockquote></p><p> Wood is also OK with companies like Tesla issuing more stock to raise money to fund futuristic projects like autonomous vehicles. Some investors are wary of that strategy because the new shares lower the value of existing investors' holdings, but she thinks that's a short-sighted argument, particularly from Tesla bears.</p><p><blockquote>伍德也同意特斯拉等公司发行更多股票来筹集资金，为自动驾驶汽车等未来项目提供资金。一些投资者对这一策略持谨慎态度，因为新股会降低现有投资者持股的价值，但她认为这是一种短视的观点，尤其是来自特斯拉空头的观点。</blockquote></p><p> \"We're not afraid of dilution ... if we think they're doing it for the right reason,\" she told CNBC. \"We wanted them to scale as quickly as possible because we think if we're right on autonomous ...Tesla could get the lion's share of that market, certainly in the United States.\"</p><p><blockquote>“我们不怕稀释……如果我们认为他们这样做是出于正确的原因，”她告诉CNBC。“我们希望他们尽快扩大规模，因为我们认为如果我们在自动驾驶方面是正确的……特斯拉可以获得该市场的最大份额，当然是在美国。”</blockquote></p><p> Ark's big investment in Tesla is a bet on Musk continuing to innovate beyond the business of electric cars, Wood explained in an&nbsp;interview with Bloomberg Radio&nbsp;in August. She raved about Tesla's plans to&nbsp;build a humanoid robot, for example.</p><p><blockquote>伍德在8月份接受彭博电台采访时解释说，方舟对特斯拉的巨额投资是押注马斯克在电动汽车业务之外继续创新。例如，她对特斯拉制造人形机器人的计划赞不绝口。</blockquote></p><p> \"Every passing day, especially the more we learn about their AI expertise and how they're really driving the space ... we believe they have the pole position,\" she said, noting that Ark analysts were \"blown away\" by Musk's presentation.</p><p><blockquote>“日复一日，尤其是我们对他们的人工智能专业知识以及他们如何真正推动该领域的了解越多……我们相信他们拥有领先地位，”她说，并指出方舟分析师被马斯克的演讲“震惊”了。</blockquote></p><p> <b>Growth at all costs</b></p><p><blockquote><b>不惜一切代价实现增长</b></blockquote></p><p> Wood recognizes her growth-at-all-costs way of investing is not for everyone.</p><p><blockquote>伍德认识到，她不惜一切代价实现增长的投资方式并不适合所有人。</blockquote></p><p> Tesla has lagged the broader market this year. Shares of&nbsp;Teladoc(TDOC), a telehealth company that is the second-largest holding in the Ark Innovation ETF and was a big winner at the start of the pandemic, are down more than 25% in 2021.</p><p><blockquote>特斯拉今年表现落后于大盘。Teladoc(TDOC)是一家远程医疗公司，是Ark Innovation ETF的第二大持股，也是疫情爆发之初的大赢家，其股价在2021年下跌了25%以上。</blockquote></p><p> \"We've seen higher-valuation stocks hit hard this year. But the growth for these innovative companies will still be treated well over time,\" Wood said&nbsp;during a webcast&nbsp;hosted by Cboe Global Markets in March.</p><p><blockquote>“我们看到估值较高的股票今年遭受重创。但随着时间的推移，这些创新型公司的增长仍将受到良好对待，”伍德在3月份由芝加哥期权交易所全球市场主办的网络直播中表示。</blockquote></p><p></p><p> Wood added that she thinks investors also should put a small percentage of their money in bitcoin, another risky bet. And she stressed that investors have to overlook the inevitable short-term bumps that come with any asset. It's essential to maintain longer-term convictions and invest for future growth, Wood believes.</p><p><blockquote>伍德补充说，她认为投资者也应该将一小部分资金投入比特币，这是另一个高风险的赌注。她强调，投资者必须忽视任何资产不可避免的短期波动。伍德认为，保持长期信念并为未来增长进行投资至关重要。</blockquote></p><p> \"A lot of companies catering to short-term investors who wanted profits now [have] invested more in stock buybacks and dividends over innovation,\" she said. \"That puts them in harm's way.\"</p><p><blockquote>“许多迎合想要利润的短期投资者的公司现在在股票回购和股息上的投资超过了创新，”她说。“这让他们处于危险之中。”</blockquote></p><p> A colleague describes Wood's go-big-or-go-home approach as a model for the new way of investing. Too many fund managers are afraid to look far into the future when judging a company's merits, instead focusing myopically on the prior and next quarterly earnings reports.</p><p><blockquote>一位同事将伍德的“要么做大，要么回家”方法描述为新投资方式的典范。太多的基金经理在判断一家公司的优点时不敢展望未来，而是短视地关注上一季度和下一季度的收益报告。</blockquote></p><p> \"Cathie has been focusing on Tesla for a long time. She looks at it not just as an automobile manufacturer. You can't compare it to traditional car companies,\"&nbsp;Ark Invest's Ren Leggi, who works closely with Wood on investment decisions as the company's client portfolio manager, told&nbsp;CNN Business in March.</p><p><blockquote>Ark Invest的Ren Leggi在3月份告诉CNN Business：“Cathie长期以来一直关注特斯拉。她不仅仅将其视为一家汽车制造商。你不能将其与传统汽车公司相提并论。”他作为该公司的客户投资组合经理，在投资决策上与伍德密切合作。</blockquote></p><p> <b>Wood's critics</b></p><p><blockquote><b>伍德的批评者</b></blockquote></p><p> But a growing chorus of skeptics think Wood's funds could eventually collapse. Michael Burry, one of the super-bearish investors made famous in \"The Big Short,\" recently established a short position on the Ark Innovation ETF — essentially betting that it will fall sharply.</p><p><blockquote>但越来越多的怀疑者认为伍德的基金最终可能会崩溃。迈克尔·伯里(Michael Burry)是因《大空头》而闻名的超级看跌投资者之一，他最近在Ark Innovation ETF上建立了空头头寸——本质上是押注该基金将大幅下跌。</blockquote></p><p> Some tech stock veterans also wonder if Wood is just an investing flavor of the month, comparing her to once-popular portfolio managers like Kevin Landis of Firsthand Funds, Alberto Vilar of Amerindo and Garrett Van Wagoner, who ran a popular emerging-growth fund in the late 1990s.</p><p><blockquote>一些科技股资深人士还想知道伍德是否只是本月的投资风云人物，将她与Firsthand Funds的凯文·兰迪斯(Kevin Landis)、Amerindo的阿尔贝托·维拉尔(Alberto Vilar)和在20世纪90年代末运营着一只受欢迎的新兴增长基金的加勒特·范·瓦格纳(Garrett Van Wagoner)等曾经受欢迎的投资组合经理进行了比较。</blockquote></p><p> Many of those tech funds imploded following the 2000 bubble. The<i>Wall Street Journal</i>wrote a catch-up piece about Van Wagoner and other late 1990s tech gurus in 2010&nbsp;with the headline \"From Fame, Fortune to Flamed-Out Stars. Post-Bust Fates of Tech-Fund Mavens.\"</p><p><blockquote>许多科技基金在2000年泡沫之后崩溃了。The<i>华尔街日报</i>2010年，他写了一篇关于范·瓦格纳和其他20世纪90年代末科技大师的后续文章，标题是“从名声、财富到燃烧的明星。科技基金专家的破产后命运。”</blockquote></p><p> Is Wood destined for similar ignominy?</p><p><blockquote>伍德注定会遭受类似的耻辱吗？</blockquote></p><p> Rivals take issue with Wood making such big bets on only a handful of stocks. The Ark Innovation ETF, for example, has nearly half its assets concentrated in its top 10 holdings. Beyond Tesla, that fund also owns sizable stakes in&nbsp;Roku(ROKU),Coinbase,Zoom(ZM)&nbsp;and&nbsp;Square(SQ).</p><p><blockquote>竞争对手对伍德只在少数股票上下如此大的赌注提出异议。例如，Ark Innovation ETF近一半的资产集中在其前10名持股中。除了特斯拉之外，该基金还拥有Roku（Roku）、Coinbase、Zoom（ZM）和Square（SQ）的大量股份。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c02cbbe0138a0aaa5b930521275ad26e\" tg-width=\"1100\" tg-height=\"619\" width=\"100%\" height=\"auto\"><span>Roku is another example of a high-risk/high-reward stock that Wood loves.</span></p><p><blockquote><p class=\"t-img-caption\"><span>Roku是伍德喜欢的高风险/高回报股票的另一个例子。</span></p></blockquote></p><p> \"Our investment approach is similar to Ark in that we are focusing on tech. But we're different in that we avoid concentration,\"Jeremie Capron, head of research at ROBO Global, told CNN Business in March.</p><p><blockquote>ROBO Global研究主管Jeremie Capron 3月份对CNN Business表示：“我们的投资方式与Ark类似，因为我们专注于科技。但我们的不同之处在于我们避免集中。”</blockquote></p><p> The top 10 holdings in theROBO Global Robotics and Automation Index(ROBO)ETF&nbsp;account for less than 20% of the fund's total assets, and the fund owns about 80 stocks. Ark funds typically own shares in only about 30 to 50 companies.</p><p><blockquote>theROBO全球机器人与自动化指数（ROBO）ETF的前10大持股占该基金总资产的比例不到20%，该基金拥有约80只股票。方舟基金通常只拥有大约30到50家公司的股票。</blockquote></p><p> For the time being, Wood is having the last laugh.</p><p><blockquote>目前，伍德笑到了最后。</blockquote></p><p> Yes, her fund's returns may be volatile year-to-year — the Ark Innovation ETF fell nearly 25% in 2018 before rebounding 30% in 2019 — but it has tended to smooth out. The five-year average annualized return for the Ark Innovation ETF through mid-2021 was 48.6%, compared to 17.7% for the S&amp;P 500.</p><p><blockquote>是的，她的基金的回报可能逐年波动——Ark Innovation ETF在2018年下跌了近25%，然后在2019年反弹了30%——但它已经趋于平稳。截至2021年中期，Ark Innovation ETF的五年平均年化回报率为48.6%，而标普500为17.7%。</blockquote></p><p> As long as that long-term trend continues, Ark acolytes may forgive a down year every now and then as Wood continues to swing for the fences.</p><p><blockquote>只要这种长期趋势持续下去，方舟的追随者可能会时不时地原谅低迷的一年，因为伍德继续摇摆。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://edition.cnn.com/2021/09/07/investing/cathie-wood-risk-takers/index.html\">CNN Business</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKG":"ARK Genomic Revolution ETF","ARKK":"ARK Innovation ETF","TSLA":"特斯拉","ARKW":"ARK Next Generation Internet ETF","ARKF":"ARK Fintech Innovation ETF"},"source_url":"https://edition.cnn.com/2021/09/07/investing/cathie-wood-risk-takers/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180788041","content_text":"New York (CNN Business) - At a time when many investors are content to follow the crowd and buy top techs like Apple, Amazon and Microsoft, Cathie Wood is looking for the next big innovators in buzzy fields like robotics, fintech and space exploration.\nIt's a high-flying, high-risk, high-reward tier of investing. And it's put Wood's fans on a white-knuckle ride in 2021.\nLast year, Wood's strategy paid huge dividends for investors in her flagship Ark Innovation(ARKK) exchange-traded fund. It surged nearly 150% in 2020 and helped turn her into a Wall Street superstar — sort of the Warren Buffett of momentum investing.\nCathie Wood, CEO of Ark Investment Management, has become the face of the growth stock movement on Wall Street.\nBut this year hasn't been nearly as kind to Wood as the last. The Innovation ETF was down 2.5% through late August, despite a red-hot market for tech with the Nasdaq up more than 18% so far in 2021.\nWood wasn't available to comment for this story, but she doubled down in an interview with CNBC in August. She's not worried that the Ark strategy of looking for new tech leaders will end badly, and she maintains that this current rally will not be a repeat of the epic 2000 dot-com implosion.\n\"I don't think we're in a bubble, which is what I think many bears think we are,\" Wood told CNBC. \"We have nothing like that right now. In fact, you see a lot of IPOs or SPACs coming out and falling to Earth. We couldn't be further away from a bubble.\"\nHow Wood developed her strategy\nWood speaks from experience. She's no millennial or Gen Z investor for whom the 2000 tech implosion is merely a war story told by older traders. The 65-year-old Wood lived through the last major tech crash, as well as the infamous Black Monday of 1987.\nShe worked for Prudential-owned money manager Jennison Associates for 18 years in the 1980s and 1990s and then spent a dozen years at AllianceBernstein before leaving in 2013.\nBut then, AllianceBernstein passed on her idea to launch a suite of actively managed exchange-traded funds. So she struck out on her own and started Ark in 2014.\n\"I have been watching disruptive innovation for my entire career — why don't I help my own sector along?\" she told Forbes in a 2014 interview.\nThat focus on disruption means Wood ties her ETF's fortunes to visionary but mercurial leaders.\nIn the most prominent example, Wood remains an unabashed fan of Tesla(TSLA) and CEO Elon Musk. The EV maker is the top stock, by far, in Ark's Innovation ETF, accounting for more than 10% of the fund's holdings. It's also the biggest position in Ark's Autonomous Technology & Robotics(ARKQ) and Next Generation Internet(ARKW) ETFs.\nWood is a vocal fan of Tesla, which is a top holding in several of Ark's funds.\nWood is also OK with companies like Tesla issuing more stock to raise money to fund futuristic projects like autonomous vehicles. Some investors are wary of that strategy because the new shares lower the value of existing investors' holdings, but she thinks that's a short-sighted argument, particularly from Tesla bears.\n\"We're not afraid of dilution ... if we think they're doing it for the right reason,\" she told CNBC. \"We wanted them to scale as quickly as possible because we think if we're right on autonomous ...Tesla could get the lion's share of that market, certainly in the United States.\"\nArk's big investment in Tesla is a bet on Musk continuing to innovate beyond the business of electric cars, Wood explained in an interview with Bloomberg Radio in August. She raved about Tesla's plans to build a humanoid robot, for example.\n\"Every passing day, especially the more we learn about their AI expertise and how they're really driving the space ... we believe they have the pole position,\" she said, noting that Ark analysts were \"blown away\" by Musk's presentation.\nGrowth at all costs\nWood recognizes her growth-at-all-costs way of investing is not for everyone.\nTesla has lagged the broader market this year. Shares of Teladoc(TDOC), a telehealth company that is the second-largest holding in the Ark Innovation ETF and was a big winner at the start of the pandemic, are down more than 25% in 2021.\n\"We've seen higher-valuation stocks hit hard this year. But the growth for these innovative companies will still be treated well over time,\" Wood said during a webcast hosted by Cboe Global Markets in March.\nWood added that she thinks investors also should put a small percentage of their money in bitcoin, another risky bet. And she stressed that investors have to overlook the inevitable short-term bumps that come with any asset. It's essential to maintain longer-term convictions and invest for future growth, Wood believes.\n\"A lot of companies catering to short-term investors who wanted profits now [have] invested more in stock buybacks and dividends over innovation,\" she said. \"That puts them in harm's way.\"\nA colleague describes Wood's go-big-or-go-home approach as a model for the new way of investing. Too many fund managers are afraid to look far into the future when judging a company's merits, instead focusing myopically on the prior and next quarterly earnings reports.\n\"Cathie has been focusing on Tesla for a long time. She looks at it not just as an automobile manufacturer. You can't compare it to traditional car companies,\" Ark Invest's Ren Leggi, who works closely with Wood on investment decisions as the company's client portfolio manager, told CNN Business in March.\nWood's critics\nBut a growing chorus of skeptics think Wood's funds could eventually collapse. Michael Burry, one of the super-bearish investors made famous in \"The Big Short,\" recently established a short position on the Ark Innovation ETF — essentially betting that it will fall sharply.\nSome tech stock veterans also wonder if Wood is just an investing flavor of the month, comparing her to once-popular portfolio managers like Kevin Landis of Firsthand Funds, Alberto Vilar of Amerindo and Garrett Van Wagoner, who ran a popular emerging-growth fund in the late 1990s.\nMany of those tech funds imploded following the 2000 bubble. TheWall Street Journalwrote a catch-up piece about Van Wagoner and other late 1990s tech gurus in 2010 with the headline \"From Fame, Fortune to Flamed-Out Stars. Post-Bust Fates of Tech-Fund Mavens.\"\nIs Wood destined for similar ignominy?\nRivals take issue with Wood making such big bets on only a handful of stocks. The Ark Innovation ETF, for example, has nearly half its assets concentrated in its top 10 holdings. Beyond Tesla, that fund also owns sizable stakes in Roku(ROKU),Coinbase,Zoom(ZM) and Square(SQ).\nRoku is another example of a high-risk/high-reward stock that Wood loves.\n\"Our investment approach is similar to Ark in that we are focusing on tech. But we're different in that we avoid concentration,\"Jeremie Capron, head of research at ROBO Global, told CNN Business in March.\nThe top 10 holdings in theROBO Global Robotics and Automation Index(ROBO)ETF account for less than 20% of the fund's total assets, and the fund owns about 80 stocks. Ark funds typically own shares in only about 30 to 50 companies.\nFor the time being, Wood is having the last laugh.\nYes, her fund's returns may be volatile year-to-year — the Ark Innovation ETF fell nearly 25% in 2018 before rebounding 30% in 2019 — but it has tended to smooth out. The five-year average annualized return for the Ark Innovation ETF through mid-2021 was 48.6%, compared to 17.7% for the S&P 500.\nAs long as that long-term trend continues, Ark acolytes may forgive a down year every now and then as Wood continues to swing for the fences.","news_type":1,"symbols_score_info":{"ARKK":0.9,"ARKW":0.9,"ARKG":0.9,"ARKF":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":573,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814279210,"gmtCreate":1630833660230,"gmtModify":1631884234829,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"htmlText":"This lady fickle minded, be more careful if u follow her. Anyway, she's right this time to buy into China mkt&nbsp;","listText":"This lady fickle minded, be more careful if u follow her. Anyway, she's right this time to buy into China mkt&nbsp;","text":"This lady fickle minded, be more careful if u follow her. Anyway, she's right this time to buy into China mkt","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/814279210","repostId":"2164808914","repostType":4,"isVote":1,"tweetType":1,"viewCount":636,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":883295372,"gmtCreate":1631241789396,"gmtModify":1631883559586,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"See, con women, say Tesla worth $3000/share, but dump it after her announcement not long ago. Her followers all have to safe keep those she dumped&nbsp;","listText":"See, con women, say Tesla worth $3000/share, but dump it after her announcement not long ago. Her followers all have to safe keep those she dumped&nbsp;","text":"See, con women, say Tesla worth $3000/share, but dump it after her announcement not long ago. Her followers all have to safe keep those she dumped","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/883295372","repostId":"1117851011","repostType":4,"isVote":1,"tweetType":1,"viewCount":829,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814279210,"gmtCreate":1630833660230,"gmtModify":1631884234829,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"This lady fickle minded, be more careful if u follow her. Anyway, she's right this time to buy into China mkt&nbsp;","listText":"This lady fickle minded, be more careful if u follow her. Anyway, she's right this time to buy into China mkt&nbsp;","text":"This lady fickle minded, be more careful if u follow her. Anyway, she's right this time to buy into China mkt","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/814279210","repostId":"2164808914","repostType":4,"isVote":1,"tweetType":1,"viewCount":636,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":824922247,"gmtCreate":1634271546601,"gmtModify":1634274410181,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Too high already, time for it to cool down&nbsp;","listText":"Too high already, time for it to cool down&nbsp;","text":"Too high already, time for it to cool down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/824922247","repostId":"2175197255","repostType":4,"isVote":1,"tweetType":1,"viewCount":2827,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877922815,"gmtCreate":1637881319600,"gmtModify":1637881319742,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Will it ? Well market is insane, anything can happen&nbsp;[开心]&nbsp;[开心]&nbsp;","listText":"Will it ? Well market is insane, anything can happen&nbsp;[开心]&nbsp;[开心]&nbsp;","text":"Will it ? Well market is insane, anything can happen [开心] [开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/877922815","repostId":"2186916023","repostType":4,"isVote":1,"tweetType":1,"viewCount":2516,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":867564866,"gmtCreate":1633302618177,"gmtModify":1633302618389,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Still need to be careful with amc, virus situation still bad. It could mutate again and become more resilient and powerful&nbsp;","listText":"Still need to be careful with amc, virus situation still bad. It could mutate again and become more resilient and powerful&nbsp;","text":"Still need to be careful with amc, virus situation still bad. It could mutate again and become more resilient and powerful","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/867564866","repostId":"1134305481","repostType":4,"repost":{"id":"1134305481","kind":"news","pubTimestamp":1633152909,"share":"https://www.laohu8.com/m/news/1134305481?lang=zh_CN&edition=full","pubTime":"2021-10-02 13:35","market":"us","language":"en","title":"3 Stocks That Can Double Again in the Fourth Quarter<blockquote>四季度可以再次翻倍的3只股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1134305481","media":"The motley fool","summary":"Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this mo","content":"<p>Key Points</p><p><blockquote>要点</blockquote></p><p> <ul>  <li>Crocs has jacked up its guidance every quarter this year. It reports again later this month.</li>  <li>AMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.</li>  <li>Upstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.</li> </ul> </p><p><blockquote><ul><li>Crocs今年每个季度都上调了指引。它将于本月晚些时候再次报道。</li><li>AMC必须在此基础上翻一番才能重温6月份的高点。查看即将上映的影院上映名单，了解为什么电影院会变得更好。</li><li>Upstart正在彻底改变消费贷款中确定信用度的方式，并且一直笑到银行。</li></ul></blockquote></p><p> It's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?</p><p><blockquote>对于股市来说，今年是动荡的一年，但自然有些投资的表现比其他投资更好。超过300只股票在2021年上涨了一倍多。如果许多获胜的投资能够在今年最后三个月保持这些收益，那将是幸运的，但那些有潜力再次翻倍的投资呢？</blockquote></p><p> <b>Crocs</b>&nbsp;(NASDAQ:CROX),<b>AMC Entertainment</b>(NYSE:AMC), and<b>Upstart</b>&nbsp;(NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.</p><p><blockquote><b>卡骆驰</b>（纳斯达克：CROX），<b>AMC院线</b>（纽约证券交易所代码：AMC），以及<b>暴发户</b>（纳斯达克：UPST）的价值在2021年前9个月翻了一番多。让我们看看为什么他们有能力在第四季度重复这一壮举。</blockquote></p><p> 1. Crocs</p><p><blockquote>1.Crocs</blockquote></p><p> Remember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.</p><p><blockquote>还记得那双有洞的亮色胶鞋吗？他们大举回来了。自疫情爆发以来，Crocs的销量一直在蓬勃发展，该股也紧随其后，在2021年前9个月上涨了129%。</blockquote></p><p> The comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.</p><p><blockquote>舒适的树脂鞋在新冠肺炎危机之前就已经卷土重来，2019年的收入实现了两位数的增长，然后在2020年重复了这一壮举。动力才是真正让Crocs在2021年更上一层楼的原因。</blockquote></p><p> The year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?</p><p><blockquote>今年年初，这家鞋类制造商在2月份预计全年营收将增长20%至25%。下个季度的指引被上调至40%至50%之间。这种情况在今年夏天再次发生，Crocs现在的目标是2021年全年收入增长60%至65%。如果本月晚些时候公布第三季度业绩时这些目标被推得更高，您认为会发生什么？</blockquote></p><p> Despite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.</p><p><blockquote>尽管自2019年初以来，Crocs的股价已上涨近六倍，但鉴于其加速增长，其定价合理。该公司今年市盈率为21倍，明年目标市盈率仅为17倍。显然还有增加这些市盈率的空间，华尔街终于像客户一样对Crocs作为一项投资感到满意。</blockquote></p><p> 2. AMC Entertainment</p><p><blockquote>2.AMC院线</blockquote></p><p> You may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.</p><p><blockquote>你可能会惊讶地发现这个国家领先的多厅影院运营商在这个名单上，但情节曲折是电影如此优秀的原因。AMC院线确实已经升值——无论是股价还是流通股数量都增长了五倍——以至于其估值相对于同行来说已经不正常了。如果您想对电影院行业的复苏进行纯粹的投资，您会发现价格更具吸引力的股票。</blockquote></p><p> However, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?</p><p><blockquote>然而，作为一种流行的股票和文化现象，很难否认AMC在复苏过程中将其在散户投资者中的受欢迎程度转化为合法的市场份额抢夺。今年没有一家公司的市值像AMC那样膨胀，但这也是一只进入第四季度的股票，股价仅为6月份峰值时的一半多一点。简而言之，它必须在这里翻倍才能重温历史高点——但对于2021年动量股的典型代表来说，这难道不总是可能的吗？</blockquote></p><p> Fundamentally speaking, the catalysts are also there.<i>Shang-Chi and the Legend of the Ten Rings</i>shattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.</p><p><blockquote>从根本上说，催化剂也在。<i>尚气与十环传说</i>劳动节周末打破了票房记录，但最初的兴奋随着随后的周末糟糕透顶而消失。然而，这一切都与管道有关。当德尔塔变异毒株导致新冠肺炎病例激增时，电影公司将9月的上映推迟到10月及以后。我们现在看到备受期待的电影开始回归，从下周末的新詹姆斯·邦德电影开始。该行业第四季度的表现应该比反对者想象的要强劲得多，如果AMC股价回到6月初的水平——这次基本上是盈利的——那么它将不得不在此基础上翻一番。</blockquote></p><p> 3. Upstart</p><p><blockquote>3.暴发户</blockquote></p><p> I love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.</p><p><blockquote>我喜欢颠覆成熟的行业被颠覆，这就是Upstart在贷款行业所做的事情。Upstart使用人工智能和机器学习来更好地评级评估那些通常不会获得消费贷款批准的人的风险状况和信用度。</blockquote></p><p> Growth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.</p><p><blockquote>增长是疯狂的。收入似乎正在急剧减速，过去三年的增长分别放缓了89%、52%和27%。现在，消费者开始意识到Upstart是发薪日贷款和其他掠夺性贷款产品的更好替代品，业务正在飙升。第一季度收入增长90%，但在最新报告中却飙升了1,018%。不，这不是错别字。</blockquote></p><p></p><p> With Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.</p><p><blockquote>随着Upstart现在扩展到汽车贷款市场，其更好的替代乏味信用评分的潜力才刚刚开始。该股在2021年前三个季度已上涨七倍，但对于这款颠覆性喷气式飞机来说，跑道还很长。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Can Double Again in the Fourth Quarter<blockquote>四季度可以再次翻倍的3只股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Can Double Again in the Fourth Quarter<blockquote>四季度可以再次翻倍的3只股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The motley fool</strong><span class=\"h-time small\">2021-10-02 13:35</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Key Points</p><p><blockquote>要点</blockquote></p><p> <ul>  <li>Crocs has jacked up its guidance every quarter this year. It reports again later this month.</li>  <li>AMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.</li>  <li>Upstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.</li> </ul> </p><p><blockquote><ul><li>Crocs今年每个季度都上调了指引。它将于本月晚些时候再次报道。</li><li>AMC必须在此基础上翻一番才能重温6月份的高点。查看即将上映的影院上映名单，了解为什么电影院会变得更好。</li><li>Upstart正在彻底改变消费贷款中确定信用度的方式，并且一直笑到银行。</li></ul></blockquote></p><p> It's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?</p><p><blockquote>对于股市来说，今年是动荡的一年，但自然有些投资的表现比其他投资更好。超过300只股票在2021年上涨了一倍多。如果许多获胜的投资能够在今年最后三个月保持这些收益，那将是幸运的，但那些有潜力再次翻倍的投资呢？</blockquote></p><p> <b>Crocs</b>&nbsp;(NASDAQ:CROX),<b>AMC Entertainment</b>(NYSE:AMC), and<b>Upstart</b>&nbsp;(NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.</p><p><blockquote><b>卡骆驰</b>（纳斯达克：CROX），<b>AMC院线</b>（纽约证券交易所代码：AMC），以及<b>暴发户</b>（纳斯达克：UPST）的价值在2021年前9个月翻了一番多。让我们看看为什么他们有能力在第四季度重复这一壮举。</blockquote></p><p> 1. Crocs</p><p><blockquote>1.Crocs</blockquote></p><p> Remember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.</p><p><blockquote>还记得那双有洞的亮色胶鞋吗？他们大举回来了。自疫情爆发以来，Crocs的销量一直在蓬勃发展，该股也紧随其后，在2021年前9个月上涨了129%。</blockquote></p><p> The comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.</p><p><blockquote>舒适的树脂鞋在新冠肺炎危机之前就已经卷土重来，2019年的收入实现了两位数的增长，然后在2020年重复了这一壮举。动力才是真正让Crocs在2021年更上一层楼的原因。</blockquote></p><p> The year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?</p><p><blockquote>今年年初，这家鞋类制造商在2月份预计全年营收将增长20%至25%。下个季度的指引被上调至40%至50%之间。这种情况在今年夏天再次发生，Crocs现在的目标是2021年全年收入增长60%至65%。如果本月晚些时候公布第三季度业绩时这些目标被推得更高，您认为会发生什么？</blockquote></p><p> Despite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.</p><p><blockquote>尽管自2019年初以来，Crocs的股价已上涨近六倍，但鉴于其加速增长，其定价合理。该公司今年市盈率为21倍，明年目标市盈率仅为17倍。显然还有增加这些市盈率的空间，华尔街终于像客户一样对Crocs作为一项投资感到满意。</blockquote></p><p> 2. AMC Entertainment</p><p><blockquote>2.AMC院线</blockquote></p><p> You may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.</p><p><blockquote>你可能会惊讶地发现这个国家领先的多厅影院运营商在这个名单上，但情节曲折是电影如此优秀的原因。AMC院线确实已经升值——无论是股价还是流通股数量都增长了五倍——以至于其估值相对于同行来说已经不正常了。如果您想对电影院行业的复苏进行纯粹的投资，您会发现价格更具吸引力的股票。</blockquote></p><p> However, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?</p><p><blockquote>然而，作为一种流行的股票和文化现象，很难否认AMC在复苏过程中将其在散户投资者中的受欢迎程度转化为合法的市场份额抢夺。今年没有一家公司的市值像AMC那样膨胀，但这也是一只进入第四季度的股票，股价仅为6月份峰值时的一半多一点。简而言之，它必须在这里翻倍才能重温历史高点——但对于2021年动量股的典型代表来说，这难道不总是可能的吗？</blockquote></p><p> Fundamentally speaking, the catalysts are also there.<i>Shang-Chi and the Legend of the Ten Rings</i>shattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.</p><p><blockquote>从根本上说，催化剂也在。<i>尚气与十环传说</i>劳动节周末打破了票房记录，但最初的兴奋随着随后的周末糟糕透顶而消失。然而，这一切都与管道有关。当德尔塔变异毒株导致新冠肺炎病例激增时，电影公司将9月的上映推迟到10月及以后。我们现在看到备受期待的电影开始回归，从下周末的新詹姆斯·邦德电影开始。该行业第四季度的表现应该比反对者想象的要强劲得多，如果AMC股价回到6月初的水平——这次基本上是盈利的——那么它将不得不在此基础上翻一番。</blockquote></p><p> 3. Upstart</p><p><blockquote>3.暴发户</blockquote></p><p> I love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.</p><p><blockquote>我喜欢颠覆成熟的行业被颠覆，这就是Upstart在贷款行业所做的事情。Upstart使用人工智能和机器学习来更好地评级评估那些通常不会获得消费贷款批准的人的风险状况和信用度。</blockquote></p><p> Growth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.</p><p><blockquote>增长是疯狂的。收入似乎正在急剧减速，过去三年的增长分别放缓了89%、52%和27%。现在，消费者开始意识到Upstart是发薪日贷款和其他掠夺性贷款产品的更好替代品，业务正在飙升。第一季度收入增长90%，但在最新报告中却飙升了1,018%。不，这不是错别字。</blockquote></p><p></p><p> With Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.</p><p><blockquote>随着Upstart现在扩展到汽车贷款市场，其更好的替代乏味信用评分的潜力才刚刚开始。该股在2021年前三个季度已上涨七倍，但对于这款颠覆性喷气式飞机来说，跑道还很长。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/\">The motley fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UPST":"Upstart Holdings, Inc.","AMC":"AMC院线","CROX":"卡骆驰"},"source_url":"https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134305481","content_text":"Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this month.\nAMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.\nUpstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.\n\n\nIt's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?\nCrocs (NASDAQ:CROX),AMC Entertainment(NYSE:AMC), andUpstart (NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.\n1. Crocs\nRemember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.\nThe comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.\nThe year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?\nDespite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.\n2. AMC Entertainment\nYou may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.\nHowever, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?\nFundamentally speaking, the catalysts are also there.Shang-Chi and the Legend of the Ten Ringsshattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.\n3. Upstart\nI love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.\nGrowth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.\nWith Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.","news_type":1,"symbols_score_info":{"CROX":0.9,"AMC":0.9,"UPST":0.9}},"isVote":1,"tweetType":1,"viewCount":1360,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":867566905,"gmtCreate":1633302436726,"gmtModify":1633302436922,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"V good recommendations. I will include visa also&nbsp;","listText":"V good recommendations. I will include visa also&nbsp;","text":"V good recommendations. I will include visa also","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/867566905","repostId":"2172614079","repostType":4,"isVote":1,"tweetType":1,"viewCount":957,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699267737,"gmtCreate":1639815129172,"gmtModify":1639815129921,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Semicon industry nvr die","listText":"Semicon industry nvr die","text":"Semicon industry nvr die","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699267737","repostId":"1161245886","repostType":4,"repost":{"id":"1161245886","kind":"news","pubTimestamp":1639806035,"share":"https://www.laohu8.com/m/news/1161245886?lang=zh_CN&edition=full","pubTime":"2021-12-18 13:40","market":"us","language":"en","title":"Wedbush's Dan Ives: Don't throw in the towel on tech<blockquote>韦德布什的丹·艾夫斯：不要在科技上认输</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1161245886","media":"Seeking Alpha","summary":"Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.\"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.Calling the current era \"a fourth industrial revolution,\" Ives backed such stocks as $CyberArk Software $, $Palo Alto Networks $, $Zscaler $, $NVIDIA $ and $Apple $.\"This is an opportunity, not the start of a downtrend ","content":"<p>Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.</p><p><blockquote>Wedbush Securities董事总经理Dan Ives建议投资者坚持持有科技股，尽管美联储加息可能会导致估值紧缩。</blockquote></p><p> \"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.</p><p><blockquote>“现在不是向科技认输的时候，”他周五对CNBC表示。</blockquote></p><p> Calling the current era \"a fourth industrial revolution,\" Ives backed such stocks as <a href=\"https://laohu8.com/S/CYBR\">CyberArk Software </a>, <a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks </a>, <a href=\"https://laohu8.com/S/ZS\">Zscaler </a>, <a href=\"https://laohu8.com/S/NVDA\">NVIDIA </a> and <a href=\"https://laohu8.com/S/AAPL\">Apple </a>.</p><p><blockquote>艾夫斯将当前时代称为“第四次工业革命”，他支持以下股票：<a href=\"https://laohu8.com/S/CYBR\">赛博方舟软件</a>,<a href=\"https://laohu8.com/S/PANW\">帕洛阿尔托网络</a>,<a href=\"https://laohu8.com/S/ZS\">Zscaler</a>,<a href=\"https://laohu8.com/S/NVDA\">英伟达</a>和<a href=\"https://laohu8.com/S/AAPL\">苹果</a>.</blockquote></p><p> \"This is an opportunity, not the start of a downtrend for tech,\" he said.</p><p><blockquote>“这是一个机会，而不是科技股下跌趋势的开始，”他说。</blockquote></p><p> Ives argued that a large number of tech names will see significant growth in coming years thanks to heavy spending on technologies like cybersecurity, 5G and further moves into the cloud.</p><p><blockquote>艾夫斯认为，由于在网络安全、5G等技术上的大量支出以及进一步向云的转移，大量科技公司将在未来几年实现显着增长。</blockquote></p><p> He estimated that this \"digital transformation\" would fuel another $2T in spending over the next six to seven years.</p><p><blockquote>他估计，这种“数字化转型”将在未来六到七年内推动另外2T美元的支出。</blockquote></p><p> That said, Ives warned investors that they had to be selective with their portfolios, as some stocks will lose momentum once the massive pandemic-related stimulus comes to an end.</p><p><blockquote>尽管如此，艾夫斯警告投资者，他们必须有选择性地选择投资组合，因为一旦与大流行相关的大规模刺激措施结束，一些股票将失去动力。</blockquote></p><p> \"You have to separate the winners from the losers and the long-term winners versus the ones that benefited from the pandemic,\" he said.</p><p><blockquote>他说：“你必须区分赢家和输家，区分长期赢家和从大流行中受益的人。”</blockquote></p><p> Rather, Ives suggested investors \"double down on their winners.\"</p><p><blockquote>相反，艾夫斯建议投资者“加倍押注赢家”。</blockquote></p><p> Looking at some of the stocks mentioned by Ives, NVDA has done by far the best in 2021, more than doubling over the course of the year. ZS and PANW have both risen nearly 50%. AAPL lags behind its smaller rivals, although it has rallied about 30% for 2021.</p><p><blockquote>从艾夫斯提到的一些股票来看，NVDA在2021年的表现是迄今为止最好的，一年中上涨了一倍多。ZS和PANW均上涨近50%。尽管苹果公司2021年股价上涨了约30%，但仍落后于规模较小的竞争对手。</blockquote></p><p> The main laggard in the group is CYBR, which is basically flat on the year:</p><p><blockquote>集团内主要落后者为CYBR，同比基本持平：</blockquote></p><p> <img src=\"https://static.tigerbbs.com/25aa45389fe8b89d41006f304e02894e\" tg-width=\"1201\" tg-height=\"405\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wedbush's Dan Ives: Don't throw in the towel on tech<blockquote>韦德布什的丹·艾夫斯：不要在科技上认输</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWedbush's Dan Ives: Don't throw in the towel on tech<blockquote>韦德布什的丹·艾夫斯：不要在科技上认输</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-12-18 13:40</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.</p><p><blockquote>Wedbush Securities董事总经理Dan Ives建议投资者坚持持有科技股，尽管美联储加息可能会导致估值紧缩。</blockquote></p><p> \"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.</p><p><blockquote>“现在不是向科技认输的时候，”他周五对CNBC表示。</blockquote></p><p> Calling the current era \"a fourth industrial revolution,\" Ives backed such stocks as <a href=\"https://laohu8.com/S/CYBR\">CyberArk Software </a>, <a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks </a>, <a href=\"https://laohu8.com/S/ZS\">Zscaler </a>, <a href=\"https://laohu8.com/S/NVDA\">NVIDIA </a> and <a href=\"https://laohu8.com/S/AAPL\">Apple </a>.</p><p><blockquote>艾夫斯将当前时代称为“第四次工业革命”，他支持以下股票：<a href=\"https://laohu8.com/S/CYBR\">赛博方舟软件</a>,<a href=\"https://laohu8.com/S/PANW\">帕洛阿尔托网络</a>,<a href=\"https://laohu8.com/S/ZS\">Zscaler</a>,<a href=\"https://laohu8.com/S/NVDA\">英伟达</a>和<a href=\"https://laohu8.com/S/AAPL\">苹果</a>.</blockquote></p><p> \"This is an opportunity, not the start of a downtrend for tech,\" he said.</p><p><blockquote>“这是一个机会，而不是科技股下跌趋势的开始，”他说。</blockquote></p><p> Ives argued that a large number of tech names will see significant growth in coming years thanks to heavy spending on technologies like cybersecurity, 5G and further moves into the cloud.</p><p><blockquote>艾夫斯认为，由于在网络安全、5G等技术上的大量支出以及进一步向云的转移，大量科技公司将在未来几年实现显着增长。</blockquote></p><p> He estimated that this \"digital transformation\" would fuel another $2T in spending over the next six to seven years.</p><p><blockquote>他估计，这种“数字化转型”将在未来六到七年内推动另外2T美元的支出。</blockquote></p><p> That said, Ives warned investors that they had to be selective with their portfolios, as some stocks will lose momentum once the massive pandemic-related stimulus comes to an end.</p><p><blockquote>尽管如此，艾夫斯警告投资者，他们必须有选择性地选择投资组合，因为一旦与大流行相关的大规模刺激措施结束，一些股票将失去动力。</blockquote></p><p> \"You have to separate the winners from the losers and the long-term winners versus the ones that benefited from the pandemic,\" he said.</p><p><blockquote>他说：“你必须区分赢家和输家，区分长期赢家和从大流行中受益的人。”</blockquote></p><p> Rather, Ives suggested investors \"double down on their winners.\"</p><p><blockquote>相反，艾夫斯建议投资者“加倍押注赢家”。</blockquote></p><p> Looking at some of the stocks mentioned by Ives, NVDA has done by far the best in 2021, more than doubling over the course of the year. ZS and PANW have both risen nearly 50%. AAPL lags behind its smaller rivals, although it has rallied about 30% for 2021.</p><p><blockquote>从艾夫斯提到的一些股票来看，NVDA在2021年的表现是迄今为止最好的，一年中上涨了一倍多。ZS和PANW均上涨近50%。尽管苹果公司2021年股价上涨了约30%，但仍落后于规模较小的竞争对手。</blockquote></p><p> The main laggard in the group is CYBR, which is basically flat on the year:</p><p><blockquote>集团内主要落后者为CYBR，同比基本持平：</blockquote></p><p> <img src=\"https://static.tigerbbs.com/25aa45389fe8b89d41006f304e02894e\" tg-width=\"1201\" tg-height=\"405\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3781354-dont-throw-in-the-towel-on-tech-wedbushs-dan-ives\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZS":"Zscaler Inc.","CYBR":"Cyber-Ark Software","PANW":"Palo Alto Networks","NVDA":"英伟达"},"source_url":"https://seekingalpha.com/news/3781354-dont-throw-in-the-towel-on-tech-wedbushs-dan-ives","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161245886","content_text":"Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.\n\"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.\nCalling the current era \"a fourth industrial revolution,\" Ives backed such stocks as CyberArk Software , Palo Alto Networks , Zscaler , NVIDIA  and Apple .\n\"This is an opportunity, not the start of a downtrend for tech,\" he said.\nIves argued that a large number of tech names will see significant growth in coming years thanks to heavy spending on technologies like cybersecurity, 5G and further moves into the cloud.\nHe estimated that this \"digital transformation\" would fuel another $2T in spending over the next six to seven years.\nThat said, Ives warned investors that they had to be selective with their portfolios, as some stocks will lose momentum once the massive pandemic-related stimulus comes to an end.\n\"You have to separate the winners from the losers and the long-term winners versus the ones that benefited from the pandemic,\" he said.\nRather, Ives suggested investors \"double down on their winners.\"\nLooking at some of the stocks mentioned by Ives, NVDA has done by far the best in 2021, more than doubling over the course of the year. ZS and PANW have both risen nearly 50%. AAPL lags behind its smaller rivals, although it has rallied about 30% for 2021.\nThe main laggard in the group is CYBR, which is basically flat on the year:","news_type":1,"symbols_score_info":{"ZS":0.9,"PANW":0.9,"CYBR":0.9,"NVDA":0.9}},"isVote":1,"tweetType":1,"viewCount":3643,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":895424082,"gmtCreate":1628767853846,"gmtModify":1631889326805,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Not worth buying. Follow her and die faster&nbsp;","listText":"Not worth buying. Follow her and die faster&nbsp;","text":"Not worth buying. Follow her and die faster","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/895424082","repostId":"2158257251","repostType":4,"isVote":1,"tweetType":1,"viewCount":551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":827350558,"gmtCreate":1634425900287,"gmtModify":1634425900490,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"GOOD PICK&nbsp;","listText":"GOOD PICK&nbsp;","text":"GOOD PICK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/827350558","repostId":"2175112192","repostType":4,"isVote":1,"tweetType":1,"viewCount":3492,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829164011,"gmtCreate":1633481487949,"gmtModify":1633481488214,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Dead cat rebound&nbsp;","listText":"Dead cat rebound&nbsp;","text":"Dead cat rebound","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/829164011","repostId":"1101968131","repostType":4,"isVote":1,"tweetType":1,"viewCount":884,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":889183816,"gmtCreate":1631114512235,"gmtModify":1631889326757,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"She's playing with fire. Hopeful to win big. A dangerous speculators. Not worth following.&nbsp;","listText":"She's playing with fire. Hopeful to win big. A dangerous speculators. Not worth following.&nbsp;","text":"She's playing with fire. Hopeful to win big. A dangerous speculators. Not worth following.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/889183816","repostId":"1180788041","repostType":4,"repost":{"id":"1180788041","kind":"news","pubTimestamp":1631062558,"share":"https://www.laohu8.com/m/news/1180788041?lang=zh_CN&edition=full","pubTime":"2021-09-08 08:55","market":"us","language":"en","title":"Wall Street's hottest investor is betting big on a handful of stocks. Critics say she's playing with fire<blockquote>华尔街最炙手可热的投资者正在少数股票上下大赌注。批评者说她在玩火</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1180788041","media":"CNN Business","summary":"New York  - At a time when many investors are content to follow the crowd and buy top techs like Apple, Amazon and Microsoft, Cathie Wood is looking for the next big innovators in buzzy fields like robotics, fintech and space exploration.It's a high-flying, high-risk, high-reward tier of investing. And it's put Wood's fans on a white-knuckle ride in 2021.Last year, Wood's strategy paid huge dividends for investors in her flagship Ark Innovation exchange-traded fund. It surged nearly 150% in 2020","content":"<p><b>New York (CNN Business)&nbsp;-&nbsp;</b>At a time when many investors are content to follow the crowd and buy top techs like Apple, Amazon and Microsoft, Cathie Wood is looking for the next big innovators in buzzy fields like robotics, fintech and space exploration.</p><p><blockquote><b>纽约（CNN商业）——</b>当许多投资者满足于随大流并购买苹果、亚马逊和微软等顶级科技公司时，凯西·伍德正在机器人、金融科技和太空探索等热门领域寻找下一个大创新者。</blockquote></p><p> It's a high-flying, high-risk, high-reward tier of investing. And it's put Wood's fans on a white-knuckle ride in 2021.</p><p><blockquote>这是一个雄心勃勃、高风险、高回报的投资层次。这让伍德的粉丝们在2021年感到紧张。</blockquote></p><p> Last year, Wood's strategy paid huge dividends for investors in her flagship&nbsp;Ark Innovation(ARKK)&nbsp;exchange-traded fund. It surged nearly 150% in 2020 and helped turn her into a Wall Street superstar — sort of the Warren Buffett of momentum investing.</p><p><blockquote>去年，伍德的策略为其旗舰方舟创新（ARKK）交易所交易基金的投资者带来了巨额股息。2020年股价飙升近150%，帮助她成为华尔街巨星——有点像动量投资界的沃伦·巴菲特。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/120f0d157792edd784c8787a1c05e955\" tg-width=\"1100\" tg-height=\"619\" width=\"100%\" height=\"auto\"><span>Cathie Wood, CEO of Ark Investment Management, has become the face of the growth stock movement on Wall Street.</span></p><p><blockquote><p class=\"t-img-caption\"><span>方舟投资管理公司首席执行官凯西·伍德(Cathie Wood)已成为华尔街成长股运动的代言人。</span></p></blockquote></p><p> But this year hasn't been nearly as kind to Wood as the last. The Innovation ETF was down 2.5% through late August, despite a red-hot market for tech with the Nasdaq up more than 18% so far in 2021.</p><p><blockquote>但是今年对伍德来说并不像去年那么好。尽管科技市场炙手可热，2021年迄今为止纳斯达克上涨了18%以上，但截至8月底，创新ETF仍下跌了2.5%。</blockquote></p><p> Wood wasn't available to comment for this story, but she doubled down in&nbsp;an interview with CNBC&nbsp;in August. She's not worried that the Ark strategy of looking for new tech leaders will end badly, and she maintains that this current rally will not be a repeat of the epic 2000 dot-com implosion.</p><p><blockquote>伍德无法对此事发表评论，但她在8月份接受CNBC采访时加倍了评论。她并不担心寻找新科技领导者的方舟战略会以糟糕的结局告终，她坚持认为当前的反弹不会重演2000年史诗般的互联网内爆。</blockquote></p><p> \"I don't think we're in a bubble, which is what I think many bears think we are,\" Wood told CNBC. \"We have nothing like that right now. In fact, you see a lot of IPOs or SPACs coming out and falling to Earth. We couldn't be further away from a bubble.\"</p><p><blockquote>伍德对CNBC表示：“我不认为我们处于泡沫之中，我认为许多空头认为我们处于泡沫之中。”“我们现在没有这样的东西。事实上，你会看到很多IPO或SPAC上市，然后落地。我们离泡沫已经不远了。”</blockquote></p><p> <b>How Wood developed her strategy</b></p><p><blockquote><b>伍德如何制定她的战略</b></blockquote></p><p> Wood speaks from experience. She's no millennial or Gen Z investor for whom the 2000 tech implosion is merely a war story told by older traders. The 65-year-old Wood lived through the last major tech crash, as well as the infamous Black Monday of 1987.</p><p><blockquote>伍德凭经验说话。她不是千禧一代或Z世代投资者，对他们来说，2000年的科技内爆只是年长交易者讲述的战争故事。65岁的伍德经历了上一次重大科技崩盘，以及1987年臭名昭著的黑色星期一。</blockquote></p><p> She worked for Prudential-owned money manager Jennison Associates for 18 years in the 1980s and 1990s and then spent a dozen years at AllianceBernstein before leaving in 2013.</p><p><blockquote>20世纪80年代和90年代，她在保诚旗下的基金管理公司Jennison Associates工作了18年，然后在联博工作了十几年，然后于2013年离职。</blockquote></p><p> But then, AllianceBernstein passed on her idea to launch a suite of actively managed exchange-traded funds. So she struck out on her own and started Ark in 2014.</p><p><blockquote>但随后，联博传递了她的想法，推出了一套主动管理型交易所交易基金。因此，她独自一人，在2014年创办了Ark。</blockquote></p><p> \"I have been watching disruptive innovation for my entire career — why don't I help my own sector along?\" she&nbsp;told Forbes&nbsp;in a 2014 interview.</p><p><blockquote>“在我的整个职业生涯中，我一直在关注颠覆性创新——为什么我不帮助自己的行业呢？”她在2014年的一次采访中告诉《福布斯》。</blockquote></p><p> That focus on disruption means Wood ties her ETF's fortunes to visionary but mercurial leaders.</p><p><blockquote>这种对颠覆性的关注意味着伍德将她的ETF的命运与富有远见但善变的领导者联系在一起。</blockquote></p><p> In the most prominent example, Wood remains an unabashed fan of&nbsp;Tesla(TSLA)&nbsp;and CEO Elon Musk. The EV maker is the top stock, by far, in Ark's Innovation ETF, accounting for more than 10% of the fund's holdings. It's also the biggest position in Ark's&nbsp;Autonomous Technology &amp; Robotics(ARKQ)&nbsp;and&nbsp;Next Generation Internet(ARKW)&nbsp;ETFs.</p><p><blockquote>最突出的例子是，伍德仍然是特斯拉(TSLA)和首席执行官Elon Musk的毫不掩饰的粉丝。迄今为止，这家电动汽车制造商是Ark创新ETF中排名第一的股票，占该基金持股的10%以上。它也是Ark自主技术与机器人(ARKQ)和下一代互联网(ARKW)ETF中最大的头寸。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/425dc1ea59eb1c068eaba7a392e6c04d\" tg-width=\"1100\" tg-height=\"619\" width=\"100%\" height=\"auto\"><span>Wood is a vocal fan of Tesla, which is a top holding in several of Ark's funds.</span></p><p><blockquote><p class=\"t-img-caption\"><span>伍德是特斯拉的忠实粉丝，该公司是Ark旗下多只基金的重仓股。</span></p></blockquote></p><p> Wood is also OK with companies like Tesla issuing more stock to raise money to fund futuristic projects like autonomous vehicles. Some investors are wary of that strategy because the new shares lower the value of existing investors' holdings, but she thinks that's a short-sighted argument, particularly from Tesla bears.</p><p><blockquote>伍德也同意特斯拉等公司发行更多股票来筹集资金，为自动驾驶汽车等未来项目提供资金。一些投资者对这一策略持谨慎态度，因为新股会降低现有投资者持股的价值，但她认为这是一种短视的观点，尤其是来自特斯拉空头的观点。</blockquote></p><p> \"We're not afraid of dilution ... if we think they're doing it for the right reason,\" she told CNBC. \"We wanted them to scale as quickly as possible because we think if we're right on autonomous ...Tesla could get the lion's share of that market, certainly in the United States.\"</p><p><blockquote>“我们不怕稀释……如果我们认为他们这样做是出于正确的原因，”她告诉CNBC。“我们希望他们尽快扩大规模，因为我们认为如果我们在自动驾驶方面是正确的……特斯拉可以获得该市场的最大份额，当然是在美国。”</blockquote></p><p> Ark's big investment in Tesla is a bet on Musk continuing to innovate beyond the business of electric cars, Wood explained in an&nbsp;interview with Bloomberg Radio&nbsp;in August. She raved about Tesla's plans to&nbsp;build a humanoid robot, for example.</p><p><blockquote>伍德在8月份接受彭博电台采访时解释说，方舟对特斯拉的巨额投资是押注马斯克在电动汽车业务之外继续创新。例如，她对特斯拉制造人形机器人的计划赞不绝口。</blockquote></p><p> \"Every passing day, especially the more we learn about their AI expertise and how they're really driving the space ... we believe they have the pole position,\" she said, noting that Ark analysts were \"blown away\" by Musk's presentation.</p><p><blockquote>“日复一日，尤其是我们对他们的人工智能专业知识以及他们如何真正推动该领域的了解越多……我们相信他们拥有领先地位，”她说，并指出方舟分析师被马斯克的演讲“震惊”了。</blockquote></p><p> <b>Growth at all costs</b></p><p><blockquote><b>不惜一切代价实现增长</b></blockquote></p><p> Wood recognizes her growth-at-all-costs way of investing is not for everyone.</p><p><blockquote>伍德认识到，她不惜一切代价实现增长的投资方式并不适合所有人。</blockquote></p><p> Tesla has lagged the broader market this year. Shares of&nbsp;Teladoc(TDOC), a telehealth company that is the second-largest holding in the Ark Innovation ETF and was a big winner at the start of the pandemic, are down more than 25% in 2021.</p><p><blockquote>特斯拉今年表现落后于大盘。Teladoc(TDOC)是一家远程医疗公司，是Ark Innovation ETF的第二大持股，也是疫情爆发之初的大赢家，其股价在2021年下跌了25%以上。</blockquote></p><p> \"We've seen higher-valuation stocks hit hard this year. But the growth for these innovative companies will still be treated well over time,\" Wood said&nbsp;during a webcast&nbsp;hosted by Cboe Global Markets in March.</p><p><blockquote>“我们看到估值较高的股票今年遭受重创。但随着时间的推移，这些创新型公司的增长仍将受到良好对待，”伍德在3月份由芝加哥期权交易所全球市场主办的网络直播中表示。</blockquote></p><p></p><p> Wood added that she thinks investors also should put a small percentage of their money in bitcoin, another risky bet. And she stressed that investors have to overlook the inevitable short-term bumps that come with any asset. It's essential to maintain longer-term convictions and invest for future growth, Wood believes.</p><p><blockquote>伍德补充说，她认为投资者也应该将一小部分资金投入比特币，这是另一个高风险的赌注。她强调，投资者必须忽视任何资产不可避免的短期波动。伍德认为，保持长期信念并为未来增长进行投资至关重要。</blockquote></p><p> \"A lot of companies catering to short-term investors who wanted profits now [have] invested more in stock buybacks and dividends over innovation,\" she said. \"That puts them in harm's way.\"</p><p><blockquote>“许多迎合想要利润的短期投资者的公司现在在股票回购和股息上的投资超过了创新，”她说。“这让他们处于危险之中。”</blockquote></p><p> A colleague describes Wood's go-big-or-go-home approach as a model for the new way of investing. Too many fund managers are afraid to look far into the future when judging a company's merits, instead focusing myopically on the prior and next quarterly earnings reports.</p><p><blockquote>一位同事将伍德的“要么做大，要么回家”方法描述为新投资方式的典范。太多的基金经理在判断一家公司的优点时不敢展望未来，而是短视地关注上一季度和下一季度的收益报告。</blockquote></p><p> \"Cathie has been focusing on Tesla for a long time. She looks at it not just as an automobile manufacturer. You can't compare it to traditional car companies,\"&nbsp;Ark Invest's Ren Leggi, who works closely with Wood on investment decisions as the company's client portfolio manager, told&nbsp;CNN Business in March.</p><p><blockquote>Ark Invest的Ren Leggi在3月份告诉CNN Business：“Cathie长期以来一直关注特斯拉。她不仅仅将其视为一家汽车制造商。你不能将其与传统汽车公司相提并论。”他作为该公司的客户投资组合经理，在投资决策上与伍德密切合作。</blockquote></p><p> <b>Wood's critics</b></p><p><blockquote><b>伍德的批评者</b></blockquote></p><p> But a growing chorus of skeptics think Wood's funds could eventually collapse. Michael Burry, one of the super-bearish investors made famous in \"The Big Short,\" recently established a short position on the Ark Innovation ETF — essentially betting that it will fall sharply.</p><p><blockquote>但越来越多的怀疑者认为伍德的基金最终可能会崩溃。迈克尔·伯里(Michael Burry)是因《大空头》而闻名的超级看跌投资者之一，他最近在Ark Innovation ETF上建立了空头头寸——本质上是押注该基金将大幅下跌。</blockquote></p><p> Some tech stock veterans also wonder if Wood is just an investing flavor of the month, comparing her to once-popular portfolio managers like Kevin Landis of Firsthand Funds, Alberto Vilar of Amerindo and Garrett Van Wagoner, who ran a popular emerging-growth fund in the late 1990s.</p><p><blockquote>一些科技股资深人士还想知道伍德是否只是本月的投资风云人物，将她与Firsthand Funds的凯文·兰迪斯(Kevin Landis)、Amerindo的阿尔贝托·维拉尔(Alberto Vilar)和在20世纪90年代末运营着一只受欢迎的新兴增长基金的加勒特·范·瓦格纳(Garrett Van Wagoner)等曾经受欢迎的投资组合经理进行了比较。</blockquote></p><p> Many of those tech funds imploded following the 2000 bubble. The<i>Wall Street Journal</i>wrote a catch-up piece about Van Wagoner and other late 1990s tech gurus in 2010&nbsp;with the headline \"From Fame, Fortune to Flamed-Out Stars. Post-Bust Fates of Tech-Fund Mavens.\"</p><p><blockquote>许多科技基金在2000年泡沫之后崩溃了。The<i>华尔街日报</i>2010年，他写了一篇关于范·瓦格纳和其他20世纪90年代末科技大师的后续文章，标题是“从名声、财富到燃烧的明星。科技基金专家的破产后命运。”</blockquote></p><p> Is Wood destined for similar ignominy?</p><p><blockquote>伍德注定会遭受类似的耻辱吗？</blockquote></p><p> Rivals take issue with Wood making such big bets on only a handful of stocks. The Ark Innovation ETF, for example, has nearly half its assets concentrated in its top 10 holdings. Beyond Tesla, that fund also owns sizable stakes in&nbsp;Roku(ROKU),Coinbase,Zoom(ZM)&nbsp;and&nbsp;Square(SQ).</p><p><blockquote>竞争对手对伍德只在少数股票上下如此大的赌注提出异议。例如，Ark Innovation ETF近一半的资产集中在其前10名持股中。除了特斯拉之外，该基金还拥有Roku（Roku）、Coinbase、Zoom（ZM）和Square（SQ）的大量股份。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c02cbbe0138a0aaa5b930521275ad26e\" tg-width=\"1100\" tg-height=\"619\" width=\"100%\" height=\"auto\"><span>Roku is another example of a high-risk/high-reward stock that Wood loves.</span></p><p><blockquote><p class=\"t-img-caption\"><span>Roku是伍德喜欢的高风险/高回报股票的另一个例子。</span></p></blockquote></p><p> \"Our investment approach is similar to Ark in that we are focusing on tech. But we're different in that we avoid concentration,\"Jeremie Capron, head of research at ROBO Global, told CNN Business in March.</p><p><blockquote>ROBO Global研究主管Jeremie Capron 3月份对CNN Business表示：“我们的投资方式与Ark类似，因为我们专注于科技。但我们的不同之处在于我们避免集中。”</blockquote></p><p> The top 10 holdings in theROBO Global Robotics and Automation Index(ROBO)ETF&nbsp;account for less than 20% of the fund's total assets, and the fund owns about 80 stocks. Ark funds typically own shares in only about 30 to 50 companies.</p><p><blockquote>theROBO全球机器人与自动化指数（ROBO）ETF的前10大持股占该基金总资产的比例不到20%，该基金拥有约80只股票。方舟基金通常只拥有大约30到50家公司的股票。</blockquote></p><p> For the time being, Wood is having the last laugh.</p><p><blockquote>目前，伍德笑到了最后。</blockquote></p><p> Yes, her fund's returns may be volatile year-to-year — the Ark Innovation ETF fell nearly 25% in 2018 before rebounding 30% in 2019 — but it has tended to smooth out. The five-year average annualized return for the Ark Innovation ETF through mid-2021 was 48.6%, compared to 17.7% for the S&amp;P 500.</p><p><blockquote>是的，她的基金的回报可能逐年波动——Ark Innovation ETF在2018年下跌了近25%，然后在2019年反弹了30%——但它已经趋于平稳。截至2021年中期，Ark Innovation ETF的五年平均年化回报率为48.6%，而标普500为17.7%。</blockquote></p><p> As long as that long-term trend continues, Ark acolytes may forgive a down year every now and then as Wood continues to swing for the fences.</p><p><blockquote>只要这种长期趋势持续下去，方舟的追随者可能会时不时地原谅低迷的一年，因为伍德继续摇摆。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street's hottest investor is betting big on a handful of stocks. Critics say she's playing with fire<blockquote>华尔街最炙手可热的投资者正在少数股票上下大赌注。批评者说她在玩火</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street's hottest investor is betting big on a handful of stocks. Critics say she's playing with fire<blockquote>华尔街最炙手可热的投资者正在少数股票上下大赌注。批评者说她在玩火</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">CNN Business</strong><span class=\"h-time small\">2021-09-08 08:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>New York (CNN Business)&nbsp;-&nbsp;</b>At a time when many investors are content to follow the crowd and buy top techs like Apple, Amazon and Microsoft, Cathie Wood is looking for the next big innovators in buzzy fields like robotics, fintech and space exploration.</p><p><blockquote><b>纽约（CNN商业）——</b>当许多投资者满足于随大流并购买苹果、亚马逊和微软等顶级科技公司时，凯西·伍德正在机器人、金融科技和太空探索等热门领域寻找下一个大创新者。</blockquote></p><p> It's a high-flying, high-risk, high-reward tier of investing. And it's put Wood's fans on a white-knuckle ride in 2021.</p><p><blockquote>这是一个雄心勃勃、高风险、高回报的投资层次。这让伍德的粉丝们在2021年感到紧张。</blockquote></p><p> Last year, Wood's strategy paid huge dividends for investors in her flagship&nbsp;Ark Innovation(ARKK)&nbsp;exchange-traded fund. It surged nearly 150% in 2020 and helped turn her into a Wall Street superstar — sort of the Warren Buffett of momentum investing.</p><p><blockquote>去年，伍德的策略为其旗舰方舟创新（ARKK）交易所交易基金的投资者带来了巨额股息。2020年股价飙升近150%，帮助她成为华尔街巨星——有点像动量投资界的沃伦·巴菲特。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/120f0d157792edd784c8787a1c05e955\" tg-width=\"1100\" tg-height=\"619\" width=\"100%\" height=\"auto\"><span>Cathie Wood, CEO of Ark Investment Management, has become the face of the growth stock movement on Wall Street.</span></p><p><blockquote><p class=\"t-img-caption\"><span>方舟投资管理公司首席执行官凯西·伍德(Cathie Wood)已成为华尔街成长股运动的代言人。</span></p></blockquote></p><p> But this year hasn't been nearly as kind to Wood as the last. The Innovation ETF was down 2.5% through late August, despite a red-hot market for tech with the Nasdaq up more than 18% so far in 2021.</p><p><blockquote>但是今年对伍德来说并不像去年那么好。尽管科技市场炙手可热，2021年迄今为止纳斯达克上涨了18%以上，但截至8月底，创新ETF仍下跌了2.5%。</blockquote></p><p> Wood wasn't available to comment for this story, but she doubled down in&nbsp;an interview with CNBC&nbsp;in August. She's not worried that the Ark strategy of looking for new tech leaders will end badly, and she maintains that this current rally will not be a repeat of the epic 2000 dot-com implosion.</p><p><blockquote>伍德无法对此事发表评论，但她在8月份接受CNBC采访时加倍了评论。她并不担心寻找新科技领导者的方舟战略会以糟糕的结局告终，她坚持认为当前的反弹不会重演2000年史诗般的互联网内爆。</blockquote></p><p> \"I don't think we're in a bubble, which is what I think many bears think we are,\" Wood told CNBC. \"We have nothing like that right now. In fact, you see a lot of IPOs or SPACs coming out and falling to Earth. We couldn't be further away from a bubble.\"</p><p><blockquote>伍德对CNBC表示：“我不认为我们处于泡沫之中，我认为许多空头认为我们处于泡沫之中。”“我们现在没有这样的东西。事实上，你会看到很多IPO或SPAC上市，然后落地。我们离泡沫已经不远了。”</blockquote></p><p> <b>How Wood developed her strategy</b></p><p><blockquote><b>伍德如何制定她的战略</b></blockquote></p><p> Wood speaks from experience. She's no millennial or Gen Z investor for whom the 2000 tech implosion is merely a war story told by older traders. The 65-year-old Wood lived through the last major tech crash, as well as the infamous Black Monday of 1987.</p><p><blockquote>伍德凭经验说话。她不是千禧一代或Z世代投资者，对他们来说，2000年的科技内爆只是年长交易者讲述的战争故事。65岁的伍德经历了上一次重大科技崩盘，以及1987年臭名昭著的黑色星期一。</blockquote></p><p> She worked for Prudential-owned money manager Jennison Associates for 18 years in the 1980s and 1990s and then spent a dozen years at AllianceBernstein before leaving in 2013.</p><p><blockquote>20世纪80年代和90年代，她在保诚旗下的基金管理公司Jennison Associates工作了18年，然后在联博工作了十几年，然后于2013年离职。</blockquote></p><p> But then, AllianceBernstein passed on her idea to launch a suite of actively managed exchange-traded funds. So she struck out on her own and started Ark in 2014.</p><p><blockquote>但随后，联博传递了她的想法，推出了一套主动管理型交易所交易基金。因此，她独自一人，在2014年创办了Ark。</blockquote></p><p> \"I have been watching disruptive innovation for my entire career — why don't I help my own sector along?\" she&nbsp;told Forbes&nbsp;in a 2014 interview.</p><p><blockquote>“在我的整个职业生涯中，我一直在关注颠覆性创新——为什么我不帮助自己的行业呢？”她在2014年的一次采访中告诉《福布斯》。</blockquote></p><p> That focus on disruption means Wood ties her ETF's fortunes to visionary but mercurial leaders.</p><p><blockquote>这种对颠覆性的关注意味着伍德将她的ETF的命运与富有远见但善变的领导者联系在一起。</blockquote></p><p> In the most prominent example, Wood remains an unabashed fan of&nbsp;Tesla(TSLA)&nbsp;and CEO Elon Musk. The EV maker is the top stock, by far, in Ark's Innovation ETF, accounting for more than 10% of the fund's holdings. It's also the biggest position in Ark's&nbsp;Autonomous Technology &amp; Robotics(ARKQ)&nbsp;and&nbsp;Next Generation Internet(ARKW)&nbsp;ETFs.</p><p><blockquote>最突出的例子是，伍德仍然是特斯拉(TSLA)和首席执行官Elon Musk的毫不掩饰的粉丝。迄今为止，这家电动汽车制造商是Ark创新ETF中排名第一的股票，占该基金持股的10%以上。它也是Ark自主技术与机器人(ARKQ)和下一代互联网(ARKW)ETF中最大的头寸。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/425dc1ea59eb1c068eaba7a392e6c04d\" tg-width=\"1100\" tg-height=\"619\" width=\"100%\" height=\"auto\"><span>Wood is a vocal fan of Tesla, which is a top holding in several of Ark's funds.</span></p><p><blockquote><p class=\"t-img-caption\"><span>伍德是特斯拉的忠实粉丝，该公司是Ark旗下多只基金的重仓股。</span></p></blockquote></p><p> Wood is also OK with companies like Tesla issuing more stock to raise money to fund futuristic projects like autonomous vehicles. Some investors are wary of that strategy because the new shares lower the value of existing investors' holdings, but she thinks that's a short-sighted argument, particularly from Tesla bears.</p><p><blockquote>伍德也同意特斯拉等公司发行更多股票来筹集资金，为自动驾驶汽车等未来项目提供资金。一些投资者对这一策略持谨慎态度，因为新股会降低现有投资者持股的价值，但她认为这是一种短视的观点，尤其是来自特斯拉空头的观点。</blockquote></p><p> \"We're not afraid of dilution ... if we think they're doing it for the right reason,\" she told CNBC. \"We wanted them to scale as quickly as possible because we think if we're right on autonomous ...Tesla could get the lion's share of that market, certainly in the United States.\"</p><p><blockquote>“我们不怕稀释……如果我们认为他们这样做是出于正确的原因，”她告诉CNBC。“我们希望他们尽快扩大规模，因为我们认为如果我们在自动驾驶方面是正确的……特斯拉可以获得该市场的最大份额，当然是在美国。”</blockquote></p><p> Ark's big investment in Tesla is a bet on Musk continuing to innovate beyond the business of electric cars, Wood explained in an&nbsp;interview with Bloomberg Radio&nbsp;in August. She raved about Tesla's plans to&nbsp;build a humanoid robot, for example.</p><p><blockquote>伍德在8月份接受彭博电台采访时解释说，方舟对特斯拉的巨额投资是押注马斯克在电动汽车业务之外继续创新。例如，她对特斯拉制造人形机器人的计划赞不绝口。</blockquote></p><p> \"Every passing day, especially the more we learn about their AI expertise and how they're really driving the space ... we believe they have the pole position,\" she said, noting that Ark analysts were \"blown away\" by Musk's presentation.</p><p><blockquote>“日复一日，尤其是我们对他们的人工智能专业知识以及他们如何真正推动该领域的了解越多……我们相信他们拥有领先地位，”她说，并指出方舟分析师被马斯克的演讲“震惊”了。</blockquote></p><p> <b>Growth at all costs</b></p><p><blockquote><b>不惜一切代价实现增长</b></blockquote></p><p> Wood recognizes her growth-at-all-costs way of investing is not for everyone.</p><p><blockquote>伍德认识到，她不惜一切代价实现增长的投资方式并不适合所有人。</blockquote></p><p> Tesla has lagged the broader market this year. Shares of&nbsp;Teladoc(TDOC), a telehealth company that is the second-largest holding in the Ark Innovation ETF and was a big winner at the start of the pandemic, are down more than 25% in 2021.</p><p><blockquote>特斯拉今年表现落后于大盘。Teladoc(TDOC)是一家远程医疗公司，是Ark Innovation ETF的第二大持股，也是疫情爆发之初的大赢家，其股价在2021年下跌了25%以上。</blockquote></p><p> \"We've seen higher-valuation stocks hit hard this year. But the growth for these innovative companies will still be treated well over time,\" Wood said&nbsp;during a webcast&nbsp;hosted by Cboe Global Markets in March.</p><p><blockquote>“我们看到估值较高的股票今年遭受重创。但随着时间的推移，这些创新型公司的增长仍将受到良好对待，”伍德在3月份由芝加哥期权交易所全球市场主办的网络直播中表示。</blockquote></p><p></p><p> Wood added that she thinks investors also should put a small percentage of their money in bitcoin, another risky bet. And she stressed that investors have to overlook the inevitable short-term bumps that come with any asset. It's essential to maintain longer-term convictions and invest for future growth, Wood believes.</p><p><blockquote>伍德补充说，她认为投资者也应该将一小部分资金投入比特币，这是另一个高风险的赌注。她强调，投资者必须忽视任何资产不可避免的短期波动。伍德认为，保持长期信念并为未来增长进行投资至关重要。</blockquote></p><p> \"A lot of companies catering to short-term investors who wanted profits now [have] invested more in stock buybacks and dividends over innovation,\" she said. \"That puts them in harm's way.\"</p><p><blockquote>“许多迎合想要利润的短期投资者的公司现在在股票回购和股息上的投资超过了创新，”她说。“这让他们处于危险之中。”</blockquote></p><p> A colleague describes Wood's go-big-or-go-home approach as a model for the new way of investing. Too many fund managers are afraid to look far into the future when judging a company's merits, instead focusing myopically on the prior and next quarterly earnings reports.</p><p><blockquote>一位同事将伍德的“要么做大，要么回家”方法描述为新投资方式的典范。太多的基金经理在判断一家公司的优点时不敢展望未来，而是短视地关注上一季度和下一季度的收益报告。</blockquote></p><p> \"Cathie has been focusing on Tesla for a long time. She looks at it not just as an automobile manufacturer. You can't compare it to traditional car companies,\"&nbsp;Ark Invest's Ren Leggi, who works closely with Wood on investment decisions as the company's client portfolio manager, told&nbsp;CNN Business in March.</p><p><blockquote>Ark Invest的Ren Leggi在3月份告诉CNN Business：“Cathie长期以来一直关注特斯拉。她不仅仅将其视为一家汽车制造商。你不能将其与传统汽车公司相提并论。”他作为该公司的客户投资组合经理，在投资决策上与伍德密切合作。</blockquote></p><p> <b>Wood's critics</b></p><p><blockquote><b>伍德的批评者</b></blockquote></p><p> But a growing chorus of skeptics think Wood's funds could eventually collapse. Michael Burry, one of the super-bearish investors made famous in \"The Big Short,\" recently established a short position on the Ark Innovation ETF — essentially betting that it will fall sharply.</p><p><blockquote>但越来越多的怀疑者认为伍德的基金最终可能会崩溃。迈克尔·伯里(Michael Burry)是因《大空头》而闻名的超级看跌投资者之一，他最近在Ark Innovation ETF上建立了空头头寸——本质上是押注该基金将大幅下跌。</blockquote></p><p> Some tech stock veterans also wonder if Wood is just an investing flavor of the month, comparing her to once-popular portfolio managers like Kevin Landis of Firsthand Funds, Alberto Vilar of Amerindo and Garrett Van Wagoner, who ran a popular emerging-growth fund in the late 1990s.</p><p><blockquote>一些科技股资深人士还想知道伍德是否只是本月的投资风云人物，将她与Firsthand Funds的凯文·兰迪斯(Kevin Landis)、Amerindo的阿尔贝托·维拉尔(Alberto Vilar)和在20世纪90年代末运营着一只受欢迎的新兴增长基金的加勒特·范·瓦格纳(Garrett Van Wagoner)等曾经受欢迎的投资组合经理进行了比较。</blockquote></p><p> Many of those tech funds imploded following the 2000 bubble. The<i>Wall Street Journal</i>wrote a catch-up piece about Van Wagoner and other late 1990s tech gurus in 2010&nbsp;with the headline \"From Fame, Fortune to Flamed-Out Stars. Post-Bust Fates of Tech-Fund Mavens.\"</p><p><blockquote>许多科技基金在2000年泡沫之后崩溃了。The<i>华尔街日报</i>2010年，他写了一篇关于范·瓦格纳和其他20世纪90年代末科技大师的后续文章，标题是“从名声、财富到燃烧的明星。科技基金专家的破产后命运。”</blockquote></p><p> Is Wood destined for similar ignominy?</p><p><blockquote>伍德注定会遭受类似的耻辱吗？</blockquote></p><p> Rivals take issue with Wood making such big bets on only a handful of stocks. The Ark Innovation ETF, for example, has nearly half its assets concentrated in its top 10 holdings. Beyond Tesla, that fund also owns sizable stakes in&nbsp;Roku(ROKU),Coinbase,Zoom(ZM)&nbsp;and&nbsp;Square(SQ).</p><p><blockquote>竞争对手对伍德只在少数股票上下如此大的赌注提出异议。例如，Ark Innovation ETF近一半的资产集中在其前10名持股中。除了特斯拉之外，该基金还拥有Roku（Roku）、Coinbase、Zoom（ZM）和Square（SQ）的大量股份。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c02cbbe0138a0aaa5b930521275ad26e\" tg-width=\"1100\" tg-height=\"619\" width=\"100%\" height=\"auto\"><span>Roku is another example of a high-risk/high-reward stock that Wood loves.</span></p><p><blockquote><p class=\"t-img-caption\"><span>Roku是伍德喜欢的高风险/高回报股票的另一个例子。</span></p></blockquote></p><p> \"Our investment approach is similar to Ark in that we are focusing on tech. But we're different in that we avoid concentration,\"Jeremie Capron, head of research at ROBO Global, told CNN Business in March.</p><p><blockquote>ROBO Global研究主管Jeremie Capron 3月份对CNN Business表示：“我们的投资方式与Ark类似，因为我们专注于科技。但我们的不同之处在于我们避免集中。”</blockquote></p><p> The top 10 holdings in theROBO Global Robotics and Automation Index(ROBO)ETF&nbsp;account for less than 20% of the fund's total assets, and the fund owns about 80 stocks. Ark funds typically own shares in only about 30 to 50 companies.</p><p><blockquote>theROBO全球机器人与自动化指数（ROBO）ETF的前10大持股占该基金总资产的比例不到20%，该基金拥有约80只股票。方舟基金通常只拥有大约30到50家公司的股票。</blockquote></p><p> For the time being, Wood is having the last laugh.</p><p><blockquote>目前，伍德笑到了最后。</blockquote></p><p> Yes, her fund's returns may be volatile year-to-year — the Ark Innovation ETF fell nearly 25% in 2018 before rebounding 30% in 2019 — but it has tended to smooth out. The five-year average annualized return for the Ark Innovation ETF through mid-2021 was 48.6%, compared to 17.7% for the S&amp;P 500.</p><p><blockquote>是的，她的基金的回报可能逐年波动——Ark Innovation ETF在2018年下跌了近25%，然后在2019年反弹了30%——但它已经趋于平稳。截至2021年中期，Ark Innovation ETF的五年平均年化回报率为48.6%，而标普500为17.7%。</blockquote></p><p> As long as that long-term trend continues, Ark acolytes may forgive a down year every now and then as Wood continues to swing for the fences.</p><p><blockquote>只要这种长期趋势持续下去，方舟的追随者可能会时不时地原谅低迷的一年，因为伍德继续摇摆。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://edition.cnn.com/2021/09/07/investing/cathie-wood-risk-takers/index.html\">CNN Business</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKG":"ARK Genomic Revolution ETF","ARKK":"ARK Innovation ETF","TSLA":"特斯拉","ARKW":"ARK Next Generation Internet ETF","ARKF":"ARK Fintech Innovation ETF"},"source_url":"https://edition.cnn.com/2021/09/07/investing/cathie-wood-risk-takers/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180788041","content_text":"New York (CNN Business) - At a time when many investors are content to follow the crowd and buy top techs like Apple, Amazon and Microsoft, Cathie Wood is looking for the next big innovators in buzzy fields like robotics, fintech and space exploration.\nIt's a high-flying, high-risk, high-reward tier of investing. And it's put Wood's fans on a white-knuckle ride in 2021.\nLast year, Wood's strategy paid huge dividends for investors in her flagship Ark Innovation(ARKK) exchange-traded fund. It surged nearly 150% in 2020 and helped turn her into a Wall Street superstar — sort of the Warren Buffett of momentum investing.\nCathie Wood, CEO of Ark Investment Management, has become the face of the growth stock movement on Wall Street.\nBut this year hasn't been nearly as kind to Wood as the last. The Innovation ETF was down 2.5% through late August, despite a red-hot market for tech with the Nasdaq up more than 18% so far in 2021.\nWood wasn't available to comment for this story, but she doubled down in an interview with CNBC in August. She's not worried that the Ark strategy of looking for new tech leaders will end badly, and she maintains that this current rally will not be a repeat of the epic 2000 dot-com implosion.\n\"I don't think we're in a bubble, which is what I think many bears think we are,\" Wood told CNBC. \"We have nothing like that right now. In fact, you see a lot of IPOs or SPACs coming out and falling to Earth. We couldn't be further away from a bubble.\"\nHow Wood developed her strategy\nWood speaks from experience. She's no millennial or Gen Z investor for whom the 2000 tech implosion is merely a war story told by older traders. The 65-year-old Wood lived through the last major tech crash, as well as the infamous Black Monday of 1987.\nShe worked for Prudential-owned money manager Jennison Associates for 18 years in the 1980s and 1990s and then spent a dozen years at AllianceBernstein before leaving in 2013.\nBut then, AllianceBernstein passed on her idea to launch a suite of actively managed exchange-traded funds. So she struck out on her own and started Ark in 2014.\n\"I have been watching disruptive innovation for my entire career — why don't I help my own sector along?\" she told Forbes in a 2014 interview.\nThat focus on disruption means Wood ties her ETF's fortunes to visionary but mercurial leaders.\nIn the most prominent example, Wood remains an unabashed fan of Tesla(TSLA) and CEO Elon Musk. The EV maker is the top stock, by far, in Ark's Innovation ETF, accounting for more than 10% of the fund's holdings. It's also the biggest position in Ark's Autonomous Technology & Robotics(ARKQ) and Next Generation Internet(ARKW) ETFs.\nWood is a vocal fan of Tesla, which is a top holding in several of Ark's funds.\nWood is also OK with companies like Tesla issuing more stock to raise money to fund futuristic projects like autonomous vehicles. Some investors are wary of that strategy because the new shares lower the value of existing investors' holdings, but she thinks that's a short-sighted argument, particularly from Tesla bears.\n\"We're not afraid of dilution ... if we think they're doing it for the right reason,\" she told CNBC. \"We wanted them to scale as quickly as possible because we think if we're right on autonomous ...Tesla could get the lion's share of that market, certainly in the United States.\"\nArk's big investment in Tesla is a bet on Musk continuing to innovate beyond the business of electric cars, Wood explained in an interview with Bloomberg Radio in August. She raved about Tesla's plans to build a humanoid robot, for example.\n\"Every passing day, especially the more we learn about their AI expertise and how they're really driving the space ... we believe they have the pole position,\" she said, noting that Ark analysts were \"blown away\" by Musk's presentation.\nGrowth at all costs\nWood recognizes her growth-at-all-costs way of investing is not for everyone.\nTesla has lagged the broader market this year. Shares of Teladoc(TDOC), a telehealth company that is the second-largest holding in the Ark Innovation ETF and was a big winner at the start of the pandemic, are down more than 25% in 2021.\n\"We've seen higher-valuation stocks hit hard this year. But the growth for these innovative companies will still be treated well over time,\" Wood said during a webcast hosted by Cboe Global Markets in March.\nWood added that she thinks investors also should put a small percentage of their money in bitcoin, another risky bet. And she stressed that investors have to overlook the inevitable short-term bumps that come with any asset. It's essential to maintain longer-term convictions and invest for future growth, Wood believes.\n\"A lot of companies catering to short-term investors who wanted profits now [have] invested more in stock buybacks and dividends over innovation,\" she said. \"That puts them in harm's way.\"\nA colleague describes Wood's go-big-or-go-home approach as a model for the new way of investing. Too many fund managers are afraid to look far into the future when judging a company's merits, instead focusing myopically on the prior and next quarterly earnings reports.\n\"Cathie has been focusing on Tesla for a long time. She looks at it not just as an automobile manufacturer. You can't compare it to traditional car companies,\" Ark Invest's Ren Leggi, who works closely with Wood on investment decisions as the company's client portfolio manager, told CNN Business in March.\nWood's critics\nBut a growing chorus of skeptics think Wood's funds could eventually collapse. Michael Burry, one of the super-bearish investors made famous in \"The Big Short,\" recently established a short position on the Ark Innovation ETF — essentially betting that it will fall sharply.\nSome tech stock veterans also wonder if Wood is just an investing flavor of the month, comparing her to once-popular portfolio managers like Kevin Landis of Firsthand Funds, Alberto Vilar of Amerindo and Garrett Van Wagoner, who ran a popular emerging-growth fund in the late 1990s.\nMany of those tech funds imploded following the 2000 bubble. TheWall Street Journalwrote a catch-up piece about Van Wagoner and other late 1990s tech gurus in 2010 with the headline \"From Fame, Fortune to Flamed-Out Stars. Post-Bust Fates of Tech-Fund Mavens.\"\nIs Wood destined for similar ignominy?\nRivals take issue with Wood making such big bets on only a handful of stocks. The Ark Innovation ETF, for example, has nearly half its assets concentrated in its top 10 holdings. Beyond Tesla, that fund also owns sizable stakes in Roku(ROKU),Coinbase,Zoom(ZM) and Square(SQ).\nRoku is another example of a high-risk/high-reward stock that Wood loves.\n\"Our investment approach is similar to Ark in that we are focusing on tech. But we're different in that we avoid concentration,\"Jeremie Capron, head of research at ROBO Global, told CNN Business in March.\nThe top 10 holdings in theROBO Global Robotics and Automation Index(ROBO)ETF account for less than 20% of the fund's total assets, and the fund owns about 80 stocks. Ark funds typically own shares in only about 30 to 50 companies.\nFor the time being, Wood is having the last laugh.\nYes, her fund's returns may be volatile year-to-year — the Ark Innovation ETF fell nearly 25% in 2018 before rebounding 30% in 2019 — but it has tended to smooth out. The five-year average annualized return for the Ark Innovation ETF through mid-2021 was 48.6%, compared to 17.7% for the S&P 500.\nAs long as that long-term trend continues, Ark acolytes may forgive a down year every now and then as Wood continues to swing for the fences.","news_type":1,"symbols_score_info":{"ARKK":0.9,"ARKW":0.9,"ARKG":0.9,"ARKF":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":573,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":698891874,"gmtCreate":1640331386141,"gmtModify":1640331634599,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"It's always the up and down&nbsp;","listText":"It's always the up and down&nbsp;","text":"It's always the up and down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698891874","repostId":"2193078140","repostType":4,"isVote":1,"tweetType":1,"viewCount":3650,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":837841920,"gmtCreate":1629878190660,"gmtModify":1631889326785,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Just nice for a good meal&nbsp;[开心]&nbsp;","listText":"Just nice for a good meal&nbsp;[开心]&nbsp;","text":"Just nice for a good meal [开心]","images":[{"img":"https://static.tigerbbs.com/61f1d66c1649a52a5d1d63e3a4b16cb7","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/837841920","isVote":1,"tweetType":1,"viewCount":762,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":630619131,"gmtCreate":1642812029157,"gmtModify":1642812029359,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Cathy will be gone soon&nbsp;","listText":"Cathy will be gone soon&nbsp;","text":"Cathy will be gone soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/630619131","repostId":"1116834406","repostType":4,"isVote":1,"tweetType":1,"viewCount":2489,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693469990,"gmtCreate":1640063725361,"gmtModify":1640064058108,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Should start positioning at 86. 70 is too bearish&nbsp;","listText":"Should start positioning at 86. 70 is too bearish&nbsp;","text":"Should start positioning at 86. 70 is too bearish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693469990","repostId":"1180317442","repostType":4,"isVote":1,"tweetType":1,"viewCount":2544,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827789810,"gmtCreate":1634523506698,"gmtModify":1634523506960,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Buy. No regrets&nbsp;","listText":"Buy. No regrets&nbsp;","text":"Buy. No regrets","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/827789810","repostId":"1195761146","repostType":4,"isVote":1,"tweetType":1,"viewCount":2237,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829159740,"gmtCreate":1633482174945,"gmtModify":1633482175191,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Still a falling knife&nbsp;","listText":"Still a falling knife&nbsp;","text":"Still a falling knife","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/829159740","repostId":"2173911317","repostType":4,"isVote":1,"tweetType":1,"viewCount":1037,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864460267,"gmtCreate":1633139179949,"gmtModify":1633139635194,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"Will report at the hell. Not worth trading&nbsp;[开心]&nbsp;","listText":"Will report at the hell. Not worth trading&nbsp;[开心]&nbsp;","text":"Will report at the hell. Not worth trading [开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/864460267","repostId":"2172968387","repostType":4,"isVote":1,"tweetType":1,"viewCount":1078,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":889432961,"gmtCreate":1631167227953,"gmtModify":1631884166336,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574662162410712","idStr":"3574662162410712"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>Aviod, more downside to come.&nbsp;","listText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>Aviod, more downside to come.&nbsp;","text":"$GameStop(GME)$Aviod, more downside to come.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/889432961","isVote":1,"tweetType":1,"viewCount":596,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}